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English – Short Abstract 
The ultimate goal of the project in which this thesis took part is to develop a new series of small, 
drug-like organic molecules able to modulate the stability of protein−RNA complexes involved 
in several diseases, thus regulating gene expression with an unprecedented mode of action and 
opening the way to a new class of therapeutic agents. 
I focused my research on ELAV protein HuR due to its involvement in several pathologies (i.e., 
cancer, retinopathy, etc.) in which the protein is overexpressed/hyper-activated with 
consequences on target RNAs and their activity (i.e.,  transcription). In this context, the main 
aim would be to develop small molecules able to bind HuR and interfere with the formation 
and/or the stability of its complexes with target RNAs. 
Given the early stage of this research topic, the work was articulated in three main blocks: 
1. Implementation of a systematic biophysical and in silico approach exploiting 
complementary and informative methods; 
2. Design and synthesis of new ligands according to both a structure-based (in silico) and 
fragment-based (based on experimental fragment screening) approach; 
3. Biophysical assessment of the interaction between compounds and target protein (HuR). 
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Deutsch – Kurzzusammenfassung 
Das Ziel des Projekts, zu welchem diese Dissertation gehörte, ist die Entwicklung einer neuen 
Serie kleiner, wirkstoffartiger organischer Moleküle, die die Stabilität von Protein–RNA 
Komplexen, welche in etlichen Krankheiten eine Rolle spielen, modulieren können. Dadurch 
würde die Gen-Expression auf eine bisher unbekannte Weise reguliert und die Entwicklung 
einer neuen Klasse therapeutischer Wirkstoffe ermöglicht werden. 
Ich habe meine Forschung auf das ELAV Protein HuR fokussiert, da es in verschiedenen 
Krankheitsbildern (z.B. Krebs, Retinopathie) involviert ist. In diesen Fällen ist das Protein 
überexprimiert/hyperaktiviert, wodurch die Ziel-RNA und ihre Aktivität (z.B. Transkription) 
beeinflusst werden. In diesem Zusammenhang wäre das Hauptziel die Entwicklung kleiner 
Moleküle, die HuR binden und die Bildung und/oder die Stabilität der Komplexe mit Ziel-RNA 
beeinträchtigen können. Da sich das Forschungsthema noch in einem frühen Stadium befindet, 
wurde die Arbeit in drei Blöcken formuliert: 
1. Implementierung eines systematischen biophysikalischen und in silico Ansatzes, der 
komplementäre und informative Methoden nutzt; 
2. Design und Synthese neuer Liganden basierend sowohl auf einem struktur- (in silico), 
als auch auf einem fragmentbasierten Ansatz (experimentelles Fragmentscreening)  








English - Abstract 
The research for the present PhD thesis was carried out in co-tutelle between the University of 
Pavia (Italy) and Saarland University (Germany), on a collaborative project concerning the 
identification of new compounds as ligands of RNA-binding proteins. The work was conducted 
at the Medicinal Chemistry Laboratory of the Department of Drug Sciences (University of 
Pavia – I), the Department of Drug Design and Optimization – DDOP (Helmholtz Institute for 
Pharmaceutical Research Saarland – HIPS, Saarbrücken – D), and the NMR Unit of the 
Department of Chemistry (University of Milano – I).  
The ultimate goal of the project in which this thesis took part is to develop a new series of small, 
drug-like organic molecules able to modulate the stability of protein−RNA complexes involved 
in several diseases, thus regulating gene expression with an unprecedented mode of action and 
opening the way to a new class of therapeutic agents. 
RNA-binding proteins (RBPs) have been widely recognized for their pivotal role in the 
regulation of post-transcriptional processes. Particularly, their complexes with RNA are 
involved in numerous dysfunctions (i.e., cancer, inflammation and neurodegeneration) and thus 
pose the interesting question of whether they could be used as therapeutic targets with clinical 
relevance. In this context, particular attention deserves the recently discovered Embryonic 
Lethal Abnormal Vision (ELAV) or Hu protein class, characterized by the ability to stabilize 
mRNA by binding specific Adenine Uridine Rich elements (ARE); compounds able to 
modulate the complex stability could represent an innovative pharmacological strategy for both 
treatment and prevention of numerous diseases.  
Over the past few years, these considerations have led to a small number of studies aimed at 
investigating these proteins in their binding to mRNA to develop novel strategies against 
different diseases. The few compounds so far identified as complex modulators largely derive 
from different HTS approaches and the comparison between their results is often limited by the 
lack of homogeneity of the assays used. Along with HTS approaches, very few other 
investigations have been conducted.  
With the final aim to obtain compounds able to act on the stability of ELAV–RNA complexes 
in mind, I focused my research on ELAV protein HuR due to its involvement in several 
pathologies (i.e., cancer, retinopathy, etc.) in which the protein is shown as 
overexpressed/hyper-activated with consequences on target RNAs and their activity 
(i.e.,  transcription). In this context, the main aim would be to develop small molecules able to 
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bind HuR and interfere with the formation and/or the stability of its complexes with target 
RNAs. 
Given the early stage of this research topic, the work was articulated in three main blocks: 
1. Implementation of a systematic biophysical and in silico approach exploiting 
complementary and informative methods; 
2. Design and synthesis of new ligands according to both a structure-based (in silico) and 
fragment-based (based on experimental fragment screening) approach; 
3. Biophysical assessment of the interaction between compounds and target protein (HuR). 
The methodologies implemented in the first block, and exploited throughout the thesis, include 
saturation transfer difference (STD) NMR, molecular dynamics (MD) and docking studies. 
The second block exploits free-web based platform AnchorQuery (NucleoQuery) focused on 
multi-component reactions for the structure-based strategy which led to the first series of 
synthetic HuR ligands. Another series of compounds were, instead, developed according to a 
fragment-based approach which consisted in the following steps: (i) biophysical screening of a 
small halogen-enriched fragment library (HEFL) and selection of hit fragments (exploiting 
Surface Plasmon Resonance – SPR, STD NMR, and Thermal Shift Assay – TSA); 
(ii) fragment-based design of new HuR candidate ligands: (ii-a) molecular hybridization of hit 
fragments and one selected HuR binder; (ii-b) establishment and performance of a Dynamic 
Combinatorial Chemistry (DCC) approach based on the chemistry of acylhydrazones, using hit 
fragments to guide building block selection.  
The hit compounds identified and synthesized throughout the PhD project were submitted to 
biological and biophysical characterization against the protein and protein−RNA complex 
target. The significance of the obtained small molecules in the modulation of gene expression, 
for treating clinically relevant diseases in which HuR−RNA complexes are involved, is 
currently under evaluation. 
Given the challenging nature of the main target HuR, and the many efforts spent in optimizing 
the experimental conditions on several protein models, the first DCC experiments were 
performed in the context of a DDOP – HIPS infection target, bacterial metalloprotease LasB. 
Since the purpose of the related project goes beyond the aim of this thesis, the associated section 
will be mainly focused on the DCC approach carried out. 
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Italiano - Riassunto 
La presente tesi di dottorato è il risultato di una cotutela tra l’Università degli Studi di Pavia e 
l’Università del Saarland (Germania), nel contesto di un collaborazione focalizzata 
sull’identificazione di nuovi ligandi per proteine che legano RNA. Il lavoro è stato svolto presso 
il laboratorio di chimica farmaceutica del dipartimento di scienze del farmaco (Università degli 
Studi di Pavia, Italia), il dipartimento di drug design e optimization – DDOP (Helmholtz 
Institute for Pharmaceutical Research Saarland – HIPS, Saarbrücken, Germania), e 
l’unità NMR del dipartimento di chimica (Università degli Studi di Milano, Italia). 
Obiettivo ultimo del progetto in cui questa tesi si inserisce è di costruire una nuova serie di 
piccole molecole capaci di modulare la stabilità di quei complessi proteina−RNA che sono 
implicati in diverse patologie, regolando l’espressione genica con un meccanismo d’azione 
peculiare ed innovativo, e dando il via allo sviluppo di una nuova classe di agenti terapeutici. 
Le proteine che legano RNA (RBP) hanno un ruolo fondamentale nella regolazione dei processi 
post-trascrizionali. In particolare, i loro complessi con RNA sono coinvolti in numerose 
disfunzioni (ad esempio, cancro, processi infiammatori e neurodegenerativi); recentemente è 
quindi sorta la domanda se RBP e i loro complessi con RNA possano essere utilizzati come 
bersagli terapeutici con rilevanza clinica. In questo contesto, ha richiamato particolare 
attenzione la classe di proteine Embryonic Lethal Abnormal Vision (ELAV) o Hu, in grado di 
stabilizzare RNA messaggeri (mRNA) interagendo con particolari sequenze ricche di adenina 
e uracile (ARE); composti capaci di modulare la stabilità dei complessi potrebbero 
rappresentare una strategia farmacologica innovativa per il trattamento e la prevenzione di 
diverse malattie. 
Negli ultimi anni, queste considerazioni hanno stimolato un piccolo numero di studi volti ad 
investigare le proteine ELAV e il loro legame con mRNA per sviluppare nuove strategie contro 
varie patologie. I pochi composti finora identificati come modulatori dei complessi derivano 
principalmente da screening ad alta portata (HTS) e un confronto critico dei loro risultati è 
spesso limitato dalla scarsa omogeneità dei saggi utilizzati. Oltre agli screening HTS, solo pochi 
altri studi sono stati effettuati. 
Al fine di ottenere composti in grado di agire sulla stabilità dei complessi ELAV–RNA, ho 
concentrato la mia ricerca sul sottotipo HuR dato il suo coinvolgimento in diverse malattie (ad 
esempio, cancro e retinopatia), in cui la proteina è sovra espressa e iperattivata con conseguenze 
sui suoi RNA target e sulla loro attività. In questo contesto, l’obiettivo principale è quello di 
sviluppare piccole molecole capaci di legarsi a HuR ed interferire con la formazione e/o la 
stabilità dei suoi complessi con RNA bersaglio. 
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Dato lo stadio precoce della ricerca in questo campo, il lavoro è stato articolato in tre macro-
blocchi: 
1. Definizione, set up ed esecuzione di un sistema combinato basato su tecniche biofisiche 
e approcci in silico, sfruttando approcci complementari e informativi; 
2. Disegno e sintesi di nuovi ligandi sulla base di due approcci, structure-based (in silico) 
e fragment-based (basato sullo screening sperimentale di frammenti); 
3. Valutazione biofisica dell’interazione tra composti e proteina target (HuR). 
Le metodologie implementate nel primo blocco, e sfruttate durante tutto il lavoro di tesi, 
includono saturation transfer difference (STD) NMR, dinamica molecolare (MD) e studi di 
docking. Il secondo blocco comprende l’utilizzo della piattaforma web gratuita AnchorQuery 
(NucleoQuery) che ha portato al disegno e sintesi della prima serie di ligandi sintetici di HuR. 
Le serie seguenti sono state invece sviluppate secondo un approccio fragment-based formato 
dai seguenti step: (i) screening biofisico di una piccola libreria di frammenti alogenati (HEFL) 
e selezione di frammenti hit (sfruttando Surface Plasmon Resonance – SPR, STD NMR, and 
Thermal Shift Assay – TSA); (ii) design di ligandi sulla base dei frammenti selezionati: (ii-a) 
ibridazione molecolare di frammenti e un ligando di HuR selezionato; (ii-b) set up ed 
esecuzione di un approccio dynamic combinatorial chemistry (DCC) basato sulla chimica degli 
acilidrazoni, utilizzando frammenti hit per la selezione dei building block. 
I composti identificati e sintetizzati nel corso del progetto di dottorato sono stati sottomessi a 
caratterizzazione biofisica e biologica dell’interazione con la proteina e l’attività sui complessi 
proteina−RNA. È attualmente in corso la valutazione della rilevanza delle piccole molecole 
ottenute nella modulazione dell’espressione genica, per il trattamento di patologie legate alla 
sregolazione dei complessi HuR−RNA. 
Data la natura complessa del target HuR, e considerati i diversi sforzi spesi per ottimizzare le 
condizioni sperimentali su diversi modelli proteici, i primi esperimenti DCC sono stati eseguiti 
nel contesto di un target per l’infezione del DDOP – HIPS, la metallo proteasi batterica LasB. 
Poiché l’obiettivo del progetto correlato esula dallo scopo di questa tesi, la sezione relativa sarà 
prevalentemente dedicata all’approccio DCC sviluppato.  
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Deutsch - Zusammenfassung 
Die Forschung zur vorliegenden Dissertation wurde im Cotutelle-Verfahren zwischen der 
Universität Pavia (Italien) und der Universität des Saarlandes (Deutschland) durchgeführt. Das 
Kollaborationsprojekt befasste sich mit der Identifizierung neuer Verbindungen als Liganden 
für RNA-bindende Proteine. Die Arbeit erfolgte im Labor für Medizinalchemie der Abteilung 
„Drug Sciences“ (Universität Pavia – I), der Abteilung „Drug Design and Optimization“ – 
DDOP (Helmholtz-Institut für pharmazeutische Forschung Saarland – HIPS, Saarbrücken – D) 
und der NMR-Abteilung der chemischen Fakultät in Mailand (Universität Mailand – I). 
Das Ziel des Projekts, zu welchem diese Dissertation gehörte, ist die Entwicklung einer neuen 
Serie kleiner, wirkstoffartiger organischer Moleküle, die die Stabilität von Protein–RNA 
Komplexen, welche in etlichen Krankheiten eine Rolle spielen, modulieren können. Dadurch 
würde die Gen-Expression auf eine bisher unbekannte Weise reguliert und die Entwicklung 
einer neuen Klasse therapeutischer Wirkstoffe ermöglicht werden. 
RNA-bindende Proteine (RBPs) nehmen eine zentrale Rolle in der Regulierung post-
transkriptionaler Prozesse ein. Besonders ihre Komplexe mit RNA sind an vielfältigen 
Fehlfunktionen (z.B. Krebs, Entzündungen und Neurodegeneration) beteiligt, weshalb sich die 
interessante Frage stellt, ob sie als therapeutische Ansatzpunkte mit klinischer Relevanz genutzt 
werden können. In diesem Zusammenhang verdient das erst kürzlich entdeckte „Embryonic 
Lethal Abnormal Vision“ (ELAV) oder auch Hu-Proteinklasse besondere Aufmerksamkeit. Es 
zeichnet sich durch die Fähigkeit aus, mRNA zu stabilisieren, indem es spezifische Adenin-
Uridin reiche Elemente (ARE) bindet. Verbindungen, die diese Komplexstabilität modulieren 
können, könnten eine innovative pharmakologische Strategie für die Behandlung und 
Vorbeugung zahlreicher Krankheiten darstellen. 
In den vergangenen Jahren haben diese Überlegungen zu einer kleinen Anzahl an Studien 
geführt, die die Bindung dieser Proteine an mRNA untersuchten, mit dem Ziel neue Strategien 
für verschiedene Krankheiten zu entwickeln. Die wenigen Komplex-modulierenden 
Verbindungen, die bisher identifiziert wurden, stammen aus verschiedenen Hochdurchsatz-
Screenings und der Vergleich der Ergebnisse ist häufig limitiert wegen geringer 
Vergleichbarkeit der Assays. Bis jetzt wurden wenig andere Ansätze verfolgt. 
Mit dem Ziel vor Augen, Verbindungen zu erhalten, die die Stabilität der ELAV–RNA 
Komplexe beeinflussen, habe ich meine Forschung auf das ELAV Protein HuR fokussiert, da 
es in verschiedenen Krankheitsbildern (z.B. Krebs, Retinopathie) involviert ist. In diesen Fällen 
ist das Protein überexprimiert/hyperaktiviert, wodurch die Ziel-RNA und ihre Aktivität (z.B. 
Transkription) beeinflusst werden. In diesem Zusammenhang wäre das Hauptziel die 
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Entwicklung kleiner Moleküle, die HuR binden und die Bildung und/oder die Stabilität der 
Komplexe mit Ziel-RNA beeinträchtigen können. Da sich das Forschungsthema noch in einem 
frühen Stadium befindet, wurde die Arbeit in drei Blöcken formuliert: 
4. Implementierung eines systematischen biophysikalischen und in silico Ansatzes, der 
komplementäre und informative Methoden nutzt; 
5. Design und Synthese neuer Liganden basierend sowohl auf einem struktur- (in silico), 
als auch auf einem fragmentbasierten Ansatz (experimentelles Fragmentscreening)  
6. Biophysikalische Bewertung der Wechselwirkungen zwischen Molekülen und Ziel-
Protein (HuR). 
Die Methoden des ersten Blocks, die in dieser Dissertation genutzt wurden, sind „saturation-
transfer difference“ (STD) NMR, Molekulardynamik (MD) und Docking Studien. 
Der zweite Block nutzt die frei zugängliche Platform AnchorQuery (NucleoQuery), welche für 
die strukturbasierte Strategie auf Multikomponenten Reaktionen fokussiert ist. Die folgende 
Molekülserie wurden hingegen nach ein fragmentbasiertem Ansatz entwickelt, der folgende 
Schritte enthielt: (i) biophysikalisches Screening einer kleinen Halogen-angereicherten 
Fragment Bibliothek (HEFL) und Auswahl der Fragment-Hits (Nutzung von 
Oberflächenplasmonenresonanz-Spektroskopie – SPR, STD NMR und thermische 
Verschiebung Assay – TSA); (ii) Fragment-basiertes Design neuartiger  potentieller HuR 
Liganden. (ii-a) molekulare Hybridisierung der Fragment-Hits und eines ausgewählten HuR-
Binders; (ii-b) Etablierung und Durchführung der „Dynamic Combinatorial Chemistry“ (DCC) 
Methode, die auf der Chemie der Acylhydrazone basiert, mit den Fragment-Hits als Vorlage 
für die Bausteinauswahl. Das Verhalten, der während der Dissertation identifizierten und 
synthetisierten Hitverbindungen, zu dem Protein und dem Protein–RNA Komplex wurde 
biologisch und biophysikalisch charakterisiert. Die Bedeutung der erhaltenen kleinen Moleküle 
in der Modulierung der Gen-Expression für die Behandlung von klinisch relevanten 
Krankheiten, in denen HuR–RNA Komplexe involviert sind, wird derzeit evaluiert. 
Es stellte sich als sehr schwierig heraus sowohl für das HuR-Protein als auch für diverse 
Proteinmodelle die experimentellen Bedingungen zu etablieren. Daher wurden die ersten DCC 
Experimente an einem Infektionstarget der DDOP-Gruppe, der bakteriellen Metalloprotease 
LasB, durchgeführt. Da das Ziel dieses verwandten Projekts über das Ziel dieser Arbeit 
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SECTION 1: Versatile use of advanced NMR techniques for the identification 
of compounds able to interfere with ELAV protein−mRNA complexes 
1. Introduction 
Starting from the development of modern biology and biochemistry, continuous advances in 
proteomics have been unveiling new proteins with pivotal functions in the physiological and 
pathological pathways of our bodies. From a medicinal and pharmacological standpoint, these 
proteins represent potential or factual targets of clinically relevant therapies that need to be 
continuously studied and developed to keep up with the overwhelming understanding that a 
longer life-span is linked with a series of dysfunctions we do not know yet how to face. This is 
not only producing a rise in the number of protein targets to consider, but also a paradigm shift, 
from traditional targets, such as receptors and enzymes, to novel targets,1 i.e. protein–protein 
interactions,2 intrinsically-disordered proteins3 and, finally, non-protein targets such as nucleic 
acids;4–6 this rather drastic shift is forcing us to redefine and redesign research concepts and 
techniques of classical pharmacology and medicinal chemistry to better respond to this growing 
demand.  
One of these unusual targets, and main topic of this doctoral dissertation, is represented by 
RNA-binding proteins (RBPs). The involvement of this protein class in the post-transcriptional 
modifications related to many physio-pathological mechanism makes it an interesting target for 
uphill gene regulation.  
1.1 RNA-binding proteins 
RNAs in cells are bound to RBPs to form ribonucleoprotein (RNP) complexes, which influence 
their structure and interactions in their journey from the nucleus (i.e., alternative splicing, poly-
adenylation, nuclear export) to the ribosome (i.e., cytoplasmic localization, stability, translation 
rate). Eukaryotic cells encode a large number of RBPs (thousands in vertebrates), each with a 
unique RNA-binding activity, and type of RNA-binding domain (RBD) and protein–protein 
interaction characteristics.7–13 
Focusing solely on the role of RBPs in the stabilization of target mRNAs, we can recognize the 
possible implications of their dysregulation9,10,12,14–17 in different tissues and organs of the 
human body, as a change in mRNA function and stability can cause inhibition/augmentation in 
the production and function of their codified proteins. This can often relate directly with the 
evolution of pathologies such as neurodegenerative diseases, inflammation and cancer.18–25 
This realization has recently raised the question of whether RBPs and their complexes with 
RNAs could constitute therapeutically relevant targets to modulate gene expression.26,27  





Figure 1. An RNA-binding protein (RBP) can interact with RNA through defined RNA-binding 
domains (RBDs) to regulate RNA metabolism and function. For certain ribonucleoprotein complexes 
(RNP), the interaction occurs with high specificity and is mediated, on the protein side, by a RNA-
recognition motif type domain (RRM) and, on the RNA side, by adenine-uridine rich sequences (ARE). 
(Adapted from Hentze et al., 201811) 
 
Figure 2. Statistics reported on PubMed for the number of publications including RBPs along the years 
since their discovery (complete data reported until the end of 2018; platform accessed in September 
2019 - https://www.ncbi.nlm.nih.gov/pubmed/). 
Few approaches have been envisioned to target RBPs and modulate RNP complexes and, so 
far, most of them have included RNA interference-based oligonucleotides (e.g. siRNA, 
microRNAs and RNA decoys) targeting different types of RBDs.28–32 A more recent, strictly 
MedChem, approach involves the identification of small molecules able to modulate the 
stability and/or formation of RNP complexes or directly of the target RNA itself. This approach 
is intrinsically challenging, due to the fact that this type of proteins often do not have a 
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or RBP by developing small molecule ligands in the classical sense, is nowadays still quite a 
difficult task. Nonetheless, few pioneering examples of rationally designed compounds 
targeting RBPs can be found in literature; perhaps, the most promising is represented by 
H3B-880033–35 (see Figure 3), the first RBP-targeting small molecule to reach, in 2018, the first 
stage of clinical phase for acute myelogenous leukemia and chronic myelomonocytic leukemia. 
This compound was developed through an iterative medicinal chemistry effort starting from a 
scaffold based on pladienolide, a naturally occurring antitumor macrolide targeting splicing 
factor 3B1 (SF3B1) protein.36 H3B-8800 preferentially targets cells with spliceosome 
complexes containing mutant SF3B1, modulating intron splicing and leading to increased death 
in cancer cells while having little effect on the viability cells with wild-type SF3B1; it is thought 
to bind to a site similar to pladienolide on the SF3B complex within the spliceosome-1. Once 
bound, it induces increased retention of short (< 300 nucleotides) GC-rich introns through 
modulation of pre-mRNA processing. These intron-retained mRNA sequences are then thought 
to be destroyed through the nonsense-mediated decay pathway. 41 of 404 genes encoding 
spliceosome proteins contain GC-rich sequences whose retention was induced by H3B-8800, 
and this is presumed to be key to the specificity of H3B-8800 lethality. Since cancer cells, as in 
myelodysplasia, experience SF3B1 mutations much more frequently than host cells, this allows 
H3B-8800 to be used to preferentially target these cells by inducing intron-retention in critical 
spliceosome component pre-mRNA, leading to destruction of nonsense mature RNA and 
ultimately cell death due to the lack of critical proteins.33–35 
 
Figure 3. Structure of H3B-8800, the first RBP-targeting small molecule to reach, in 2018, the first stage 
of clinical phase for acute myelogenous leukemia and chronic myelomonocytic leukemia. 
The success of H3B-8800 is an encouragement to keep pursuing RBPs as pharmacological 
targets with clinical relevance. In this study field, since 2007, the focus of our research group 
revolves around the Embryonic Lethal Abnormal Vision (ELAV) or Hu protein family, a class 
with a pivotal role in neuron development37,38 and maintenance as well as in cancer,20,39,40 and 
inflammation,40 recently proposed as an interesting pharmacological target.12,26 
H3B-8800
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1.2 ELAV/Hu protein family 
The ELAV protein class is thoroughly studied and described from a biochemical and functional 
point of view. In particular, four ELAV proteins are known in mammals: ubiquitous HuR 
(ELAVL1), and prevalently neuronal subtypes HuB (ELAVL2), HuC (ELAVL3), and HuD 
(ELAVL4).39 These proteins are characterized by a high degree of sequence homology 
(70−85%) and are approximately 40 kDa in size. They contain three 
RNA recognition motif-type (RRM) domains, each approximately 90 amino acids long:41 the 
first two consecutive domains (RRM1 and 2) are near the N-terminus and connect to the third 
domain (RRM3) by an unconserved hinge region, mainly responsible for the 
nuclear/cytoplasmic shuttling occurring after protein activation.37,42,43 The RRM1 and RRM2 
domains directly interact with the ARE sequences of target transcripts through the highly 
conserved RNP1 and RNP2 sequences (8 and 6 amino acids, respectively),44 while the RRM3 
domain is involved in binding to the poly(A) tail of the target mRNAs and has a crucial role in 
the homo- and heteromultimerization processes of ELAV proteins.45–47 
 
Figure 4.  ELAV domains and their involvement in protein function (adapted from Vasile et al., 2018, 
see appendix III, article 1). 
While in basal conditions, neuronal ELAVs are mainly found in the cytoplasm and ubiquitous 
HuR mostly in the nucleus, there is no strict compartmentalization for both localization and 
function, since ELAV proteins can shuttle between the cytoplasm and the nucleus under specific 
stimuli, and thus affect any step of the post-transcriptional gene regulation. In fact, neuronal 
ELAVs in the nucleus of neurons regulate splicing and polyadenylation, whereas, in the 
cytoplasm, they control mRNA target stability, translation, and transport.48,49 All mammalian 
ELAVs can interact with many mRNAs, giving rise to various ELAV protein−mRNA 
complexes with different physiological roles38,50–52 and it has been suggested that both 
structure-specificity and subcellular localization could affect protein−target RNA specificity.53 
In fact, mRNAs encoding proteins involved in neuronal plasticity, outgrowth, and neuronal 
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metabolism maintenance are mainly targeted by neuronal ELAV proteins, while HuR has been 
described to possess a greater binding affinity for transcripts implicated in oxidative stress 
defense, inflammation, cell growth, and cell cycle regulation.48,49 Notably, the importance of 
HuR in these processes is so relevant that HuR has been proposed as a prognostic factor for 
different types of cancer,21,54,55 while neuronal ELAV impairments have been suggested to 
contribute to the development of neurodegenerative disorders, such as Alzheimer’s disease56 
and paraneoplastic neurological syndrome.15 Overall, this evidence suggests that ELAV 
proteins have potential as pharmacological targets in several pathologies. Each pathology 
presents a different impairment in the function, activation and/or expression of one or more 
ELAV subtypes, thus the search for modulators of ELAV−RNA modulators can be in principle 
aimed at either increasing the stabilization of the complex (or of the target RNA), i.e. in some 
neurodegenerative diseases, or at preventing the formation/destabilizing the complex, i.e in 
some cancers, inflammatory processes and diabetic retinopathy. In the context of this thesis, 
the focus will revolve around building technical and pharmacological tools to develop a 
therapeutic approach which can interfere with or disrupt selected ELAV−RNA complexes. 
1.3 Compounds able to interfere with ELAV−mRNA complexes 
As underlined in the previous paragraph, the ELAV protein class is thoroughly characterized 
from a biochemical and functional point of view, and several studies have gained us knowledge 
on the structural features of the protein domains interacting with some target RNAs. 
Nonetheless, regardless of the potential of ELAV proteins as pharmacological targets in various 
diseases, related medicinal chemistry research is still at an early stage: only few compounds 
able to interfere with ELAV–RNA complexes have been identified and very little is known 
about the features of the ELAV–small molecule interaction, even for compounds which are 
proven interferers of the ELAV–RNA binding. When approaching a new target, the elucidation 
of the structural hot-spots is fundamental for the rational discovery of new ligands but, at the 
time this thesis was started, all literature-described ligands for these targets had been identified 
as a result of high-throughput screenings (HTS); a thorough description of the state-of-the-art 
on this topic at the time this thesis was started can be found in a perspective review of our 
research group (see Figure 5).26 The main findings are briefly reported hereinafter. 
Meisner’s team was the first to approach the ELAV–RNA system from a medicinal chemistry 
perspective in 2007, focusing on subtype HuR.57 A screening and purification of 50,000 extracts 
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from natural sources, against both the full-length protein and a truncated variant, based on 
fluorescence intensity distribution analysis (FIDA),58,* allowed isolation  and  characterization 
 
Figure 5. Compounds able to interfere with ELAV–RNA complexes from high-throughput screenings 
(HTS);26,59 natural products are enclosed in a green rectangle, synthetic compounds in a red rectangle. 
of 1–3; these exerted concentration-dependent in vitro inhibitory activity, attributed to their 
interaction with RRM1 and 2 domains. The postulated mechanism of interaction was further 
investigated on the HuR RRM1/2–RNA complex combining experimental and in silico results, 
allowing to advance the following points: a) HuR exists as a homodimer; b) it binds RNA in a 
2:1 or 1:1 stoichiometric ratio; c) RRM domains may mediate homodimerization; d) certain 
compounds (1 and 2) can interfere with homodimerization. These findings partially clarified 
the interaction mechanism of exogenous ligands and ELAV proteins, stressing the importance 
 
* FIDA is a fluorescence-based technique that detects the variation of fluorescence of a compound bound to the 
target by considering the statistics of the intensities of the generated photon bursts. A typical biochemical 
application in an HTS is a ligand binding assay, which measures the binding of a ligand to the target and its 
displacement by tested compounds. 
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of RRM sequences, posing a milestone in this field and opening the concept of chemical 
druggability of the ELAV protein family. 
In 2009, a set of flavonoids able to inhibit HuC–RNA complexes were identified by screening 
52 natural compounds with anti-inflammatory and anti-tumorigenic activities through a non-
radioactive RNA electrophoretic mobility gel shift assay (REMSA),† a technique affirmed for 
characterizing protein–RNA interactions.60,61 IC50 values were assessed for the best 
compounds, 4–9, ranging from 0.2 to 1.8 μM. 
The same technique was applied on HuR–RNA complexes involved in inflammatory diseases,62 
affording nine candidates based on their inhibitory effect; the determination of IC50 values by 
a filter-binding assay allowed the further selection of compounds 6,12 and 13. 
In 2013, Provenzani’s team proposed amplified luminescent proximity homogeneous assay 
screen (AlphaScreen)‡ to identify new compounds able to interfere with HuR–RNA 
complexes.63 The screening of a library of 2,000 molecules, afforded 16 compounds further 
evaluated by REMSA to exclude false-positives. Interestingly, in agreement with results 
previously reported by Meisner, mitoxantrone (20) was found to disrupt HuR–RNA complexes. 
Upon approach validation, a new compound library was screened against the HuR–ARE 
(RNATNFα) complex using AlphaScreen to select hits and REMSA for confirmation.64 Among 
eight hits identified, 10 emerged as the most potent in preventing complex formation 
(IC50 = 0.15 μM).  
In 2015, a screening was performed on 6,000 compounds by using a fluorescence polarization 
(FP)§,65 binding assay on HuR and a particular ARE sequence related to malignancy and 
proliferation of gliomas and melanomas.66 This study led to the discovery of six coumarins (14–
19) able to disrupt the complex. All compounds showed lower IC50 and Ki values for the full-
length protein than for the RRM1 and 2 domains, although related data did not provide 
information about the binding region involved (direct binding to HuR was confirmed by Surface 
Plasmon Resonance, SPR).** 
 
† REMSA is an affinity electrophoresis technique used to study protein–RNA interactions. It can determine if a 
protein or mixture of proteins is capable of binding a given RNA sequence, and can sometimes indicate the 
stoichiometry of the binding complex. A set up where compounds to test are added to the complexes can highlight 
displacement. Detection can be performed through radioactivity and fluorescence (using the appropriate probe). 
‡ AlphaScreen is a bead-based proximity assay developed from diagnostic assay LOCI (Luminescent Oxygen 
Channeling Assay). It is a channeling immunoassay in which an immune reaction directs two bead components 
into close proximity on a defined surface. One produces a product which stimulates a second component, thereby 
yielding a detectable signal. Its extensive use results from both the simplicity of its protocols and its high 
sensitivity. These features, as well as the absence of wash-up and separation steps, allow for the automation of a 
range of related assays. 
§ FP is a solution-based technique that allows rapid and quantitative analysis of diverse molecular interactions and 
enzyme activities. The principle of FP derives from the fact that the intrinsic fluorescence intensity of a fluorophore 
may change upon binding. 
** A more thorough description of SPR can be found in chapter 3, paragraph 3.2.1. 
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In the same year, 1,597 compounds were screened by FP based on their ability to inhibit HuR–
RNAc-fos complex formation; twelve gave IC50 values ranging from 2.7 to 97.4 μM, (among 
them, 21–23).67 A successive NMR-based screening, 1H–15N heteronuclear single quantum 
correlation (HSQC),†† provided evidence of direct interaction with the target protein and with 
RRM1 and 2 domains for 21. 
The most recent studies in 2017 and 2018, brought to the discovery of natural product 
azaphilone-9 (11)59 and suramin, an antitrypanosomal drug;68 due to its high molecular weight 
( > 1000 Da) suramin does not comply to the small molecule definition and is thus excluded 
from this recollection. As for 11, similarly to 21–23, it was discovered through a FP assay 
against HuR–ARE-RNAc-fos with a IC50 of 1.2 μM; direct binding was confirmed by SPR 
(against HuR) and 1H–15N HSQC (against HuR RRM1/2). 
Despite their undeniable significance, the obtained outcomes could not afford enough data to 
lead to a concrete discovery for the identification of new small molecules, directed at ELAV–
RNA complexes, with therapeutic value. In fact, these studies were carried out separately not 
following a consistent method or taking into account respective results, and as a consequence, 
aside for few overlapping data, their results are often hard to compare and exploit. Namely, 
because of the structural variability of the derived compounds and the different techniques and 
experimental conditions employed for the screenings, a direct definition of a structure–activity 
relationship (SAR) cannot be accomplished.26 
1.4 ELAV–RNA interface 
The importance of elucidating in detail the relationship between structural and functional 
hot-spots of a new target, for the rational discovery of new ligands, has been stressed in the 
previous paragraph, along with the lack thereof for this interesting family of proteins and small 
interacting molecules. Nonetheless, as reported in paragraph 1.2, several studies have allowed 
to obtain this information for the interaction between protein and target RNAs.44,69–75 Given the 
large size of the protein–RNA interface and the high flexibility of this protein class, it is hard 
to directly pinpoint the breaking point of the complex interaction, but, at the same time, we can, 
among superficial and deeper interactions, recognize some useful hotspots. The main findings, 
from the co-crystal structures to a functional and structural study of selected ELAV peptides, 
will be illustrated in the next paragraphs. 
 
†† 1H–15N HSQC is a bidimensional protein-observed NMR technique to study protein-ligand interactions and to 
detect, thanks to selective signal shifts, which residues of the protein are in contact with the ligand. It allows to 
detect direct binding and pinpoint the binding site as only the resonances of interacting residues will shift. It 
requires 15N-labeled protein.  
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1.4.1 ELAV–RNA co-crystals 
As reported in paragraph 1.2 and Figure 2, the structure of ELAV proteins includes three RRM 
domains. The two N-terminal tandem RRM domains can selectively bind AU-rich elements, 
while the third RRM domain (RRM3) contributes to interactions with the poly-A tail of target 
mRNAs. Regardless of the importance of RRM3,46,47,74 focus of the attention for specific RNA 
binding is on the first two RRMs and the highly conserved RNP1 and 2 sequences of each 
RRM1/2, of 8 and 6 amino acids, respectively.44,75 Studies reported on the co-crystal structure 
of HuD (PDB 1FXL)44 and HuR (PDB 4ED5)75 RRM1/2 and AREs of target transcript c-fos, 
the comparison of the latter with the RRMs free form (PDB 4EGL), and additional FP assays 
afforded interesting and useful information: a) both the co-crystal structure and the FP show 
that RRM1 is the main ARE binding domain in HuR and that the conformational changes cause 
subsequent contacts of the RNA substrate with the inter-domain linker and RRM2, greatly 
improving the complex binding affinity. In the HuR RRM1/2–RNA complex, RRM1 
recognizes five nucleotides U5–U8 and U10, the inter-domain linker interacts with U9, and 
RRM2 with U3–U4. The capability to recognize four or five consecutive uracil-recognition 
groups gives RRM1 a high RNA-binding capacity in solution, while the ability of the inter-
domain linker and RRM2 to recognize one or two uracil residues is not sufficient to subtract 
the RNA segment from solution (see Figure 6 a).  
 




Figure 6. (a) HuR−RNA contacts (PDB code 4ED5). Red lines show side-chain contacts; green lines 
show main-chain contacts; dashed orange lines show stacking interactions. Distances are expressed in Å 
(adapted from Wang et al., 201375); (b) Comparison of closed and open form of HuR RRM1/2 (the open 
form shown was reproduced with Molecular Dynamics simulations from PDB 4ED5 to show the quick 
loss in contacts with RNA).18  
b) Due to the high sequence homology of ELAV proteins, NMR studies on HuC and SPR 
experiments on HuD revealed the same RNA-binding properties, which are consistent with the 
above results.70 In the HuD RRM1/2–RNA complex the two individual RRM domains also 
recognize the RNA substrate in the same conserved manner as in HuR. 
c) The two crystal structures of free HuR RRM1/2 and its RNA complex present two distinct 
conformations: an open state (free form) and a closed state (bound form). Though the protein 
folds of the single RRM domains in the bound form are basically the same as the free form, the 
tertiary structure undergoes dramatic conformational changes upon RNA binding (see Figure 6 
b) to form the RNA-binding cleft.75 
1.4.2 Studies on ELAV peptides (RRM1/2 RNP1/2)–RNA 
In parallel with the study of the previous paragraph, the first involvement of our research group 
with the ELAV puzzle focused on the investigation of the significance of the RNP sequences 
in binding and stabilizing two target RNAs, RNANOVA1 and RNAVEGF. Briefly, four peptides 
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and Figure 7) were synthesized and their behavior towards the RNA transcripts was evaluated 
through: a) PCR (stabilization of RNA);76 b) in silico methods (prediction of binding modes);77 
c) STD NMR and diffusion-ordered spectroscopy (DOSY) (binding and structural 
considerations).78 
PEPTIDE DOMAIN AMINO ACID SEQUENCE 
P1 RRM1_RNP1 Leu-Gly-Tyr-Gly-Phe-Val-Asn-Tyr 
P2 RRM1_RNP2 Leu-Ile-Val-Asn-Tyr-Leu 
P3 RRM2_RNP1 Arg-Gly-Val-Gly-Phe-Ile-Arg-Phe 
P4 RRM2_RNP2 Leu-Tyr-Val-Ser-Gly-Leu 
Table 1. Amino acid sequence of the four ELAV-derived peptides synthesized for the study. 
The four peptides were able to stabilize the target RNAs when used as a equimolar mixture of 
all four or two by two (P1–P2 and P3–P4). In particular, in accordance with the study reported 
in paragraph 1.4.1, P1 and P2 play greater roles in stabilizing RNA. This evidence was further 
confirmed by in silico predictions and NMR binding studies. 
 
Figure 7. Co-crystal structure of HuD RRM1/2–RNATNFα (PDB 1G2E). The protein is shown as gray 
and RNA as orange cartoons. RRM1_RNP1 is shown in pink, RRM1_RNP2 in red, RRM2_RNP1 in 
blue, and RRM2_RNP2 in green. (Image generated with PyMOL v1.7.4.5 Edu, Schrödinger LLC) 
It is very important at this point to underline once again that RNP sequences are highly 
conserved in the ELAV protein class. In fact, by comparing the four sequences for subtype HuD 
and HuR we notice only two differences in residue substitution, namely Ala for Gly in 
RRM2_RNP1 and Ile for Val in RRM2_RNP2. Taking this into account, together with the 
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conclusions of the study illustrated in paragraph 1.4.1, the considerations made for the HuD 
peptides could be extended to the whole family. 
1.5  Postulated binding site for small molecules: preliminary docking of literature 
compounds on subtype HuR 
Based on these considerations and the literature recollection of compounds interfering with 
ELAV–RNA complexes shown in paragraph 1.3 (Figure 5), a preliminary molecular modeling 
study was performed by our research group on subtype HuR RRM1/2, chosen as model (PDB 
4ED5).26 Aim of the investigation was to gather all the literature compounds and, despite their 
structural diversity and different experimental data, submit them to the same docking process 
to hypothesize a common binding site. This region can reasonably be identified between the 
RRM domains, especially in the site hosting the RNA recognition sequence (AUUUA). Exactly 
at this point, the two asymmetric units of the protein are in proximity, providing a deeper and 
narrower pocket, which is partially basic due to the presence of arginine and asparagine 
residues.  
Starting point was the co-crystal structure of HuR RRM1/2–RNAc-fos (PDB 4ED5). The 
compounds were subjected to the investigation using the FlexX docking module in the LeadIT 
suite (BioSolveIT GmbH) and the following evaluations exploiting the scoring function HYDE 
in SeeSAR (BioSolveIT GmbH). The binding site in the protein was restricted to 6.5 Å around 
the co-crystallized RNA, the 30 top-scored (FlexX) solutions were retained and subsequently 
post-scored with SeeSAR, and the best-scored poses were then selected. Results of these 
explorations revealed that, though they occupy different sites of the interaction site, most 
compounds bind to the same pocket on HuR, benefiting from interactions with the RNP1/2 
sequences of the RRM1/2 domains of the protein in the deep part of the pocket. In accordance 
with experimental data, 23 did not show interaction with the RRM1/2 domains. Aside for 23, 
each compound can be superimposed with at least one nucleotide of the RNAc-fos sequence, 
with U4/U8 as the most represented.26 
Accordingly, these scouting docking studies identified the possible interactions of compounds 
already recognized as inhibitors of ELAV–RNA and hinted at possible complex breaking 
points; moreover, they showed the potential of using computer-aided drug design (CADD) in 
future drug-discovery programs. 




Figure 8. Summary timeline to recap the milestones in ELAV research at the time this thesis was started.  
  
2010 2017
RNA or its derivatives proposed
for inhibiting the expression of
genes critical to the progression
of several diseases.
RNA-binding proteins (RBPs)
proved to affect the fate of target
mRNAs coding for proteins
essential for key cellular functions
1990
ELAV/Hu proteins proved to interact with
many mRNAs, to form ELAV–RNA
complexes.
ELAV involvement in neuronal plasticity,
outgrowth and metabolism, oxidative stress
defense, inflammation, cell growth and cell
cycle regulation demonstrated.
2000
ELAV–mRNA complexes attract interest of
pharmacologists and medicinal chemists.




















The ultimate goal of the project in which this thesis took part is to develop a new series of small, 
drug-like organic molecules able to modulate the stability of protein−RNA complexes involved 
in several diseases, thus regulating gene expression with an unprecedented mode of action and 
opening the way to a new class of therapeutic agents. 
Within this context, the present thesis focuses on the ELAV RBP family, and in particular on 
subtype HuR and its complexes with RNA due to their involvement in numerous dysfunctions 
(i.e. cancer, retinopathy, etc.).  
Given the early stage of this research topic, the research gaps in the state-of-the-art at the 
moment this thesis was started (October 2016), and the highly challenging character of the 
target, the aim of the present PhD project was split into three “sub” aims to reach ideally in 
series and consequentially but with the potential to be carried out in parallel and separately: 
1. Establishment of a systematic biophysical and in silico approach exploiting 
complementary and informative methods to apply to all obtained compounds; 
2. Design and synthesis of new ligands according to (a) a fragment-based (fragment 
screening and linking) approach followed by the application of DCC, or, in case of 
failure, (b) a structure-based (in silico) approach. 
Finally, to perform the biophysical assessment of the interaction between compounds and target 
protein (HuR), to select compounds for biological evaluation. 
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3. Methodologies and Strategies 
As stated in the previous chapter, aim of the present thesis is to establish a systematic and 
informative approach to evaluate the interaction between potential ligands/inhibitors and the 
chosen target HuR, and to exploit this approach and the deriving data to design and synthesize 
new compounds and iteratively evolve them to develop new molecules as HuR ligands able to 
modulate its complexes with RNA. From the recap provided in introduction, it is clear that our 
knowledge of the HuR−RNA−small molecule system is still very preliminary. For this reason, 
to tackle this challenging target, different and complementary techniques and approaches were 
employed in the research work related to this thesis.  
Here below, the main methodologies and strategies applied will be briefly introduced and 
described for clarity purposes. The chapter articulates in different paragraphs, starting from the 
main technique chosen for the project, NMR, additional biophysical approaches exploited, 
surface plasmon resonance and thermal shift assay, and a brief paragraph on supporting in silico 
methodologies used. The following paragraphs concern the two approaches exploited for HuR 
ligand discovery, structure-based and fragment-based, and the chapter ends highlighting three 
useful strategies, multi-component reactions, dynamic combinatorial chemistry and microwave 
heating which could be applied to accelerate ligand discovery by affording diverse and rich 
compound libraries.  
3.1 NMR techniques to study small molecule−macromolecule interactions 
Biological functions generally depend on the interaction between ligands and macromolecular 
targets (proteins, nucleic acids, etc) and to understand the biological function we need to study 
the underlying recognition events at an atomic level. Several biophysical methods have been 
developed to supply to this very need, as understanding how a certain macromolecule interacts 
with natural or known ligands, allows us to develop other more potent substances that may then 
serve as pharmacological tools or even drug candidates. Among these, NMR techniques are 
recognized as powerful techniques to understand the binding process at a molecular or atomic 
level as they occur in solution. They can be exploited for several purposes in medicinal 
chemistry and drug discovery: a) screening compound libraries, b) obtaining detailed 
identification of the groups involved in the interaction, thus gaining essential structural 
information, c) characterizing thermodynamic and kinetic parameters of the binding events, and 
finally d) identifying competitive binding as well as allosteric effects.79 
While, in principle, all NMR parameters could be exploited for monitoring the binding activity 
of a ligand to a macromolecule, in practice, only those that can be obtained easily and with high 
sensitivity are of significance; among these, are changes in chemical-shift, relaxation times, 
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diffusion constants, nuclear Overhauser effect (NOE), or transfers of saturation. Different 
experimental formats have been thus been developed, which can be divided into two main 
groups, those based on observing the binding from the small molecule perspective (ligand-
based or ligand-observed) and those focused on the macromolecule signals (target-based or 
target-observed). The first approach usually utilizes NOE effects between macromolecule and 
ligand, while the second focuses on chemical-shift changes of the target upon binding of the 
ligand; the two approaches can thus be considered complementary to build a complete map of  
the interaction and have different advantages and limitations.  
A complete and more detailed panoramic on this subject is reported in several articles and 
reviews (Meyer et al., 2003;79 Ciulli, 2013;80 Mittermaier et al., 2013;81 Li et al., 2017;82 Sugiki 
et al., 2018;83 Barile et al., 2019;84 Maity et al., 2019;85). In the following sections, the focus 
will revolve around ligand-observed technique saturation transfer difference (STD) NMR and 
its very recent derivation differential epitope mapping (DEEP) by STD NMR, exploited to study 
the interaction between small molecules and target protein HuR.  
3.1.1 Ligand-observed NMR: Saturation Transfer Difference (STD) NMR 
 In the context of ligand-based NMR, saturation transfer difference (STD) NMR has become a 
leading technique to characterize ligand−macromolecule interactions as they occur in 
solution.79,86 For this reason, it is considered a powerful tool for screening compounds, 
identifying lead structures or ligand moieties important for binding to target.87 The STD 
experiment is based on the NOE effect and exploits the transfer of the magnetization from the 
macromolecule, selectively irradiated, to the ligand. Rather than gaining a only yes/no answer 
on the binding, STD can also afford information on the structural features of the binding event, 
as those regions of the ligand which are in closer contact with the macromolecule receive the 
magnetization more efficiently than those which are farther from it. Practically, this means that 
protons of the ligand which receive a higher magnetization produce more intense signals on a 
1D 1H-STD spectrum (see Figure 9). In the STD NMR literature, these protons as a whole are 
often referred to as binding epitope; the epitope mapping can be performed on single ligands, 
as well as to rank and determine best binding ligands in a mixture (with the condition that each 
component of the mixture has been assigned).88 A sample containing the macromolecule at low 
concentration and a large molar excess of the ligand (1:50 up to 1:1000) is generally employed 
to preclude the perturbations of absolute STD intensities due to rebinding effects (i.e., a ligand 
already saturated associates with the target again, without prior full relaxation), which would 
compromise the correct group epitope mapping. Additionally, STD NMR is ideal for studying 
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relatively weak binding events (dissociation constant in a low μM to mM range) in which there 
is exchange between the bound and the free ligand state.  
To obtain the STD spectrum two spectra are acquired: one in which the macromolecule has 
been selectively saturated (on-resonance spectrum obtained by irradiating at a region of the 
spectrum that contains only resonances of the macromolecule with signal intensities ISAT), and 
one recorded without macromolecule saturation (off-resonance spectrum, with signal intensities 
I0). Though the resonances of macromolecules can be quite shifted from those of small 
molecules, the chemical shift ranges considered for a small molecule 1H NMR still apply to a 
certain degree. If we consider a protein as macromolecular target, formed by different amino 
acids, we can irradiate in both aromatic and aliphatic regions of the spectrum where the variety 
of amino acid side chains can receive the magnetization. Most often, the selected frequency for 
STD experiments lies in the range between – 2 ppm and 0.5 ppm where most of the aliphatic 
resonances are found within proteins, with a relatively low chance of irradiating the small 
molecule contained in the sample, thus preventing artifacts. Nonetheless, blank experiments 
(spectra acquired on samples containing the sole small molecules) should always be performed 
to optimized the irradiation frequency.  
 
Figure 9. The STD NMR experiment. (a) The macromolecule (in the example shown, a protein) is 
selectively irradiated and transfers the magnetization via spin diffusion, through the NOE effect, to the 
bound ligands. The ligand which has received the magnetization goes back into solution; (b) Comparison 
between 1D 1H NMR and 1H-STD NMR spectra: though visually similar, peak intensities in the 1H 
NMR are related to the number of protons resonating at that chemical shift while, in the 1H-STD NMR 
spectrum, peak intensities are related to the vicinity of single protons to the protein. Protons closer to 
the protein give higher signals while protons which have lower interaction with the protein give 
progressively lower signals (down to no signal with non-interacting protons). 
The STD spectrum is thus the difference spectrum between off-resonance and on-resonance 
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single ligands involves the calculation of two related values, absolute and relative STD 
intensities; both values are normally given as percentages. To obtain absolute STD %, the value 
of each peak area in the STD spectrum needs to be compared with the same peak area in the 
off-resonance spectrum: for each peak, absolute STD % = (areaSTD / area0) *100; in case of 
multiple protons under the same chemical shift this number needs to be normalized. To facilitate 
comparison of protons within a single molecule, and to compare epitope maps within a series 
of structurally-related compounds, relative STD % can be subsequently calculated. Within a 
molecule, the proton with the highest absolute STD % is given the arbitrary value of 100%; the 
values of the other protons are then calculated relative to this proton. By dividing different 
ranges of relative STD % and specific codes (e.g. color or size), it is possible to give visual 
representations of these maps for quick examination.  
While within the same spectrum, higher absolute STD values are symptomatic of a higher 
affinity for the macromolecular target and this is often exploited for the screening of 
compound/fragment mixtures, it is not commonly accepted to compare absolute STD values of 
different spectra of different compounds to rank their affinity to the macromolecule. 
Nevertheless, if the solubility and stability of the tested compounds are favorable, STD NMR 
can be used, like many other biophysical techniques, for estimation of the dissociation constant 
(KD) which can be utilized for ranking.89 Compared to other techniques, NMR generally needs 
relatively high concentrations of compound and macromolecule in the aqueous environment 
utilized for an experiment, thus limited solubility and macromolecule instability/aggregation 
can represent limitations for some systems. Additionally to KD determination, STD NMR can 
also be used for competition experiments to evaluate displacement of known ligands/inhibitors 
or to confirm binding sites.90 
Regardless of the many advantages, in most cases STD NMR gives only partial information 
(only from the ligand perspective) and benefits from the coupling with either target-based NMR 
(when available) and, more commonly, with in silico approaches such as molecular dynamics 
(when X-ray crystallography data on the binding site are available). In the first case, 
complementary information about small molecule−macromolecule contacts can be compared 
to build a map of the interaction on both counterparts. In the second case, STD NMR can help 
to validate predicted binding poses.  
3.1.2 Ligand-observed NMR: Differential epitope mapping (DEEP) by STD NMR  
Very recently, a new STD-based methodology was developed by Angulo and collaborators 
called differential epitope mapping (DEEP) by STD NMR.91 While it remains a STD ligand-
based experiment with its own limitations, it can be exploited to gain additional data to the 
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simple STD experiment thanks to the application of differential conditions. Namely, it can 
identify the type of protein residues contacting the ligand through the generation of differential 
epitope maps, it can readily afford pharmacophore information on the protein, and, if the 3D 
structure of the protein is known, it helps in orienting the ligand in the binding pocket, with a 
higher precision compared to the single STD experiment. In the first article reporting this new 
method, two proofs of principle were performed on two protein−ligand systems with available 
co-crystals; the results of the two methods (DEEP STD and X-ray diffraction) were in 
agreement, showing the great potential of this new technique.91 Since then, few more papers 
exploiting this technique were published.92,93 
Two types of differential experiments can be performed and they are complementary to each 
other: a) exploitation of differential irradiation frequencies; b) utilization of differential solvent 
composition.  
a) Differential irradiation frequency: As mentioned in the previous paragraph, in an STD 
experiment, the on-resonance spectrum requires selective irradiation of the macromolecular 
target. Within a binding site, different amino acids are usually present. By performing different 
experiments (two are sufficient for this protocol) varying the irradiation frequency, we can 
obtain different STD spectra which, properly processed and plotted, can afford differential 
epitope maps. Briefly, while a proton close to the protein will in both cases have an enhanced 
STD signal, if it interacts with higher affinity with a specific type of amino acid side chain, we 
should be able to identify a difference in the two spectra showing us the different relevance of 
the irradiated residue-type on the binding of that proton to the protein.  
Clearly, while it is possible to pick the general type of amino acid to irradiate, two points must 
be raised to take into account: i) the irradiation cannot selectively be directed at the binding 
site, so all those amino acids will be irradiated. Moreover, to a certain degree, the magnetization 
can move along the protein. Nevertheless, though this could cause some aspecific components 
to emerge, a “good” ligand, orthosteric to the binding site considered, generally shows higher 
affinity for that binding site. For this reason, the population of ligands that have received the 
magnetization from one specific binding site, where the encounters have higher probability to 
occur, is generally the main component of the signal. ii) To selectively irradiate the 
macromolecule, the correct frequencies have to be picked where only the macromolecule is 
irradiated directly while the ligand is not. This is of particular importance to avoid artifacts, in 
fact, set up experiments to pick the irradiation should always include blanks – only compound 
samples. As mentioned above, for proteins, both aromatic and aliphatic regions can be 
irradiated; at the same time, these are structural features very common in small organic 
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molecules for drug discovery. The experiments can still be performed thanks to subtle shifts in 
macromolecule resonances but, as already stated, special care has to be put into irradiation 
frequency selection. 
b) Differential solvent composition: macromolecular systems, as many proteins, can generally 
only be studied within a small range of solvents which do not alter their native conformation 
motion range and in a prevalently aqueous environment very little variations are thus allowed. 
Nonetheless, it is still possible to perform a differential experiment through utilization of a 
completely deuterated water buffer and of a prevalently non-deuterated water buffer. In D2O, 
the polar side chains in the binding pocket have their exchangeable protons replaced by 
deuterium which is inefficient for transferring the saturation. On the other hand, in a prevalently 
H2O environment, these protons can contribute to an additional transfer of saturation. This 
process depends on their exchange rate with bulk water, with slowly exchanging polar protons 
producing the largest variations. For this reason, in H2O, ligand protons contacting polar 
residues show a relative increase in STD values compared to the binding epitopes in D2O. Once 
again, acquiring the spectra in both conditions can afford us differential epitope maps, very 
useful to correctly place the ligands in the binding site confirming in silico poses. This approach 
can thus give complementary results to the previous by highlight the influence of polar residues.  
 
Figure 10. Graphic representation of the two protocols of DEEP-STD NMR. Differential Solvent 
composition (D2O vs H2O) can highlight ligand interactions with polar amino acid residues in the 
binding site. Differential irradiation frequencies can show interactions of the small molecule with amino 
acids with different structural features (e.g. aromatic vs aliphatic) (Adapted from Monaco et al., 2017)91 
Correct processing of the spectra is key to obtaining valuable information about the 
macromolecule–small molecule interaction. Briefly, after acquisition of the two spectra at the 
two different conditions to be compared, absolute STD percentages should be calculated for 

















To obtain a consistent scale of ΔSTDi factors, exp1 should always be the experiment which 
shows larger total ligand saturation. The highlighted section of the equation represents the 
intrinsic differences in saturation levels under different conditions. For this reason, contrary to 
STD intensities which are always positive numbers or 0, in DEEP STD processing, values can 
be positive and negative, as well as numbers close to 0. Positive values indicate higher influence 
of the exp1 conditions, while negative values imply higher impact of the exp2 conditions on a 
determined proton. Finally, the protons showing low variation due to exp conditions will give 
values in a range around zero; during processing, it is quite important to define a cut-off of 
statistical significance for these values. The DEEP epitope maps can be built similarly to STD 
epitope maps with color and size codes identifying the different type of amino acid residue 
interacting with each interacting proton and thus improving the predicted placement of the 
ligand inside the binding site.  
3.2 Other biophysical approaches 
Biophysical techniques are of great importance to study small-molecule ligand interactions, 
from the screening of libraries to select hits, to their validation from both structural (binding 
mode) and energetic (binding affinity) stand-points. Though this PhD thesis mainly relies on 
ligand-observed NMR techniques for studying ligand–protein interactions, due to their highly 
informative nature, these also present some limitations. Applying a combination of different 
methods is often considered to produce the best chance for leading a robust and effective 
identification of high-quality starting points for medicinal chemistry campaigns for both drug 
discovery and development. For this reason, other methods were considered in different steps 
of this thesis. The following paragraphs will present surface plasmon resonance (SPR) and 
differential scanning fluorimetry or thermal shift assay (DSF, TSA). A brief comparison of their 
main features with NMR techniques (discussed in the previous paragraph), and other additional 
methods, isothermal titration calorimetry and protein X-ray crystallography, is also reported in 
tables 2 and 3 to provide a quick yet detailed panoramic view over the characteristics, 
advantages and disadvantages of some of the most informative techniques available. 
  
ΔSTDi = differential STD value
exp1 and 2 = two different experimental conditions
i= each proton











DSF (TSA) High Medium Up to 5 mM – 
NMR Medium Medium Low nM–10 mM Good 
ITC Low High Low nM–5 mM (Limited to 
competition) 




Low Medium Up to ligand 
solubility 
Excellent  
Table 2. Summary of parameters of different biophysical techniques utilized for small molecule 
screening and interaction studies with macromolecular targets (adapted from Ciulli, 2013).80 
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Technique Advantages Disadvantages 
DSF (TSA) § High throughput 
§ Applicable to most target 
proteins 
§ Direct binding assay 
§ Prone to false positives and 
negatives 
§ High material consumption 
§ Across-plate variability 
ligand-observed NMR  
 
§ Medium throughput 
§ Applicable to most target 
proteins (> 10 kDa) 
§ Provides quality control 
§ Prone to false positives 




§ Intermediate throughput 
§ Can identify binding site 
(need peak assignment) 
§ Can measure KD from 
ligand titrations 
§ Limited to small (< 30 kDa) 
and soluble target proteins 
§ Requires 15N-labelling of 
target proteins 
§ High material consumption 
ITC § Direct/competition 
binding assays 
§ Applicable to most target 
proteins 
§ High information content 
(KD, ΔH, ΔS and n) 
§ Low throughput 
§ High material consumption 
§ Requires large heat changes 
upon binding for reliable 
measurements 
SPR § Label-free detection and 
ease of automation 




§ Low material 
consumption 
§ High information content 
(KD, kon, koff and n) 
§ Requires immobilization of 
macromolecular target  
§ Possible artifacts due to 




X-ray crystallography § Intermediate throughput 
§ Can rapidly identify 
binding site and binding 
modes 
§ Can directly identify 
conformational changes 
§ Limited to soluble target 
proteins that can be 
crystallized 
§ Requires expensive X-ray 
sources (in-house, access to 
synchrotrons) 
§ Crystal packing may occlude 
binding site 
§ High occupancy of the 
ligand binding site required  
Table 3. Summary of relative advantages and disadvantages of different biophysical techniques with 
regard to small molecule screening, validation, and characterization of the binding to macromolecular 
targets (adapted from Ciulli, 2013).80 
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3.2.1  Surface Plasmon Resonance 
Surface plasmon resonance (SPR) is an optical technique based on the transfer of energy to 
electrons in a thin layer of metal in contact with a solution. In the standard SPR set up, a beam 
of polarized monochromatic light is shone through a prism at a thin-layer of gold coating one 
surface of the prism. The light is then reflected at the gold-coated surface, but, since it is not 
reflected precisely at the prism-gold junction, its electromagnetic field penetrates into and 
beyond the gold for a certain distance (formation of the evanescent wave). At a specific angle 
of incidence, the electrons in the gold absorb some of the light exciting charged density waves 
or “surface plasmons” which propagate along the metal surface. At a resonance condition where 
transfer of momentum matches that of the plasmons i.e., at a specific incident angle, the 
intensity of the reflected light is significantly decreased. Since the evanescent wave extends 
only ~100–200 nm into the solution (after which it decays quickly) if the gold layer is 
sufficiently thin, the resonance condition/angle is dependent on the refractive index of the 
adjacent medium. For this reason, SPR is highly sensitive to changes in the environment at the 
interface between gold and aqueous flowing medium; a change in the refraction index at the 
surface of the sensor (due to interactions occurring near the surface) can be monitored as a shift 
in the resonance angle.80,94,95  
A typical SPR setup involves a “chip” composed by a glass surface coated by a thin layer of 
gold; the solution side of the gold film is functionalized with a dextran matrix (covalently 
attached through a linker layer) to allow immobilization of target molecules (usually called 
ligands in SPR experiments) such as proteins (see Figure 11 a). Immobilization of the protein 
to the sensor surface is required and is of primary importance to the design of a successful 
assay; several immobilizations can be considered depending on the studied target to obtain a 
highly stable association and prevent signal drift.96,97  
As mentioned above, when an analyte (the ligand studied) in solution binds to the protein, the 
refractive index near the surface changes and an SPR shift is detected, which can be monitored 
in real time producing a “sensogram”. A schematic representation of sensogram is shown in 
Figure 11 b where signal increases until the protein binding sites are saturated (equilibrium), 
and successively only buffer is flowed over the chip progressively removing the interacting 
analyte. Due to the dependence of the refractive index, and thus the SPR signal to the mass 
bound at the surface, it is possible to measure the thermodynamic and kinetic parameters of the 
interaction. 
  




Figure 11. (a) A typical SPR biosensor setup. The glass of the sensor chip is coated with a thin layer of 
gold, a dextran matrix is attached via a linker layer to the gold and receptors are cross-linked to the 
dextran. An incident light is directed onto a SPR sensor chip via a prism, and the reflected beam is 
detected via a photodetector or imager. At an appropriate angle (resonance angle), the incident light 
excites the surface plasmons in the sensor chip (metal film) and the intensity of the reflected light drops 
to a minimum. The electromagnetic field produced penetrates the medium and probes molecular binding 
processes taking place on the surface: changes in the refractive index of the flowing medium are 
observed that are proportional to the amount of material bound. A plot of resonance signal vs time, the 
sensogram (b), can be monitored in real time (adapted from http://biosensingusa.com, 2019). 
Both the on-rate and off-rate constants of the binding process can be determined and their ratio 
gives an accurate estimate of affinity. Generally, the latter can also be evaluated through 
injection of a range of analyte concentrations producing different sensorgrams, and affinity can 
be determined from the ligand concentration dependence of the response at equilibrium of the 
ligand-complex formation. SPR is now an established method for primary fragment98–100 and 
small molecule library screening in addition to it exploitation for studying several binding 
events (i.e., protein–protein interactions)94,101,102 thanks to its experimental versatility, 
customization of chip matrixes and immobilization strategies available. 
3.2.2 Thermal Shift Assay 
Since its first description in 2001,103 differential scanning fluorimetry or thermal shift assay 
(DSF, TSA, also found as thermofluor) has been used increasingly for drug discovery. In this 
methodology, proteins are incubated with a fluorescent dye which binds specifically to 
hydrophobic sites; when this binding occurs, a progressive change in the dye fluorescence can 
be recorded. When a protein undergoes a thermal cycle (heating), it gradually exposes its 
hydrophobic parts due to temperature-dependent unfolding. The dye will consequently bind to 
a growing number of hydrophobic regions of the protein; monitoring the change in fluorescence 
against the rising temperature gives characteristic traces (see Figure 12) allowing to determine 
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proteins exist in thermodynamic equilibrium between several different conformational states; 
upon interaction with a ligand the populations of these states can be altered. If we consider a 
two-state system with a folded (native) and an unfolded (denatured) state, the population of the 
unfolded state will grow with increasing temperature. Binding of a small-molecule to a 
structurally defined site of the native state of a protein can stabilize it, increasing the population 
of the protein native state during a thermal cycle, producing a shift in the protein Tm to higher 
values. By comparing Tm measurements, in the presence and absence of a small molecule, it is 
possible to determine protein–ligand binding. Similarly, TSA can be applied to determine 
optimal experimental conditions for protein stability (i.e., type of buffer, pH, ionic strength, 
DMSO percentage, and so on).104–106 
This experiment can be carried out in small volumes in any commercial quantitative PCR 
instrument, using different formats (48, 96 or 384-well plates). Given the length of the 
experiments (1–2 hours), this method can afford high throughput analyses.107,108 A plot of 
fluorescence signal against temperature should give a sigmoidal plot (see Figure 12 a). The 
melting temperature is determined by the point of inflection of this curve. This can most easily 
be assessed by plotting the derivative of the fluorescent signal against temperature (see Figure 
12 b). Though this method is mainly utilized for primary ligand screenings, it also has the 
potential for KD determination, by preparing wells with ranges of ligand concentration, and, 
thanks to advances in related software, these measurements can now be performed with 
increased ease and reliability.107 
 
Figure 12. Differential melting behavior of a protein and a protein–ligand complex by fluorescence. The 
solid line identifies the protein melting curve and dashed line that of the protein–ligand complex. a) TSA 
trace of a interaction study. b) Derivative of the fluorescent signal plotted against temperature. The 
minimum of the derivative plot (corresponding to the inflection point of the F vs T plot) allows a more 
convenient identification of the melting temperatures Tm, necessary for the measurement of the thermal 
shift ΔTm (adapted from Ciulli et al., 2008).109 
a) b)
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3.3 In silico methodologies: Docking and Molecular Dynamics 
As stressed in previous chapters, the binding of small molecule ligands to macromolecular 
targets is central to numerous biological processes and the accurate prediction of the binding 
modes between the ligand and target, is of great importance for the study of these mechanisms, 
for the rationalization of biophysical studies and for related drug design. The number of 
algorithms available for assessing and rationalizing ligand–target interactions is large and ever 
increasing. Though several do share common methodologies, their diversity in both complexity 
and computational speed has afforded a range of techniques to solve modern structural 
puzzles.110 Assuming the structure of the target macromolecule is available, a primary challenge 
is to predict both ligand orientation and binding affinity, generally referred to as molecular 
docking. Molecular docking aims at computationally simulating the molecular recognition 
process; it has been commonly described as a “lock-and-key” model, as we want to find the 
correct relative orientation of the “key” (ligand) which will open up the “lock” (target 
macromolecule) finding out where the key hole is, how to turn the key inside the hole, and so 
on. Nonetheless, since both ligand and macromolecular target are flexible, a “hand-in-glove” 
analogy might be more fitting than “lock-and-key”.111  
During the interaction, both ligand and macromolecule adjust their conformation; in fact, the 
atoms in a biomolecule are in constant motion and both molecular function and intermolecular 
interactions are correlated to the dynamics of the molecules involved. Rather than studying just 
a static snapshot, the ideal observation should consider these biomolecules in action, to perturb 
them at the atomic level, and to see how they respond. Since this would be rather difficult and 
time-consuming, an attractive alternative is to work with an atomic-level computer simulation 
of the target macromolecules under study.112 In this context, molecular dynamics (MD) 
simulations can come in play, as the can predict how every atom in a protein or other 
macromolecular system will move based on a general model of the physics involved in 
interatomic interactions.113 Exploiting these simulations we can capture a large variety of 
important biomolecular processes, including conformational change, ligand binding, and 
protein folding as a function of time.114 MD simulations are often used in combination with a 
wide variety of experimental structural biology techniques, including X-ray crystallography, 
cryogenic electron microscopy (cryo-EM), and NMR.112  
3.4  Drug Discovery Strategies 
One of the main steps in the search for small-molecule drugs is to identify one or more new 
chemical leads, molecules whose good potency in biological assays reflects the targeted 
mechanism. Leads are also characterized by other chemical, physical and biological properties 
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important for drugs and drug-like molecules (i.e., favorable absorption, distribution and 
metabolism profile, ADMET).  
A number of medicinal chemistry approaches can be used to identify hits, generate leads, as 
well as to accelerate the development of high quality drug candidates,115 such as modification 
of an existing lead or drug, a natural product or an endogenous ligand, and structure-based and 
fragment-based approaches. 
In the following paragraphs, the approaches utilized for the generation of HuR ligands will be 
described. 
3.4.1 Structure-based ligand design 
By understanding the structural and chemical binding features of drug targets pivotal in 
biologically relevant pathways, we can design small molecules able to modulate specific target 
functions closely connected to human diseases and dysfunction.116–118 Identifying these 
promising hits to develop and optimize is a major challenge faced for researchers and although 
the trial and error nature is intrinsic in drug research, rationalization and in silico methodologies 
are widely exploited in this field. In this context, Structure-Based Drug Design (SBDD) is a 
well-established, positively successful strategy based on three-dimensional (3D) protein 
structure information to develop new active molecules.119–121 Understanding of the spatial and 
energetic aspects of protein ligand interactions is crucial for structure-based studies; assuming 
the shape and chemical nature of the binding site of the target and the possible interactions 
between ligands and the protein have been identified, this information can be directly employed 
to identify new ligands or optimize lead compounds. The aim is to boost the search for lead 
molecules at the same time limiting the number of compounds to be evaluated experimentally. 
Hits can be identified by docking small molecule ligands (i.e., from databases) into protein 
binding sites or by using target-based pharmacophore models. Moreover, potential drug 
candidates can be designed de novo by improving the complementary properties of lead 
compounds and the respective target. The target-based approach can, in principle, be carried 
out iteratively, through multiple computational and experimental steps until an optimized lead 
compound with high affinity, selectivity, and optimized pharmacokinetic properties is 
developed. 
3.4.2  Fragment-based ligand design 
Fragment-based drug discovery (FBDD) is a relatively recent approach, emerged as an 
alternative to HTS,122,123 increasingly used in medicinal research, for reducing attrition and 
providing leads for challenging biological targets. FBDD identifies low-molecular-weight 
ligands (~150 Da) which can bind to biologically relevant macromolecules. Compared with 
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HTS, the fragment-based approach requires fewer compounds to be screened, and, despite the 
lower initial potency of the screening hits, it can offer more efficient optimization campaigns.115 
In FBDD, fragment libraries are typically screened using a series of progressively more 
restrictive biophysical techniques. The fragments are between 150–250 Da MW and a general 
unfocused fragment library will be chosen to contain a diverse set of chemical scaffolds and 
functionalities that are well precedented in drugs.122 The experimental binding mode of 
fragment hits is usually established in the protein target of interest, the 3D experimental binding 
mode of these fragments can be determined using X‑ray crystallography or NMR spectroscopy, 
and used to facilitate their optimization into potent molecules with druglike properties. 
Fragments are grown to form new interactions using structure-based drug design. Fragment 
linking can also be used if different fragments are observed to bind to proximal sites in the 
protein. Although initial fragment hits have low potency due to their small size, they form high-
quality interactions and can be readily optimized into potent lead molecules.115 Regardless of 
the initial skepticism, more than ten FBDD leads targeting different protein families involved 
in diverse diseases have made it into clinical trials (see references123,124 for examples). The 
fragment approach has been enthusiastically taken up in different areas of drug discovery 
research (academia, large pharma and biotech companies) and a number of rule-of-three-
compliant125 fragment libraries are now commercially available. 
 
Figure 13. Schematic representation of the fragment-based ligand design approach (adapted from 
Murray et al., 2009).115 
3.4.3 Multi-component Reactions 
Multicomponent reactions (MCRs) are chemical transformations in which three or more 
reactants form a product whose structure derives all of the components added.126 Although 
‘cascade’, ‘domino’ and ‘one-pot’ processes are generally included in MCRs, a more specific 
definition can help to understand the main differences and advantages. Performing successive 
reactions in a vessel can be an efficient way to access molecular diversity, but a carrying out a 
series of ‘two-component’ reactions following a specific order of addition is radically different 
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Figure 14. Schematic comparison of multi-step versus multi-component synthesis. 
MCRs have been known for over a century, and although it may be hard to pinpoint the first 
example of an MCR, the Hantzsch dihydropyridine synthesis was reported in 1882,130 followed 
by the Biginelli 3CR in 1893.131 The first isocyanide-based MCRs were described by Passerini 
(3CR)132 and Ugi (4CR)133 in 1921 and 1959. Subsequently, several variations of the Passerini 
and Ugi reactions based on the unique reactivity of isonitriles have been described;129 the 
interest in MCRs grew in the early 1990s contextually with the development of combinatorial 
chemistry and the establishment of academic HTS.134,135 MCRs fill a unique niche in the 
synthesis of libraries and the complex follow-up associated with drug development or 
optimization of selective pharmacological tools, with several advantages over conventional 
synthesis.128 First of all, MCRs can afford a high number of compounds with small synthetic 
effort; for example, a 3CR could provide 1000 products when 10 variants of each component 
are combined. Secondly, MCRs can provide an intrinsic SAR information within a single 
library by providing sets of compounds with related core structures. Finally, MCR library hits 
could represent a starting point for follow-up allowing for rapid preparation of ‘focused’ 
libraries. On the other hand, the use of MCRs carries the potential issue of having over-
represented core-structures within a library; the diversity of a MCR library can be limited by 
the structure of the components. Nonetheless, this liability can be addressed by applying new 
variants of traditional MCRs that result in fundamentally different structures, as well as by using 
MCRs as a starting point for subsequent reactions, thus achieving efficiency and diversity.128 
3.4.4  Dynamic Combinatorial Chemistry 
Dynamic combinatorial chemistry (DCC) is a powerful tool for the identification of bioactive 
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obtain dynamic combinatorial libraries (DCLs) composed by interchanging products.136–139 
Since the reaction between building blocks is reversible, the product distribution is determined 
by the thermodynamic stability of the compounds formed; a DCL is thus responsive to external 
stimuli such as the addition of a target. DCL members binding the target with the strongest 
affinity are subtracted from the equilibrium, causing a re-equilibration of the library (see Figure 
15).137 Ultimately, this leads to amplification of the best binders, which can be directly 
identified from the mixture, avoiding the synthesis, purification and characterization of each 
individual library member.  
From an operational point of view, several important factors should be considered, including 
biocompatibility, pH dependence, temperature, solubility and stability of the components.140 
This is especially important to avoid artifacts, deriving, for example, from events such as 
precipitation of the protein or DCL members leading to false negatives or positives due to 
undesired shifts in the equilibrium. Additionally, to obtain meaningful results from DCC 
experiments, the protein sample should represent its native state.141–143 For these reasons, 
experimental conditions, including type of buffer, pH, ionic strength, protein concentration and 
DMSO content should be determined prior to performing DCC experiments. 
 
Figure 15. The principle of protein-templated DCC. A member of the DCL that interacts with the 
protein, will be amplified compared to the other members. The amplification can be monitored by an 
appropriate biophysical technique such as HPLC-UV. The product formed can be identified univocally 
with the coupling of the HPLC-UV system with a MS detector. 
The effect of the buffer components on a protein can be measured in a straightforward way, by 
determining the melting point of the target protein, via a thermal-shift assay/differential 
scanning fluorimetry (TSA/DSF), and following its behavior over a range of time compatible 
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titration calorimetry (ITC) and circular dichroism spectroscopy (CD) could also be used to gain 
information on the buffer-related interactions and possible stabilization of the protein, but they 
require a high amount of protein and/or long measurement time; SDS-PAGE (Sodium Dodecyl 
Sulphate-PolyAcrylamide Gel Electrophoresis) can only be used to check for cleavage of the 
protein backbone. For enzymatic targets, a functional assay can be used instead of TSA and 
PAGE measurements for the assessment of long-term protein stability; given its univocal 
evaluation of the enzyme catalytic activity, if available, this should be the method of choice.140 
To date, only a limited number of reversible reactions have been used.140 One of the most 
frequently used is the formation of acylhydrazones combining carbonyl (ketone or aldehyde) 
building blocks with acylhydrazides, as it can take place in water, and is thus biocompatible;145 
additionally, the preparation of the related building blocks is generally straightforward and 
many are commercially available. Acylhydrazone formation and exchange also depend on the 
buffer, more specifically on the pH, and at physiological conditions, neutral pH and room 
temperature, they are relatively slow, while at acidic pH, the equilibrium is reached quickly. 
This does not pose a conflict with the conditions required by the protein, as, if necessary, the 
pH-dependence can be influenced by adding a nucleophilic catalyst (i.e., aniline and 
derivatives).146,147 
To allow a comparative analysis of DCLs, the protein-templated DCC and a blank reaction 
(building blocks of the DCL without the protein), should be run in parallel. The reaction 
mixtures can then be “frozen”, to avoid possible shifts in the library equilibrium at the time of 
the analysis; focusing on acylhydrazone chemistry, this can be achieved by increasing the pH. 
Denaturation of the protein (by heat, addition of a solvent or ultracentrifugation) releases all 
binders protein before analysis.140 Different techniques could be used to evaluate the samples 
to identify hits: a commonly applied method to analyze DCC experiments is HPLC-UV-MS. A 
proper chromatographic method can in fact separate the formed products from each other (as 
well as possible residual unreacted building blocks), while a MS-detector can help to univocally 
identify the formed products based on their exact mass. Finally, integration of UV peaks allows 
to accurately compare peak areas for the same products in blank and protein-templated reaction 
to detect amplification and identify hit compounds (see figure 17).  
Protein-templated DCC thus offers an efficient and powerful approach for the acceleration of 
the identification and optimization of novel ligands for biological targets, and therefore holds a 
great potential for drug discovery combining synthesis of ligands and screening for affinity for 
the drug target in a single operation where the target selects its own ligands.139,148–151 
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3.4.5 Microwave-assisted procedures 
To accelerate reactions, in the conventional one-molecule-at-a-time synthesis, as well as in 
combinatorial chemistry and multi-component reactions, heating is undoubtedly the most 
common practice. Yet, since some organic compounds are unstable at high temperatures, heat 
can lead to a number of issues; excessive heating might cause the formation of side products 
and need for further purification along with affected yields. In this context, Microwave-Assisted 
Organic Synthesis (MAOS),152 together with other applications of microwaves (e.g. 
Microwave-Assisted Extraction, MAE),153 has gained growing interest in the process of Drug 
Discovery, for both lead generation and optimization, due to its many interesting features, 
including faster chemistry (ability to reduce reaction times from days or hours to minutes), 
greater versatility and formation of cleaner products, compared to conventional synthetic 
methods, eventually potentially speeding the whole drug discovery process. In addition, the 
implementation of techniques combining microwave-assisted strategies with other high-
performing approaches such as combinatorial chemistry, together with the optimization of 
associated instrumentation and procedures, has opened the way to the use of microwaves in 
even more effective applications. In the field of Drug Discovery, several microwave-assisted 
techniques are currently used with manifold applications not limited to organic synthesis related 
areas. Microwave-enhanced technologies are also used in target discovery, pharmacognosy, 
screening, pharmacokinetics and even in the clinic.152–156 Microwave heating differs from 
conventional heating in several ways. First of all, the energy is only transferred directly to those 
components that are susceptible to microwave polarization. This improves energy efficiency, 
decreasing the need to heat vessels or the heating apparatus itself; it allows the energy to be 
directed into specific parts of the reactive system such as metal particles, or susceptible solid 
supports, reducing in some cases the need for solvents, with obvious economic and 
environmental benefits. Secondly, through direct heating it is possible to raise the sample 
temperature much faster compared to conventional methods, frequently leading to quite 
different kinetics.157,158  
Within this thesis, the exploitation of microwave heating in the process of discovering new HuR 
ligands was considered from the beginning for both MAOS and MAE applications. 
Nonetheless, given the preliminary stage of the topic, though microwaves were indeed 
exploited for some synthesis and extraction procedures, a thorough and systematic study of the 
possible advantages of microwave-enhanced procedures was finally not carried out within the 
main topic of the thesis. The research done in preparation was exploited to write the book 
chapter “The use of microwaves in drug discovery” (see appendix IV, book chapter). Two MAE 
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applications, performed during a research period in the context of drug discovery from plants, 
are described in the two articles “(R)-(-)-Aloesaponol III Methyl Ether from Eremurus persicus: 
A Novel Compound against Leishmaniosis” (see appendix IV, article 3) and “The use of a 
microwave assisted solvent extraction coupled with HPLC-UV/PAD to assess the quality of 
Marrubium Vulgare L. (white horehound) herbal raw material” (see appendix IV, article 4). 
 
Nevertheless, it is quite interesting to consider the possibility to apply microwaves to some of 
the reactions performed in this thesis, especially considering that microwave-assisted 
combinatorial synthesis (MICROCOS) and microwave-assisted high speed parallel synthesis 
can often find successful applications in the field of multi-component reactions (described in 
paragraph 3.4.3).152 In fact, by combining multiple starting materials with different moieties, 
these can lead to a high efficient and “greener” formation of multifunctional/complex target 
compounds;159 thus coupling MCRs with microwave techniques further increases the 
advantages of the multi-component method, creating molecular diversity with quicker one-step 
procedures that oppose the commonly costly and time-consuming traditional drug discovery 
process.152,159 The most interesting applications found in literature, so far involve Hantzsch, 
Biginelli and Ugi reactions,160–162 but the continuous evolution of research can grant us a 
growing number of applications.
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4.  Exploration of HuR−ligand binding modes 
The present chapter represents the application of the first systematic medicinal chemistry 
approach towards a rational identification of compounds able to interfere with HuR−RNA 
complexes. In particular, we set out to study the interaction between HuR and a small series of 
compounds, all natural products including known HuR/ELAV−RNA interferers and 
derivatives, namely flavonoids, coumarins and structurally-related (see figure 16); the 
compounds subjected to the study were selected according to their structural features, solubility 
and stability in water-based buffers, with the aim to explore the chemical space around the 
structures of literature-reported ELAV–RNA interferers (see figure 5, paragraph 1.3). To 
achieve our goal, we applied ligand-based NMR technique STD NMR, which can be employed 
to investigate weak and transient protein–ligand complexes that are difficult to study by other 
structural methods (see paragraph 3.1.1). The epitope maps identified for each ligand, were 
compared with molecular dynamics and docking simulations, thus affording an improved 
understanding of ligand–HuR interactions. In particular, molecular dynamics simulations were 
necessary to reproduce the protein high mobility and flexibility, allowing us to study the 
possible conformational rearrangements occurring upon binding to HuR, according to results 
previously reported by Wang et al., 201375 (see paragraph 1.4.1).  All compounds which 
experimentally showed direct binding to HuR (1–12) were predicted to bind in the same pocket-
like region within the RRM1/2 region of HuR, in its closed conformation, identifying repeated 
residues in the interaction site and showing, in some cases, similar or overlapping binding 
modes for some moieties, when superimposed. The same was not found for compound 13; in 
fact, in accordance with the experimental data, in silico simulations could only place the 
structure outside of the cavity, where only superficial contacts are available (see figure 17). 
Similar results are found for open or closed conformation of HuR, though a slightly higher 
number of contacts could be established between 13 and open HuR; this could rationalize the 
absence of direct binding observed with the target protein, as it is hypothesized that active 
compounds should be able to stabilize a closed conformation of the protein.163 Additionally, the 
results for all interacting compounds where analyzed within structural class (flavan-3-ols, 
flavonols, flavones, coumarins and structurally-unrelated, see figure 16), allowing us to 
elucidate how different substitutions on the same or a similar flavonoid-like core produce not 








Figure 16. Structures, common names and epitope maps of all compounds submitted to the study with 
HuR. Relative STD percentages are conveyed by color code: black dots indicate the most intense signal 
(100% relative STD), dark red dots over 80%, orange dots over 40%, and lime green dots under 40% 
relative to the most intense STD signal. No epitope map is reported for Asiaticoside (13), for which we 
could not observe any direct binding with HuR. (Adapted from Vasile et al., 2018, see appendix III, 
article 1). 
Thus, the combination of NMR and in silico studies of the interaction process proved to be a 
reliable tool for understanding HuR–ligand binding modes and their exploitation laid the 
foundation for the design of ad hoc molecules acting as HuR ligands, potentially able to 






























































































1, Epigallocatechin gallate 2, Epicatechin 3, Catechin
4, Hyperoside 5, Rutin 6, Vitexin Rhamnoside 7, Isovitexin
8, Aesculin 9, Novobiocin







Figure 17. left side: 3D representation of HuR RRM1 and RRM2 domain-RNAc-fos complex in its 
“closed” conformation; right side: superimposition of all studied compounds in the “closed” 
conformation of the HuR–RNA interaction site. HuR RRM1/2 and RNAc-fos are represented as light-
orange and bright-orange cartoon, respectively; all compounds are depicted as green sticks. All 
interacting compounds are predicted to bind within the same pocket-like region, while the structure of 
compound 13 is clearly laying on the outer side of the protein, establishing only superficial contacts. 
(Adapted from Vasile et al., 2018, see appendix III, article 1). 
The full work is reported in the form of a published article: “Exploration of ligand binding 
modes towards the identification of compounds targeting HuR: a combined STD NMR and 
Molecular Modelling approach”, Scientific Reports, 2018 (see appendix III, article 1). 
A recent follow up to this research, reported in paragraph 4.1, consists in the setup of newly 
reported DEEP-STD NMR methodology (see paragraph 3.1.2) on selected natural products (5, 
8 and 9, rutin, aesculin and novobiocin). While traditional STD NMR approaches can gain only 
partial information, this new methodology91 can provide a more detailed picture of the small 
molecule−HuR interaction thanks to the development of differential epitope maps which add 







4.1 Set up and application of differential epitope mapping (DEEP) by STD NMR on 
selected natural products: 5, 8 and 9 (rutin, aesculin and novobiocin) 
The still current lack of experimental data concerning a small molecule binding site on HuR 
finds its causes in the absence of both small molecule-HuR co-crystals and the issues in 
applying protein-observed NMR encountered so far by other groups i.e. low solubility of small 
molecule inhibitors.163,164 Though it can be argued that traditional STD NMR approaches can 
grant only partial information, new STD-based methodology DEEP-STD NMR91 can help to 
fill some gaps by generating differential epitope maps which can aid the validation of predicted 
binding poses by adding information on the nature of the amino acids involved in the binding 
event (additional details on the technique are described in paragraph 3.1.2). This rather new 
methodology, is to be included in the systematic approach exploited for the study of small 
molecule-HuR interactions, especially for the study of novel synthetic compounds with still 
completely unreported profiles. The setup of the methodology was performed on the native 
protein, exploited for the studies so far described in the present thesis, and three selected natural 
products of the previous paragraph, 5, 8 and 9. These three compounds were chosen based on 
their structures including quite diverse moieties and substituents (aromatic, aliphatic, polar) 
with the idea that such widespread substitution could afford interactions with different types of 
amino acids, detected by DEEP-STD. Given the high aromaticity of the compounds studied, 
and the presence of additives in the native protein samples (necessary to insure protein stability 
and integrity), a differential frequency approach was avoided in order to reduce the possibility 
of artifacts (coming in this case from aspecific irradiation); in fact, only a differential solvent 
approach could be so far applied in this system. Nonetheless, given the recently introduced 
possibility to perform experiments on different protein constructs (see Chapter 7), characterized 
by different stability and solubility, more complete studies might be performed in the future 
pending optimization and readjustment of the experimental conditions. 
All experiments reported in this section were thus performed applying an irradiation frequency 
of -30 Hz (-0.05 ppm); differential solvent conditions were obtained by measuring the samples 
in 100% D2O and H2O:D2O 90:10. The next paragraphs describe and discuss the results divided 
by compound.  
Rutin (5) DEEP-STD data were analyzed according to the equation shown in paragraph 3.1.2: 
since in D2O the global saturation was larger than in H2O, we set it as exp1; thus, positive DSTD 
factors would identify ligand protons with a relative increase in STD intensities in D2O, 






a relative decrease in STD intensities in D2O to indicate that they are adjacent to slow 
exchanging protons and, consequently, polar residues. By calculating the ratio and the average 
ratio of STD intensities over all protons as well as their DEEP-STD factor (data reported in 
table 4) we observed several DSTD factors, confirming the ligand binding epitope map changes 
in the two different solvents (see figure 18 for graphic representation). Positive DSTD factors 
were found for proton 2’, 6’ and 6, while negative DSTD factors for proton 1’’’ and 6’’’. 
Different protons of 5 thus seem to occupy distinct areas of HuR binding pocket lined by either 
apolar or polar protons (differential epitope map shown in figure 18). The DEEP-STD results 
are in agreement with the docking pose of the complex between rutin and HuR (see figure 18), 
where the ligand sits between apolar and polar patches in the protein binding pocket. In 
particular, the ligand protons 2’, 6’ and 6 point towards apolar residues (Ile23 and Ile133), while 
1’’’ and 6’’’ are positioned near polar residues (Arg97, Ser99 and Lys104). To interpret the 
outcomes from the DEEP-STD NMR experiment, only the strongest DSTD were considered; 
we experimentally determined that DSTD greater than 0.4 in magnitude are significant (the 
threshold always depends on the STD values of the protein–ligand system under study and can 
be determined from the standard deviation).  




2’ 0.78 0.21 3.71 1.36 
6’ 0.77 0.24 3.21 0.86 
5’ 0.48 0.23 2.09 -0.26 
8 0.60 0.25 2.4 0.05 
6 1.03 0.30 3.43 1.08 
1’’’ 0.27 0.21 1.29 -1.06 
6’’ 0.25 - - - 
6’’’ 0.68 2.12 0.32 -2.03 





Table 4. Raw and processed data of the differential solvent (D2O/H2O) DEEP-STD NMR experiment of 







Figure 18. Graphic representation of the DEEP experiment of the 5–HuR complex. (a) DSTD histogram: 
significant negative DSTD factor (< -0.4) are shown in blue, while significant positive DSTD factors ( 
> 0.4) in orange; (b) DEEP mapping of the ligand. Blue surfaces indicate ligand contacts with protein 
side chains carrying slowly exchanging protons; orange surfaces indicate ligand contacts with apolar 
residues. (c) Docking pose of the complex (only residues relevant to the DEEP mapping are shown). 
Aesculin (8) For compound 8, DSTDs calculated as described for 5 (data and graphic 
representation shown in table 5 and figure 19). Protons 4 and 5 show negative DSTD values, 
indicating that they are near to polar residues, while proton 8 display positive DSTD value, 
denoting that it looks towards apolar residues. This is in agreement with the docking pose of 
the complex, in which protons 4 and 5 sit between Arg97 and Arg153, and proton 8 is in 
proximity of Ile133 (see figure 19). 
Proton STD% D2O STD% H2O 
Ratio STD 
D2O / H2O 
DSTD 
4 0.50 0.30 1.67 -0.60 
5 0.26 0.16 1.62 -0.65 
8 0.99 0.26 3.80 1.53 








Table 5. Raw and processed data of the differential solvent (D2O/H2O) DEEP-STD NMR experiment of 
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(a) DEEP-STD factor, ΔSTD (D2O/H2O)







Figure 19. Graphic representation of the DEEP experiment of the 8–HuR complex. (a) DSTD histogram: 
significant negative DSTD factor (< -0.4) are shown in blue, while significant positive DSTD factors ( 
> 0.4) in orange; (b) DEEP mapping of the ligand. Blue surfaces indicate ligand contacts with protein 
side chains carrying slowly exchanging protons; orange surfaces indicate ligand contacts with apolar 
residues. (c) Docking pose of the complex (only residues relevant to the DEEP mapping are shown). 
Novobiocin (9) The experiment performed for compound 9 produced negligible DSTD factors 
for several protons indicating that the change of the solvent did not significantly affect them. 
Conversely, the methyl group in position 6 of the noviose moiety shows a great interaction with 
exchangeable protons, probably due to the presence of Lys55, Ser99, Ser100 and Lys104 as 
evidenced from docking studies (see figure 20). On the other hand, the methyl groups in 
position 17 and 18 show interactions with hydrophobic residues that, from docking studies, 










4 5 8 3
(a) DEEP-STD factor, ΔSTD (D2O/H2O)






Proton STD% D2O STD% H2O 
Ratio STD 
D2O / H2O 
DSTD 
6 1.10 - - - 
14 1.29 -   
1’ 0.81 0.64 1.27 -0.08 
4’ 1.60 - - - 
2’ 1.03 - - - 
OCH3 0.66 0.44 1.5 0.15 
15 0.70 0.45 1.56 0.21 
9 1.13 0.69 1.64 0.29 
17 - 18 0.96 0.52 1.85 0.5 
6’a 1.31 1.02 1.28 -0.07 
6’b 0.90 2.53 0.36 -0.99 





Table 6. Raw and processed data of the differential solvent (D2O/H2O) DEEP-STD NMR experiment of 
the 9–HuR complex. 
 
Figure 20. Graphic representation of the DEEP experiment of the 9–HuR complex. (a) DSTD histogram: 
significant negative DSTD factor (< -0.4) are shown in blue, while significant positive DSTD factors ( 
> 0.4) in orange; (b) DEEP mapping of the ligand. Blue surfaces indicate ligand contacts with protein 
side chains carrying slowly exchanging protons; orange surfaces indicate ligand contacts with apolar 
residues. (c) Docking pose of the complex (only residues relevant to the DEEP mapping are shown). 
  
(a) DEEP-STD factor, ΔSTD (D2O/H2O)






Based on the data so far available to us, following initial setup, the DEEP-STD experiment with 
differential solvent conditions seems to be a valid method to study the HuR–small molecule 
system coupled with in silico methodologies (molecular dynamics and docking). The additional 
information gathered on the interaction between certain protons and particular amino acid 
residues can help us understand the position of these small compounds in the binding site. Given 
the rather favorable solubility and stability in aqueous buffers of the three compounds chosen, 
these will be considered for setting up a protein-observed NMR methodology with the support 
of a newly launched partnership.‡‡ The confirmation of the predicted poses and the building of 
a complete map of the HuR–small molecule interaction for the natural product series would 
produce the first experimentally validated binding site model for small molecules. 
  
 






5. Structure-based approach to obtain new HuR ligands. 
This chapter reports on the structure-based design and the synthesis of new HuR ligands based on 
four different scaffolds corresponding to four different MCRs. These compounds represent the first 
HuR MedChem campaign of our research group. The investigation of their interactions with HuR 
was performed using the combination of STD NMR and in silico studies set up and presented in the 
previous chapter. 
Briefly, based on the results of chapter 4, for the design of new compounds, we focused on a pocket-
like region hosting the small HuR ligands, formed by the two asymmetric units of the protein, 
belonging to RNP1 and RNP2 of RRM1. Inspection of the cocrystal structure of the HuR RRM1/2 
domains in complex with the ARE sequence of RNAc‑fos (PDB 4ED5) confirms that this region 
corresponds to binding site of RNA uridine residues 8 and 9 (U8−U9) (see figure 21). We started our 
search for new scaffolds for HuR ligands from the key interactions shown in figure 21 and utilized 
the free web-based virtual screening platform AnchorQuery;165,166 we selected U8 and U9 as anchors 
and investigated whether one of the two nucleotides may be a pharmacophore in terms of occupied 
position and interactions. The anchors were modified and grown to bear an additional phenyl group 
to afford a π−π-stacking interaction with Tyr63 (see figure 21). Among several structures generated, 
the candidates for synthesis were selected based on visual inspection and molecular recognition 
studies, according to the following criteria: (a) the anchor should show good overlap with the 
corresponding uracil ring, preserving the same hydrogen bonds with Arg97 and Lys92, while (b) the 
additional aromatic rings should gain the desired interaction with Tyr63. We selected the most 
promising scaffolds and replaced the uracil moiety with an easy-to-handle starting material, thus 
designing compounds 1−4 (see figure 21), characterized by different scaffolds. The structures 
designed with AnchorQuery can be prepared through MCR or equally efficient processes. Thus, 
compound 1 was obtained by a Castagnoli−Cushman reaction (CC-3CR)167 followed by amidation; 
2 by a Groebke−Blackburn−Bienaymé (GBB-2CR);168 3 was synthesized by a Van Leusen reaction 
(vL-3CR),169 and 4 by a reductive amination170 followed by acylation. Herein, the synthetic strategies 








Figure 21. Structure-based design strategy for novel ligands of target protein HuR exploiting a nucleotide 
extension of the platform AnchorQuery. The docked poses of the compounds from chapter 4 (placement guided 
by STD NMR results) identify repeated sites on the protein. A comparison with RRM1/2–RNAc‑fos co-crystal 
(PDB 4ED5) highlights residues U8–U9 in the same positions. This site is chosen for the structure-based 
design strategy. The four compounds selected for synthesis and interaction studies are shown on the bottom. 
Anchors, original and modified, are shown highlighted in blue, additional rings for Tyr 63 interaction are 
encircled in dashed orange, and the different core structures obtained by MCR are highlighted in bold.  
Amidation of the acid intermediate trans (±) 9 with amine 10 afforded compound (±) 1 as racemate. 
The key intermediate trans-6-oxopiperidine-3-carboxylic acid 9 was obtained in good yield and 



























































7, and glutaric anhydride 8 (see scheme 1a).167 A microwave-assisted GBB-2CR,168 involving 
isocyanide 12, aldehyde 6, and amino-thiazole 13, produced compound 2. Isocyanide 12 was obtained 
starting from amine 11, which was converted into the corresponding formamide and subsequently 
dehydrated (see scheme 1b).  
 
Scheme 1. Synthetic pathways of compounds 1 and 2. Reagents and conditions: 
a) Compound (±) 1: i) 6, 7, HCOOH, ACN, mw 120°C, 50 W, 30 min; ii) 8, p-xylene, reflux, 10h, yield 62%; 
iii) TBTU, DIPEA, THF, rt, 12h, yield 71%. 
b) Compound 2: i) Ethyl formiate, 10h; ii) TEA, POCl3, DCM, rt, 4h, yield 62%; iii) 6, 13, HCOOH, ACN, 
mw 120°C, 30 min; iv) 12, ZrCl4, 80 °C, 10h, yield 21% (adapted from Della Volpe et al., 2019, see 
appendix III, article 2). 
A vL-3CR27 on commercially available aldehyde 18, isobutylamine 7, and substituted TosMIC 
derivative 17 led to compound 3. This MCR allows access to functionally rich imidazoles in a single 
pot via cycloaddition of TosMIC reagents on imines, generated in situ from an aldehyde and an amine 
under mildly basic conditions. We synthesized 17 starting from p-toluenesulfinic acid 14, which 
afforded the intermediate formamide derivative upon reaction with commercially available 3-
phenoxybenzaldehyde 15, formamide 16, and chlorotrimethylsilane; subsequent dehydration 
furnished isocyanide 17 (Scheme 2c). Compound 4 was obtained by reductive amination of aldehyde 












































































Scheme 2. Synthetic pathways of compounds 3 and 4. Reagents and conditions: 
c) Compound 3: i) H2O, 30 min; ii) HCl, MTBE, 30 min; iii) 15, 16 Me3SiCl, ACN, Toluene, N2, 50°C, 5 h; 
iv) 14, 16h, yield 62%; v) POCl3, triethylamine, THF, 10°C, 45 min, 85%; vi) 18, 7 dry DMF, rt, 4h; vii) 17, 
K2CO3, rt, 72h, yield 15%. 
d) Compound 4: i) PPTS, 3,4-DHP, dry DCM, rt, 1.5h, yield 94%; ii) DIBAL-H, dry DCM, N2, –78°C, 30 min, 
yield 49%; iii) NaBH(OAc)3, THF, N2, rt, 24h, yield 85%; iv) HOBt, EDC∙HCl, DIPEA, dry DMF, N2, rt, 24h, 
yield 60%; v) PPTS, EtOH, 55°C, 16h, 75% (adapted from Della Volpe et al., 2019, see appendix III, article 2). 
Of four compounds synthesized, three (1, 3 and 4) were subjected to the combined STD NMR and 
in silico investigation of their interactions with HuR (according to the format set up and presented in 
the previous chapter), thanks to their favorable solubility in water-based buffers. Finally, 1 and 4 were 
selected as promising compounds to develop in the next steps of our MedChem campaign. In 
particular, compound 4 shows interesting binding modes which appear so far to be in accordance with 
the initial design: while all rings interact with the target, the anchor, as hypothesized, appears to be 
the most interacting moiety. 
On the contrary, compound 1, though directly binding to the target, shows a different interaction 






































































play into the differences of compound 1: first of all, this was initially synthesized and tested as a 
racemic mixture of the two trans enantiomers,171 so it is likely that the two enantiomers may have 
different interaction with the target (as it often happens with a chiral molecule within a chiral 
environment), thus they should be separated and investigated individually. Moreover, the modified 
anchor of compound 1, though similar to 4, has both hydroxyls substituted; though the additional 
methyl group is rather small, it changes the binding capacity of the anchor (i.e. the anchor now lacks 
hydrogen-bond donors) and could thus be responsible for the different binding mode. Finally, the 
compound could have higher affinity for a different protein site, which we cannot detect with 
STD NMR but need a protein observed NMR method, rather than X-ray diffraction.  
The structure-based design, synthesis and preliminary results of the STD NMR and in silico 
interaction studies are described in the published article “Novel Compounds Targeting the 
RNA-Binding Protein HuR. Structure-Based Design, Synthesis, and Interaction Studies”. 
ACS Medicinal Chemistry Letters, 2019 (see appendix III, article 2).  
Additional studies on the two hits 1 and 4 have thus been performed and some are still ongoing. 
Concerning compound 1, a second part of the study is reported in paragraph 5.1, while a follow-up 
investigation to design derivatives of compound 4 is reported in chapter 6, paragraph 6.4. 
5.1 Resolution of (±) 1 enantiomers and differential interaction study 
Compound 1 was initially synthesized and studied as a racemic mixture of the two trans enantiomers 
but, given its interesting behavior, the obvious next step involved the resolution of the racemate in 
the two separate enantiomers by enantioselective HPLC. Both were studied by STD NMR and the 
differences in their binding modes elucidated by applying an enantio-application of DEEP-STD 
NMR. Additionally, differential solvent composition was used for DEEP-STD NMR experiments on 
each enantiomer to understand the importance of polar residues in their respective binding to HuR. 
Pending the assignment of their absolute configuration via crystallization and X-ray diffraction, the 
collected spectroscopic information will guide the synthesis of several derivatives with modified 
anchors (to understand the importance of anchor substitution), for improved affinity and RNA 
displacement ability.  
Chiral resolution via enantioselective HPLC  
To develop a separation method able to afford the two enantiomers of 1 on a semi-preparative scale, 
two immobilized polysaccharide-based chiral stationary phases were initially tested at the analytical 
scale, amylose and cellulose (REGISPACK IA and CHIRALPAK IC columns, respectively) with the 
screening protocol as reported in the experimental section (see experimental section). The best 






0.1 % DEA, and n-Hex-IPA 80:20 with 0.1 % DEA (details reported in the experimental section ). 
Looking  at the chromatographic profiles it is quite evident that n-Hexane:IPA:DEA 80:20:0.1 (v/v/v) 
(see figure 22, top) affords the best resolution though with longer times, thus it is not suitable for 
scale-up; on the contrary, the elution with n-Hex:IPA:DEA 75:25:0.1 affords a good resolution in 
more appropriate timeframes (see figure 22, bottom). 
 
Figure 22. Top: Analysis performed using Chiralpak IC (4.6 mm I.D. x 250 mm), n-Hex:IPA:DEA 80:20:0.1 
(v/v/v), flow: 1 mL/min, 25°C, λ = 220 nm. Injection volume 10 µL (1 mg/mL in IPA). Rt1 = 56.240 min; 
Rt2 = 67.920 min; α = 1.231; Rs = 2.530. Bottom: Analysis performed using Chiralpak IC (4.6 mm I.D. x 
250 mm), n-Hex:IPA:DEA 75:25:0.1 (v/v/v), flow: 1 mL/min, 25°C, λ = 220 nm. Injection volume 10 µL 
(1 mg/mL in IPA). Rt1 = 34.333 min; Rt2 = 39.600 min; α = 1.184; Rs = 1.896. 
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To obtain each enantiomer in sufficient quantity for interaction studies, a semi-preparative column 
Chiralpak IC (1 cm I.D. x 25cm, s-5µm) was used. Four 1 mL samples of 10 mg/mL (n-Hex:IPA 
75:25) were injected. Three fractions were collected in each run, and those with comparable 
enantiomeric excess (ee) of the same enantiomer were pooled and evaporated affording 25 mg of the 
first enantiomer eluted (ee = 99%) and 12.5 mg of the second enantiomer eluted (ee = 95.6%) 
(see figure 23). The specific rotation of each was determined in MeOH: [𝛼]D20 = + 74.0° for the first 
enantiomer and [𝛼]D20 = – 74.6° for the second enantiomer (see figure 23). 
 
 
Figure 23. Chromatographic profile of the two enantiomers, first (ee 99%) and second elute (ee 95.66%) after 
separation. Analyses performed using Chiralpak IC (4.6 mm I.D. x 250 mm), n-Hex:IPA:DEA 80:20:0.1 
(v/v/v), flow: 1 mL/min, 25°C, λ = 220 nm. Injection volume 10 µL (1 mg/mL in n-Hex:IPA 75:25). 
Interaction studies with HuR of (+) 1 and (–) 1 by enantio- and solvent- DEEP-STD 
The two enantiomers thus obtained were exploited for interaction studies with the target HuR 
according to the DEEP-STD protocol reported in the previous chapter for both comparison of the two 
enantiomers and to build a differential solvent epitope map. The results are hereby reported and 
discussed.  
STD NMR spectra were recorded for both enantiomers of 1 in the same conditions as reported for all 
previous compounds (see experimental section). Absolute and relative STD % for each enantiomer 
are stated in tables 7 (for compound (+) 1) and 8 (for compound (–) 1), while a schematic 
representation of each enantiomer epitope mapping is shown in figure 24; the color code of the dots 
associated to each proton is once again conveying a range value of relative STD percentage 
(see figure 24). 
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atom Absolute STD % Relative STD % 
Ring A (2, 3, 4) 0.62 100 
Ring A (1, 5) 0.44 71 
Ring B (3) 0.38 61 
Ring B (1, 5) 0.34 55 
16 0.15 24 
OCH3 0.26 42 
5 0.40 65 
3 0.43 69 
9/10 0.17 27 
Table 7. Absolute and relative STD % of compound (+) 1. 
atom Absolute STD % Relative STD% 
Ring A (2, 3, 4) 0.79 100 
Ring A (1, 5) 0.32 41 
Ring B (3) 0.21 27 
Ring B (1, 5) 0.22 28 
16 0.28 35 
OCH3 0.15 19 
5 0.56 71 
3 0.34 43 
9/10 0.27 34 
Table 8. Absolute and relative STD % of compound (–) 1. 
 
Figure 24. Representation of the group epitope map for (+) 1 and (–) 1 binding to HuR. Relative STD % ranges 
are conveyed by color code: black dots for 100%, orange dots for values between 40 and 80%, and green dots 
for values below 40%. 
Nonetheless, as anticipated in paragraph 3.1, absolute STD values coming from different STD 
spectra, cannot be directly compared, due to possible differences in sample preparation or instrument 
setting. For this reason, in order to obtain a comparison between the interaction of the two separate 
enantiomers with HuR, we exploited the DEEP equation reported in paragraph 3.1.2. The experiment 
of (+) 1 was chosen as exp1 (since the global saturation is larger than that of (–) 1), and the ratio and 
































values for each proton. The raw and processed data and DSTD factors are shown in table 9 and 
represented schematically in figure 25. We recorded positive DSTD factors for the protons of ring B 
and its methoxy group, while negative DSTD factors were observed for protons 5, 9/10 and 16. These 
differences suggest that the two enantiomers interact with the same protons but different orientation 
into the binding site. Positive DSTD factors suggest which moieties are most involved in the 
interaction of (+) 1 with HuR, while negative DSTD factors for (–) 1 and HuR. 




(+) 1/ (–) 1 DSTD 
Ring A (2, 3, 4) 0.62 0.79 0.78 -0.37 
Ring A (1, 5) 0.44 0.32 1.38 0.23 
Ring B (3) 0.38 0.21 1.81 0.66 
Ring B (1, 5) 0.34 0.22 1.55 0.4 
16 0.15 0.28 0.54 -0.61 
OCH3 0.26 0.15 1.73 0.58 
5 0.40 0.56 0.71 -0.44 
3 0.43 0.34 1.26 0.11 
9/10 0.17 0.27 0.63 -0.52 





Table 10. Raw and processed data of the enantio DEEP-STD NMR experiment of the (+) 1–HuR  and    (–) 1–
HuR complexes in D2O. 
 
Figure 25. Enantio application of the DEEP-STD experiment. The STD spectra of (+) 1 and   (–) 1 in D2O are 
compared thanks to the equation exploited in the differential approach. Stronger binding components are 
reported in purple for the first enantiomer eluted (+) 1 and green for the second (–) 1. Grey dots indicate no 
significant difference in moiety contribution for the two enantiomers tested. The size of the colored circles 
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Since (+) 1 shows a stronger contribution of the anchor moiety (ring B) compared to (–) 1, we decided 
to start differential solvent experiments on this enantiomer, following the procedure described in 
paragraph 4.1 for selected natural products. The experiment highlighted that that ring A points 
towards apolar residues, while protons 16 and 9/10 are projected towards polar residues. (All data are 
reported in table 10 and represented in figure 26). 
Proton STD% D2O STD% H2O 
Ratio STD 
D2O / H2O 
DSTD 
Ring A (2, 3, 4) 0.63 0.38 1.66 0.14 
Ring A (1, 5) 0.44 0.12 3.67 2.15 
Ring B (3) 0.38 0.29 1.31 -0.21 
Ring B (1, 5) 0.34 0.21 1.62 0.1 
16 0.15 0.31 0.48 -1.04 
OCH3 0.27 0.20 1.35 -0.17 
5 0.40 - - - 
3 0.43 - - - 
9/10 0.17 0.32 0.53 -0.99 





Table 10. Raw and processed data of the differential solvent (D2O/H2O) DEEP-STD NMR experiment of the 
(+) 1–HuR complex. 
 
Figure 26. Graphic representation of the solvent DEEP-STD experiment on the (+) 1–HuR complex. Blue 
surfaces indicate ligand contacts with protein side chains carrying slowly exchanging protons; orange surfaces 
indicate ligand contacts with apolar residues.  
Differential solvent experiments are currently ongoing for the second enantiomer, (–) 1. Pending 
assignment absolute configuration the binding modes of the two enantiomers will be rationalized with 
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with modified anchors (to understand the importance of anchor substitution) and specific 
stereochemistry, for improved affinity and RNA displacement ability.§§  
 
 
§§ The completed study, including assignment of the absolute configuration and complete DEEP-STD NMR evaluation, 
is described in the just accepted article “BOPC1 enantiomers preparation and HuR interaction study. From molecular 
modeling to a curious DEEP-STD NMR application”. ACS Medicinal Chemistry Letters. This content could not be 






6. Design of new derivatives of synthetic hit 4 via fragment-based approach 
The present chapter describes the first fragment-based ligand design approach to obtain new HuR 
ligands based on the scaffold of synthetic hit 4 (described in chapter 5). 
Briefly, a small halogen-enriched fragment library (HEFL, ~ 150 fragments***), built to exploit 
halogen bonding in small substituted homo- and heterocycles, was selected to perform a biophysical 
fragment screening on native HuR. The primary screening technique chosen was Surface Plasmon 
Resonance (SPR) and STD NMR was used for confirmation of hit fragments. Three hits and few 
readily available (synthetically or commercially) derivatives were selected to build a library of 
analogs of synthetic hit compound 4 where the carboxylic acid moiety (ring C) is varied according to 
incorporate chosen fragments. The derivatives so designed are currently undergoing in silico selection 
(via the molecular dynamics and docking approach described in chapters 4 and 5). The structures 
with the best predicted affinities will be selected for synthesis and biophysical and biological 
evaluation. Structurally-related derivatives where ring B is replaced with benzylamine have also been 
designed and are under consideration for synthesis.  
 
Figure 27. Design strategy of analogs of synthetic hit 4 by molecular hybridization with selected fragments. 
6.1 Fragment screening on the native protein 
Though three techniques were initially considered for fragment screening, Surface Plasmon 
Resonance (SPR), Thermal Shift Assay (TSA) and STD NMR, the choice of SPR as primary 
 
*** The HEFL library was designed, synthesized and donated by Prof. Franck Boeckler and collaborators at the 
Pharmazeutische Chemie, Pharmazeutisches Institut Eberhard Karls, Universität Tübingen (Germany) based on the 
principles of halogen bonding.190–192 The library comprises various homo/heterocyclic compounds diversely decorated 





































screening technique was straightforward. In fact, despite its very informative nature and the fact that 
the technique had already been established, STD NMR requires comparably high amounts of protein; 
TSA suffers from similar drawbacks,  thus both were only considered as secondary screening 
approach. In both cases in fact, the protein needs to be added into each tube (NMR) or well (TSA) 
and cannot be recovered. While protein amounts can be partly reduced with STD NMR by grouping 
the compounds to be screened in mixtures, spectra recording and full assignment of each mixture 
component is required prior to the experiment, as well as thorough mixture planning to avoid signal 
overlap. Additionally, utilizing mixtures is quite discouraged with TSA due to the high risk of 
artifacts.80 On the contrary, SPR requires a much smaller amount of protein, due to the fact that one 
SPR chip with immobilized protein can be utilized for a whole screening.  
Since no study was reported on the application of TSA on HuR, preliminary analyses were carried 
out to assess the optimal experimental conditions. Unfortunately, native HuR tested at different 
concentrations was unresponsive to the thermal cycles applied.  
For these reasons, SPR was chosen as primary screening technique, followed by STD NMR to 
confirm selected hits. 
Screening of the halogen-enriched fragment library by SPR 
The screening protocol was established based on a work by Wu et al. 201566 (see paragraph 1.3, 
compounds 14–19), which exploited amine coupling for protein immobilization of two different 
constructs, different than the native protein, at unreported concentration. The conditions thus needed 
to be optimized for the protein available to us; the immobilization was finally obtained through 
application of HuR protein to the activated chip at a concentration of 50 μg/ml in 10 mM acetate 
buffer pH 4.0 at a flow rate of 5 μl/min. Epigallocatechin gallate (see chapter 4, compound 1) was 
injected as reference compound to confirm integrity of the binding site prior to the screening. A three-
concentration-point screening was performed in duplicates (250−500−1000 μM) on the (146 library 
members) allowing to select 10 fragments for KD determination; the following curves were built with 
10 concentration points (15 μM to 2 mM). Three fragments with estimated KD ≤ 1 mM were selected 
as hits (see figure 28). 
Validation of hit fragments by STD NMR 
Following the STD NMR protocol reported in the previous chapters, the interaction of the three hit 
fragments with HuR was confirmed (see figure 28). Given the small size of the fragments it was 







Figure 28. Structures, KD curves and STD NMR spectra of the three hit fragments selected against native HuR, 
identified with the letters a, b, c. 
6.2 Molecular hybridization of HuR ligand 4 and hit fragments 
Design of new derivatives of 4 for in silico screening 
The linking step was devised starting from the original design of 4 maintaining a fixed anchor 
(3,5-dihydroxyphenyl – ring A) and side chain (3-chloro benzylamine – ring B), and varying the 
carboxylic acid moiety (ring C) according to the hit fragments identified and few derivatives. The 
commercial and synthetic availability of carboxylic acid derivatives of the 3 hit fragments, assessed 
through database search (SciFinder, PubChem), afforded the design of 24 derivatives of 4 where ring 
C is replaced (see figure 29). The analogs of 4 so designed are currently undergoing in silico selection 
through the molecular dynamics and docking approach described in the previous chapters. The most 
promising compounds will be selected for synthesis and evaluation according to their predicted 




































































































































































































































Optimization of the synthetic pathway 
In view of having to synthesize a library of selected analogues of 4, the original synthetic pathway 
exploited, should be revised, to improve the general yield as well as reduce the number of steps. The 
main issue concerns the sensitivity of the O-THP groups, present on each intermediate through each 
step of the reaction, to any mildly acidic additive or purification media necessary to obtain the final 
compound, which calls for additional long purification steps and in the end can lead to poorly 
reproducible yields.  
   
Figure 30. Comparison of original and alternative synthetic pathway devised for the synthesis of derivatives 
of 4.  
To reduce its impact, a new strategy has been devised to reach the key amine intermediate necessary 



































































































The new synthesis involves a solvent-free aminolysis (step 1) of the ester to obtain the amide product; 
this is then reduced (step 2) to afford the amine ready for the amide coupling (step 3). So far, the first 
two steps were performed on a small scale (without column purification) and followed by TLC and 
1H NMR to prove feasibility.  
The synthesis is currently under scale up to obtain the key amine intermediate in quantity and purity 
suitable to synthesize the analogs of 4 currently under selection. A similar synthetic pathway could 
be applied for the synthesis of derivatives with a nude benzyl B ring. In case hydroxyl protection 
should once again be considered, to avoid side reactions occurring during the final step, this could 
be performed right before avoiding the inconvenience of having an unstable moiety throughout the 
whole pathway. In case of side protection on the secondary amine, a OH-selective protective group 
could be considered to avoid this interference. 
Experimental limits of the native HuR protein  
The fragment-based approach described in the present chapter follows a rather unusual pathway, 
mainly due to several issues encountered with the native protein. In fact, native HuR is a quite 
unstable protein, very sensitive to changes in pH (i.e., pH necessary for the immobilization reaction), 
temperature (degradation seems to occur prior to TSA thermal cycle), prone to aggregation (cannot 
be concentrated in solution, the highest concentrations reported are ≤ 10 μM) and with reduced 
stability in frozen storage. This instability is exacerbated by removal of glycerol from the preservation 
conditions, though this is necessary for most assays used. All of these characteristics made it an 
impossible candidate for DCC applications as well as additional assays. Moreover, while intra-batch 
reproducibility for SPR immobilization was quite favorable, the same was not found for inter-batch 
reproducibility. Such issues were not encountered within STD NMR experiments, probably due to 
the minimal manipulation and favorable experimental conditions necessary.  
The stability of the protein could only be investigated by SDS-PAGE and Bradford assay, since TSA 
was not an option. SDS-PAGE can highlight changes in size of the protein (cleavage, fragmentation 
and aggregation), while the Bradford assay can quantify the total protein present in a sample 
concentration through the binding of protein molecules to Coomassie dye under acidic conditions, 
resulting in a shift in color from brown to blue which can be detected with a spectrophotometer. Both 
methodologies, were chosen due to their selectivity of protein detection, compared for example with 
UV readings normally performed at 280 nm for protein detection where several interferers also absorb 
(i.e., residual imidazole from purification and “pollutant” non-protein macromolecules). Nonetheless, 
they could only afford partial information,††† confirming the limits of the native protein and clearly 
 






highlighting the quite urgent need for a solution for both current and future studies. The solution 







7. Fragment linking by protein templated dynamic combinatorial chemistry to 
identify new HuR ligands 
The present chapter aims at solving the cliffhanger at the end of chapter 6, searching for a solution to 
the experimental limits of the native protein. Thanks to a newly started collaboration with the Sattler 
group (Institute of Structural Biology, Helmholtz Centre Munich), two new protein constructs were 
introduced to support the study, one modified full length HuR (RRM1+2+3_GGS) and one truncated 
(RRM1+2, see figure 31).  
 
Figure 31. Schematic representation of the two protein constructs (full length, RRM1+2+3_GGS and 
truncated, RRM1+2) expressed, purified and shared from the Sattler Group, utilized for the next steps of the 
study.  
After initial study of the two protein constructs, both were immobilized for the fragment screening 
but, finally, only RRM1+2 gained reliable results and could be used with favorable conditions for the 
establishment and execution of the protein-templated DCC (pt-DCC) approach finally exploited for 
fragment linking. The pt-DCC experiments performed on two different dynamic combinatorial 
libraries (DCL) provided three hits and five additional derivatives to subject to interaction studies by 
STD NMR with the target protein. The optimization of the STD NMR experimental conditions for 
the new constructs are currently ongoing. 
7.1 Initial studies on the two new protein constructs 
The two constructs, expressed and purified by the Sattler group,74 represent a modified full length 
HuR, RRM1+2+3_GGS (1–326, 37 kDa), where the linker between RRM domains is substituted by 
a series of Glycine and Serine residues, and a truncated HuR, RRM1+2 (1–186, ~20 kDa), where 
only the first two RRM domains are present. Both constructs show higher stability compared to native 
protein and are less prone to aggregation and precipitation; for this reason they can be concentrated 





Construct 1: Full length protein, modified linker (Glycine–Serine); ~37 kD






in solution up to 27 μM (1 mg/mL) and 125 μM (2.5 mg/mL) respectively, and have so far shown 
better behavior in all assay performed (NMR-based assays carried out in Munich). To assess their 
potential for our objectives, both were tested in a thermal shift assay (TSA) in their native buffer 
(20 mM Phosphate buffer pH 7.0) at six protein concentrations (0.25−10 μM). Both constructs 
responded (Tm RRM1+2+3 ~58°C, Tm RRM1+2 ~56°C) at 2.5−5 μM and 5−10 μM respectively. 
Additionally, immobilization on a SPR chip was tried for both constructs following the same 
procedure exploited for the native protein via amine coupling. The immobilization was successful at 
the first trial and showed consistent signal in time (~3000 and 2000 RU respectively). For this reason, 
it was chosen to carry out the investigation in parallel on both constructs; the full length protein was 
planned to be used for the screening, and the truncated to select possible aspecific binders.  
7.2 Fragment screening on protein constructs by SPR 
The halogen enriched fragment library (HEFL) of chapter 6 was thus rescreened against the two 
constructs via SPR, following a similar protocol to the previous screening. Some of the hits selected 
show structural resemblance to the hits found for the native protein but, given the possibility to exploit 
at least one of the protein constructs for pt-DCC experiments, the hit selection was kept to a larger 
size (8 hit fragments, see figure 34) to guide choice of building blocks to design the DCLs.  
Full protein construct: RRM1+2+3_GGS linker 
After immobilization of the construct, epigallocatechin gallate (EGCG, see chapter 4, compound 160) 
was injected as reference compound prior to the screening to verify the integrity of the binding site. 
Fourteen concentration points in duplicate (25 nM–500 μM) could not reach saturation of the protein 
binding site (see figure 32). 
A second reference compound (mfm 49164) was also tested (25 nM–100 μM, due to limited 
solubility) obtaining similar results (reported estimated KD for both compounds is ~0.1 μM). An 
analogous behavior was later on observed for a selected fragment, we chose not to pursue the 
screening on the construct RRM1+2+3 construct. Moreover, obtained RU values are well over the 
expected response for 1:1 ligand–protein construct interaction.‡‡‡ 
 
‡‡‡  According to the equation:  
𝑎𝑛𝑎𝑙𝑦𝑡𝑒	𝑏𝑖𝑛𝑑𝑖𝑛𝑔	𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑦	(𝑅𝑈) =
𝑎𝑛𝑎𝑙𝑦𝑡𝑒	𝑀𝑊
𝑙𝑖𝑔𝑎𝑛𝑑	𝑀𝑊 ∗ 𝑖𝑚𝑚𝑜𝑏𝑖𝑙𝑖𝑧𝑒𝑑	𝑙𝑖𝑔𝑎𝑛𝑑	𝑙𝑒𝑣𝑒𝑙	(𝑅𝑈)	 







Figure 32. Sensorgrams and concentration curves for two reference compounds (EGCG, see chapter 4, 
compound 1 in blue, and synthetic compound mfm 49 in red) and one fragment (in orange). No reference 
compound reaches saturation on this construct, the response just keeps growing in intensity. Similar behavior 
was observed with one selected fragment. 
Truncated protein construct: RRM1+2 
The second construct was then immobilized for testing. Once again, epigallocatechin gallate (EGCG, 
see chapter 4, compound 1) and mfm 49 were injected as reference compounds prior to the screening 
to verify the integrity of the binding site. Saturation was reached for both compounds and estimated 
KD reproduced reported values within an acceptable range (curves reported in figure 33). 
 
Figure 33. KD curves for reference compounds (EGCG, see chapter 4, compound 1 in blue, and synthetic 
compound mfm 49,164 in red). Estimated KD reproduced reported values in an acceptable range. 
 A three-concentration-point screening was performed in duplicates (250−500−1000 μM) on the (146 
library members) allowing to select 20 fragments for KD estimation; the following curves were built 
with 5 concentration points (125 μM to 2 mM). Eight fragments with estimated KD below 1 mM were 
selected to guide the construction of DCLs.§§§  
 
§§§ Additional structurally-related derivatives tested within the HEFL could be considered in future studies for the 










Figure 34. Structures and molecular weights of the fragments selected via SPR screening on protein construct 
RRM1+2.  
7.3 Dynamic Combinatorial Chemistry studies 
According to the chosen chemistry of acylhydrazones, two DCL were so far built, choosing as 
building blocks commercially available aldehyde and acylhydrazide derivatives inspired to the eight 
hit fragments coming from the SPR screening. pt-DCC experiments were conducted in two buffers, 
selected according to the protein construct stability, monitored through HPLC-UV-MS against the 
same blank reaction to allow for the discovery of hits (amplified compounds). Three DCC hits were 
chosen for synthesis and evaluations along with DCC negatives and additional derivatives.  
Establishment of experimental conditions 
TSA was used to monitor protein stability over time in different buffers (10−50 mM; pH range 5−7.5; 
150 mM NaCl) with the aim of establishing the optimal experimental conditions for the pt-DCC 
experiment. The assay was performed at a compromise protein concentration between optimal TSA 
and DCC ranges. One 96-well plate was thus prepared where a 10 μM solution of protein in sixteen 
buffers and H2O containing 5% DMSO, was stored at room temperature over a time range fully 
covering DCC timeframes, and sampled every day (day 0 to day 3) for TSA experiments. Within the 
pH range tested, the protein showed little Tm variation (see experimental section); nonetheless, two 
buffers, phosphate pH 7 and acetate pH 6 were chosen to perform the pt-DCC experiments.  
Fragment-inspired dynamic combinatorial libraries 
So far, two fragment-inspired DCL libraries were built and exploited for pt-DCC on RRM1+2, 
utilizing commercially available aldehydes and hydrazides as building blocks.  
Based on past experience (both personal and of the research group), it was chosen to use small 
building blocks libraries to construct DCLs, based on the chemistry of acylhydrazones. Each building 
block library comprises two aldehydes (each 100 μM) and eight hydrazides (each 200 μM). The 
















































speed up the rate at which equilibrium is reached at the pH chosen for the experiment 
(see paragraph 3.4.4). The experiments were conducted in parallel for the same DCL in the two 
different buffers, and monitored via HPLC-UV-MS upon protein precipitation (by adding ACN) and 
pH-induced “freezing” of the reaction. As reported in paragraph 3.4.4, it is essential to separate, 
identify and quantify the amount of each DCL member formed univocally and without incurring in 
any artifacts to determine both equilibrium and pt-amplification.  
Within the two libraries (see figure 35), three hits were selected (with amplification > 80%); 
additional derivatives were chosen for synthesis and testing, for a total of eight final compounds, 
chosen among DCC negatives and hit derivatives.  
 
Figure 35. Fragment-inspired DCC libraries used for the pt-DCC experiment, and related hits and additional 
compounds synthesized for testing. 
7.4 Preliminary interaction studies 
Though the pt-DCC experiment allows in principle to combine synthesis of ligands and screening for 
affinity in one step, it is still fundamental to evaluate the affinity, study the binding modes with the 
target and evaluate the biological activity. Since the optimization of the STD NMR experiment on 
the new constructs is ongoing, a preliminary study was performed through SPR, following the 
protocol utilized for fragment screening and KD estimation. Nine concentrations were injected for 









































































































Building blocks: Library 2
















































































results need further validation. Nonetheless, this preliminary study showed a promising improvement 
in binding affinity for the DCC hits compared to the single fragments tested.  
A second affinity measurement and STD NMR study are in progress; their results will assess the 
validity of this approach for the target HuR thus, adding to the pool of strategies which can be 
exploited for the design and synthesis of new HuR ligands. In case of positive results, the compounds 
could be analyzed by DEEP-STD and protein observed NMR to build a complete map of their 
interaction with HuR. Additional assessment of their ability to displace RNA could then be performed 
(by STD NMR and Fluorescence Polarization****) to select compounds able to interfere with          
HuR–RNA binding.  
  
 







The work reported in the present thesis focused mainly on adding some puzzle pieces to a research 
project aimed at developing a new series of small, drug-like organic molecules able to modulate the 
stability of protein−RNA complexes involved in several diseases, to regulate gene expression with 
an unprecedented mode of action. The main target of this project is the ELAV protein family, a 
biochemically very well characterized group of highly homologous proteins. This class is particularly 
interesting for medicinal chemists and pharmacologists due to the involvement of related protein and 
protein–RNA dysregulations in several diseases (including cancer, neurodegeneration and 
inflammatory diseases). Regardless of the high potential of the ELAV proteins, not much is known 
about small-molecule modulators of either the proteins themselves or their complexes with RNA; 
most literature results come from independent HTSs based on different techniques and libraries, and, 
at the time this thesis was started, neither rational design nor HTS-hit evolution had been performed. 
This can be mainly attributed to the fact that, while the protein–RNA interface has been studied, this 
interaction is rather far from the more common receptor or enzyme binding sites we are used to 
studying. In particular, RNA and protein interact through a large surface, most of the times through 
a high number of superficial contacts; since we do not have any experimental evidence of the presence 
of effective and targetable hotspots, the development of a small molecule able to displace such an 
interaction requires several iterative steps.  
For this thesis, we decided to apply a strategy that focused mainly on developing compounds with 
affinity for the ELAV subtype HuR, chosen as a model protein and with high potential for therapeutic 
applications (i.e., cancer and retinopathy), by targeting a site on the large protein–RNA interface. 
While RNA is clearly also a component of the interaction, and the RBD sequences on ELAV proteins 
(as well as several RBPs) are highly homologous, we believe that targeting the protein along the RBD 
could represent a safer approach rather than targeting RNA transcripts. First of all, the diversity in 
protein-binding domains of target RNAs is even lower, as high affinity RBDs are reported to mostly 
bind AU-rich sequences (see paragraph 1.1), thus posing a greater challenge for target RNA 
selectivity; moreover, targeting RNAs could also be considered potentially less safe, due to the 
similarity of nucleic acids in general and the risky impact on cell function (as seen, for example, with 
DNA intercalating drugs172,173).  
Nevertheless, since a “proper” binding site for small molecule–HuR, as well as the related structural 
features, had not been elucidated at the time this thesis was started, we had to go back to the very 






of flavonoid and flavonoid-like compounds all derived from natural sources as well as some 
additional natural-product derivatives. Some of these compounds were directly picked out from the 
HTS hits, as compounds already known to interfere with ELAV–RNA complexes, while others were 
chosen to explore the chemical space around the flavonoid scaffold and other related and unrelated 
structures, for a total of 13 compounds finally considered. The collection so generated was utilized 
in the first study performed for this thesis (described in chapter 4) which exploited a combination of 
NMR-based ligand-observed technique, STD NMR, coupled with in silico methodologies, molecular 
dynamics and docking, to gain a comprehensive study of HuR–small molecule interactions. As 
previously described, STD NMR allows us to identify (at the atomic level) the moieties of the small 
molecule involved in the interaction with a target macromolecule as it occurs in solution; these data 
can be utilized to validate the binding modes predicted by in silico studies thus providing a two-way 
map of the interaction. Out of 13 compounds studied, 12 showed direct binding with HuR in 
STD NMR studies and one, asiaticoside (compound 13 of chapter 4) did not show any interaction; 
moreover the NMR data elaborated in epitope maps allowed us to analyze the interaction with HuR 
for each compound, but also within each structural class, showing how different substitutions affect 
binding affinity as well binding modes. NMR data were compared with in silico results; in particular, 
given the high protein mobility and flexibility which oversees the conformational changes occurring 
upon ligand binding, the HuR–RNA complex (PDB 4ED5) was studied with molecular dynamics to 
reproduce the conformational rearrangements of the protein-interaction interface. Though longer and 
computationally more demanding than rigid docking methods, this strategy gave us the chance to 
simulate the interaction in a more easily relatable way to STD NMR studies. In the following docking 
studies, all interacting compounds were predicted to bind to repeated amino acid residues of the 
protein interaction site, within a deeper pocket-like region of the HuR–RNA interface; the NMR data 
were in best accordance with binding predictions of the compounds to a closed conformation of the 
protein (see figure 36). On the other hand, in accordance with experimental data, asiaticoside was 
predicted to only bind superficially to the protein (see figure 36); the interaction was investigated 
over different conformations with little difference. According to the results obtained, the compounds 
investigated seem to comply to the theory that interfering compounds could stabilize a closed 
conformation of HuR (and other ELAV proteins) thus impeding the RNA initial contacts to the 
protein which trigger the protein conformational rearrangements that bring to the formation of the 
HuR–RNA complex.75,163 This study also allowed us to propose a postulated binding site which was 
then exploited in the next steps of the thesis work for SBLD/SBVS, and has the potential for the 







Figure 36. 3D representation of compounds divided by compound class in the HuR–RNA interaction site: (a) 
compounds 1, 2, and 3 (Epigallocatechin gallate, epicatechin and catechin, blue, green and yellow sticks, 
respectively); (b) compounds 4 and 5 (hyperoside and rutin, green and violet sticks respectively); 
(c) compounds 6 and 7 (vitexin rhamnoside and isovitexin, blue and green, respectively); (d) compounds 8 
and 9 (aesculin and novobiocin, violet and green sticks); (e) compounds 10, 11 and 12 (chlorogenic acid, 
7-hydroxymatairesinol and colchicoside, yellow, green, blue sticks, respectively); (f) compound 13 
(asiaticoside) shown as green sticks; HuR protein shown as orange cartoon (adapted from Vasile et al., 2018, 
see appendix III, article 1). 
The key features of the small molecule–HuR interaction so identified (for both ligand and protein 
counterparts) can be summarized as follows:  
a) unsaturated conjugated regions as well as aromatic rings on the ligands are of high importance in 
the interaction with HuR;  
b) these moieties appear to fit in repeated regions, and thus show hydrophobic interactions with 
repeated residues, namely Ile23, Asn25, Ser94, Ile133 and Arg153; 
c) for the sugar moieties, we observed that the rings directly attached to the aromatic ring of 
compounds 4, 5, 6, 7 and 8 and the quinic acid moiety of 10, overlap in the same region of the HuR 
binding site, establishing contacts with repeated residues (Arg97, Pro98, Ser99 and Ile 103); 
d) additional sugar moieties generally protrude outside the pocket-like region considered establishing 
more superficial contacts. 
These observations were exploited in the next step of the thesis (described in chapter 5) for our first 






hypothesized binding site and the RNA–HuR experimental binding site allowed us to identify two 
ribonucleotides involved with interactions in the same pocket-like site of the studied compounds, 
uridines 8 and 9. We focused on these two residues for the design of new compounds, searching for 
new scaffolds to build HuR-ligands utilizing the free web-based virtual screening platform 
AnchorQuery;165,166 U8 and U9 were selected as anchors to examine whether one of the two 
nucleotides could represent a pharmacophore concerning occupied position and interactions. 
Modifications were applied to grow and develop the anchors, in particular to gain an additional a 
π−π-stacking interaction with Tyr63, and to enhance synthetic feasibility. 800 candidate structures 
were generated and screened for synthesis through visual inspection and molecular recognition 
studies, to select compounds complying to the following criteria: (a) good overlap of the anchor with 
the corresponding uracil ring, preserving hydrogen bonds with Arg97 and Lys92; (b) the additional 
aromatic rings should gain the desired interaction with Tyr63. The most promising scaffolds thus 
selected brought to the synthesis of final compounds 1−4 based on four different MCRs (see 
figure 37).  
 
Figure 37. Structures of the four compounds selected for the experimental study. The modified anchors are 
highlighted with light blue full circles, while additional aromatic rings designed to interact with Tyr63 in a 
dashed orange circle. The different scaffolds (piperidinones, heterocycles, N,N-disubstituted amides) are 
highlighted in bold (adapted from Della Volpe et al., 2019, see appendix III, article 2). 
Of four compounds synthesized, three (1, 3 and 4) could be subjected to the combined STD NMR 
and in silico investigation of their interactions with HuR, owing to their favorable solubility in buffer. 
Finally, 1 and 4 were selected as hit compounds to develop in the next steps of our MedChem 
campaign; nonetheless, these two compounds show quite different binding modes. In particular, 




































initial design: while all rings interact with the target, the anchor, as hypothesized, appears to be the 
most interacting moiety.  
On the contrary, compound 1, while directly binding to the target, shows a different interaction mode 
which required further investigation prior to the design of new derivatives. Several factors could be 
involved into the differences of compound 1: first of all, we initially synthesized and tested 1 as a 
racemic mixture of the two trans enantiomers;171 as it often happens with a chiral molecule within a 
chiral environment, it is likely that the two enantiomers could have different interaction with the 
target, thus they should be separated and investigated individually. Moreover, regardless of its 
similarities with 4, the modified anchor of compound 1, has both hydroxyls substituted; though the 
additional methyl group is rather small, it can change the binding capacity of the anchor (i.e. the 
anchor now lacks hydrogen-bond donors) and could thus produce a different binding mode. Finally, 
the compound could have higher affinity for a different protein site, which we cannot detect with 
STD NMR but need a protein-observed NMR method, rather than X-ray diffraction.  
The first step for the elucidation of compound 1 binding modes involved the resolution of the 
racemate in the two separate enantiomers by enantioselective HPLC; a separation method was first 
established at the analytical scale and then transferred to the semi-preparative scale, exploiting a 
cellulose-based chiral stationary phase. We afforded both enantiomers in good enantiomeric excess 
and measured their specific rotation. (+) 1 and (–) 1 were thus subjected to STD NMR studies along 
with an enantio-application of DEEP-STD NMR to compare their STD spectra and elucidate the 
differences in their binding modes. Pending the assignment of their absolute configuration via 
crystallization and X-ray diffraction or NMR (based on the coupling with two enantiomers of a chiral 
derivatizing agent), these data will be compared with their in silico poses. This way, the collected 
spectroscopic information will guide the synthesis of several derivatives with modified anchors (to 
understand the importance of anchor substitution), for improved affinity and RNA-displacement 
ability. Nonetheless, we can already draw some conclusions, from the spectroscopic data obtained. 
In fact, the spectral differences processed through an enantio-DEEP-STD application suggest that the 
two enantiomers interact through the same protons but have different orientation into the binding site. 
In particular, (+) 1 shows a stronger contribution of the anchor moiety compared to (–) 1, and is thus 
in better accordance with the initial anchor design. This  consideration on stereochemistry will be 
taken into account for the development of derivatives. 
The second approach applied in the present thesis for the design of new HuR-ligands exploited FBLD; 
according to this method, we screened and identified low-molecular-weight ligands (~150 Da) which 






fragment-based approach requires fewer compounds to be screened, and, despite the lower initial 
potency of the screening hits, it can offer more efficient optimization campaigns;115 fragment libraries 
are typically screened using a series of progressively more restrictive biophysical techniques to refine 
the search for hit fragments and discriminate false positives and aspecific binders. Based on the 
expertise of the Hirsch group, the initial plan was to exploit pt-DCC for fragment linking to design 
and select new HuR ligands. This method allows to directly evaluate the different products which are 
part of the DCL and select the best binders through the pt-DCC experiment. Thus we could directly 
synthesize DCC hits and few derivatives, avoiding the synthesis of each DCL member for the next 
evaluation step. Based on our knowledge, literature-reported features and preliminary results we 
decided to apply SPR as primary fragment screening technique followed by STD NMR for hit 
fragment validation, and to utilize TSA only for studying the protein stability. In line with the 
previous studies reported in the thesis, the first experiments were performed on the native HuR 
protein. Though the fragment screening was successful and allowed for the selection of three hits (as 
described in chapter 6), we started to encounter several issues within experiments which could be 
reconducted to the stability of native HuR. In fact, native HuR is a quite unstable protein, very 
sensitive to changes in pH (i.e., during the immobilization step in SPR), temperature (degradation 
seems to occur prior to TSA thermal cycle), prone to aggregation (cannot be concentrated in solution, 
the highest concentrations reported are ≤ 10 μM) and with reduced stability in frozen storage. This 
instability was exacerbated by removal of glycerol from the preservation conditions, though this 
action is necessary for most of the assays used. Moreover, we observed good intra-batch 
reproducibility for SPR immobilization but the inter-batch reproducibility was very low. These issues 
had not been identified in previous experiments exploiting STD NMR, probably due to the minimal 
manipulation and favorable experimental conditions utilized. All of these characteristics made it an 
impossible candidate for DCC applications as well as additional assays. For this reason, we decided 
to look for alternative constructs, and found two (one full-length modified construct, 
RRM1+2+3_GGS, and one truncated construct composed by RRM1/2 domains, RRM1+2).  
We decided to keep the results coming from the screening on native HuR and to design a series of 
derivatives of hit compound 4 (obtained through the structure-based study of chapter 5), where ring C 
is replaced with the three hit fragments and related derivatives (see figure 28). 24 analogs were 
designed based on the availability/synthetic feasibility of the related building blocks, and are currently 
under structure-based evaluation (VS) to select the predicted most interesting candidates for 






allow for the synthesis of a key intermediate to then generate in one step the derivatives selected (see 
figure 29). 
In parallel, the two new constructs of HuR (provided by the Sattler group, see appendix V 
contributions to the research) were studied to assess their potential for both biophysical assay- and 
pt-DCC-applications. Both constructs proved to respond to TSA at reasonable concentrations for 
further studies (RRM1+2+3_GGS at 2.5−5 μM, RRM1+2 at 5−10 μM) and showed immediate and 
stable over-time immobilization on the SPR chip. For this reason, they were both considered for 
repeating the screening step. At this stage, RRM1+2+3_GGS showed to have some limits as well, as 
titration curves with two reference compounds could not reach saturation and did not reproduce 
reported KD values (one hypothesis could take into account the possibility of aspecific interaction of 
the compounds with the modified linker). The same behavior was not encountered with RRM1+2, 
which proved to gain reliable results, thus this construct was used to repeat the whole screening, 
affording the selection of 8 hit fragments with KD < 1 mM. Its general characteristics (reported in 
chapter 7), including the possibility to concentrate it in solution and the experimentally demonstrated 
stability within a useful buffer range over time (studied through TSA, see chapter 7), made it an ideal 
candidate for pt-DCC experiments. So far, two fragment-inspired DCLs were designed and subjected 
to the pt-DCC experiment producing three positive hits; additional derivatives and negatives were 
synthesized for testing, for a total of eight compounds synthesized. Preliminary SPR data reported an 
enhancement in binding affinity compared to the single fragments and pending the setup of the 
STD NMR procedure on the newly selected construct (ongoing), the compounds will be subjected to 
the NMR–in silico coupled study, so far systematically applied throughout the thesis to elucidate the 
structural features of their interaction with HuR and guide the design of new HuR-ligands as well as 
building new DCLs.  
As mentioned at the beginning of the present discussion, for this thesis, we decided to apply a strategy 
focused on developing compounds with affinity for the ELAV subtype HuR by targeting a site on the 
large protein–RNA interface and progressively assess and upgrade the NMR–in silico-built binding 
site model. Nonetheless, we are very well aware that the relevance of the compounds designed and 
synthesized in the present project in the interference/displacement of HuR–RNA complexes should 
be evaluated. Both REMSA (at single dose) and AlphaScreen (in a dose-response curve) could be 
employed to monitor the efficacy of the hits in displacing the protein–RNA complex using a protocol 
that has been already set up and reported.63 Nonetheless, our aim is to simplify this procedure by 
obtaining the same results through one single assay based on the displacement of a fluorescent RNA 






high-throughput format for selected HuR constructs,66 thus the in-house set up and execution should 
be straightforward. Additional structural studies of the displacement could be then performed only 
on active interferers by a STD NMR-based displacement/competition assay on HuR–small molecule–
RNA. Our preliminary results on this approach have underlined the sensitivity of RNA to RNAses 
which can be found on any surface and buffer solution if not properly treated. Within the instrumental 
apparatus of NMR experiments, it can be quite hard to provide and maintain this environment over 
the experiment time-range, often leading to compromised results and representing a liability. To 
overcome this issue, we have started to develop an approach based on the exploitation of PNAs 
(Peptide Nucleic Acid);174,175 while DNA and RNA have a deoxyribose and ribose sugar backbone, 
respectively, the PNA backbone is composed of repeating N-(2-aminoethyl)-glycine units linked by 
peptide bonds. The various purine and pyrimidine bases are linked to the backbone by a methylene 
bridge and a carbonyl group, thus they are not labile to RNAse action. Our preliminary study, 
performed with small derivatives and base units,†††† have already shown promising results for the 
development of a STD NMR-based competition assay.‡‡‡‡  
In the next steps, newly identified positive interferers of the HuR–RNA interaction will be subjected 
to biological studies to evaluate the modulation of HuR-binding by Ribonucleoprotein 
Immunoprecipitation (RIP) experiments, as well as the mRNA stability and translational efficiency 
of specific genes. The effects of the compounds on the stability of selected HuR target mRNAs will 
be evaluated by RT-qPCR in MCF7 cells in the presence of the transcriptional inhibitor 
Actinomycin-D, as already published.  
To complete the construction of the experimental map of the HuR–small molecule interactions, 
several options have been evaluated and a pathway has been devised. Starting from the team expertise 
and the newly published DEEP-STD experiment, we have already set up and performed 
differential-solvent experiments against native HuR on three selected natural products (see chapter 4) 
as well as compound (+) 1. By building differential maps we were able to highlight the nature of the 
amino acids present in the HuR binding site which are interacting with the compounds. Thanks to the 
features of the technique this information is gained for each interacting proton and not just for the 
general molecule. Moreover, since new constructs with different stability and different buffer 
requirements are now available to us, new experiments could be performed, including the possibility 
to try and exploit differential frequency DEEP-STD experiments. Finally, the very same collaboration 
which provided us with the new HuR constructs involves a structural biology team which performs 
 
†††† Materials provided by Dr. Cauteruccio and collaborators of the University of Milano. 






protein-observed NMR studies (see appendix V, contributions to the research). The procedures are 
currently under setup on selected compounds. The successful combinations of these approaches 
would overcome the still current lack of a defined small-molecule binding site on HuR and, compared 







Conclusion and research perspectives 
The work presented in this thesis took part in a larger collaborative project, which sees several 
competences, techniques and “mindsets” merge, aimed at solving one of the current pharmacological 
and medicinal puzzles: is it possible to drug an unusual target, in this case RNA-binding proteins and 
their complexes with RNA, and how can we do it? 
The PhD project, in particular, was carried out by focusing on the ELAV RBP family, exploiting 
subtype HuR as model protein. At the beginning of this work, much was unknown about HuR ligands 
and their interaction with HuR and its complexes with RNA, and a lot still is. Though this could 
appear as a limit, it also gave me the chance to apply, for the first time on this target, different ligand 
design approaches, structure-based and fragment-based, and to exploit different strategies for ligand 
discovery, such as multi-component reactions and protein-templated dynamic combinatorial 
chemistry.  
In spite of the realization that several differences occur in research between experimental plan 
(expectations) and experiments (reality), all initially planned activities could be performed, leading 
to 12 new compounds developed to act as HuR ligands.  
  
Figure 38. Updated summary timeline to recap the milestones in ELAV research at the time this thesis was 
finished.  
The hit compounds identified and synthesized throughout the PhD project have been submitted for 
further biological and biophysical characterization against the protein and protein−RNA complex 
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target, and the significance of the obtained small molecules in the modulation of gene expression, for 
treating clinically relevant diseases in which HuR−RNA complexes are involved, will be evaluated. 
To our knowledge, only one additional MedChem synthetic campaign was reported for HuR, 
following a different approach and gaining different results (see Manzoni et al., 2018164).  
Nonetheless, several questions remain unanswered in this study field. In particular, the definition of 
a small molecule binding site as well and the understanding of the relevance of small molecules 
inhibitors of the ELAV–RNA interaction, are the most pressing. Though this is the conclusion of the 
present thesis, the data gathered (and those still being processed) will be exploited within our group 
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Experimental Section 1 
Chapter 4: Exploration of HuR−ligand binding modes 
NMR spectra assignment in D2O for all compounds (283K) 
 
 
1H C  
6.73 109.70 2’’-6’’ 
6.34 106.27 2’-6’ 
5.89 95.44 6-8 
5.36 68.50 3 
4.80 76.69 2 
2.80 







1H C  
6.78 114.51 6’ 
6.68 119.05 2’ 116.21 5’ 
5.85 95.53 8 
5.83 95.84 6 
4.74 78.70 2 
4.06 66.20 3 
2.67 
27.60 4 2.52 
 
1H C  
6.67 114.66 2’ 116.66 5’ 
6.60 119.69 6’ 
5.84 95.43 8 
5.75 94.54 6 
4.55 80.50 2 
3.96 66.17 3 
2.62 
25.56 4 2.27 
 
1H C  
7.39 116.51 6’ 
7.28 122.47 2’ 
6.30 115.85 5’ 
6.03 95.84 8 
5.85 101.40 6 
4.63 102.77 1’’ 
3.60 67.76 4’’ 
3.51 71.00 2’’ 
3.33 72.18 3’’ 
3.32 59.80 6’’ 







































1H C  
7.33 116.5 2’ 
7.24 122.76 6’ 
6.65 115.38 5’ 
6.02 95.53 8 
5.85 101.60 6 
4.68 102.09 1’’ 
4.28 100.62 1’’’ 
3.51 67.57 6’’ 
3.41 69.92 2’’’ 
3.29 73.53 2’’ 
3.25 69.92 3’’’ 
3.20 75.60 3’’ 
3.14 68.89 5’’ 
3.12 74.73 4’’’ 
3.06 69.74 4’’ 
3.02 71.81 5’’’ 
0.82 16.52 6’’’ 
 
 
1H C  
7.69 128.69 2’-6’ 
6.75 115.70 3’-5’ 
6.32 102.22 3 
5.89 101.00 6 
4.81 72.11 1’’ 
4.75 100.22 1’’’ 
4.00 76.20 2’’ 
3.66 69.57 2’’’ 
3.51 71.20 5’’ 
3.48 79.23 3’’ 
3.39 61.81 6’’ 3.29 
3.32 79.89 4’’ 
3.24 69.09 3’’’ 
2.86 71.00 4’’’ 
2.02 68.44 5’’’ 


























1H C  
7.54 128.47 2’-6’ 
6.64 116.43 3’-5’ 
6.23 102.20 3 
6.10 96.90 6 
4.61 73.74 1’’ 
4.16 70.16 2’’ 
3.64 60.83 6’’ 3.54 
3.32 69.76 3’’ 
3.30 78.10 4’’ 
3.28 80.48 5’’ 
 
1H C  
7.61 146.50 4 
6.98 113.22 5 
6.42 104.38 8 
5.88 107.49 3 
4.77 101.4 1’ 
3.70 60.44 6’ 3.52 
3.40 75.71 2’ 
3.38 73.20 4’ 
3.35 72.88 5’ 
3.25 69.19 3’ 
 
 
1H C  
7.50 121.0 10 
7.47 nd 5 
7.44 nd 13 
6.89 108.8 6 
6.70 114.6 14 
5.43 96.1 1 
5.12 nd 16 
5.09 70.5 4’ 
4.07 68.0 2’ 
3.35 80.7 3’ 
3.31 60.3 OCH3 
3.08 27.4 15 
2.03 nd CH3 
1.47 24.5 17-18 
1.17 26.6 6’a 






























1H C  
7.40 146.10 7’ 
6.93 114.81 2’ 
6.85 122.49 6’ 
6.66 116.28 5’ 
6.13 114.82 8’ 
5.06 70.90 5 
3.97 70.32 3 
3.61 72.51 2 
1.93 37.70 6 1.80 
1.85 37.19 4 1.75 
 
1H C  
6.47 115.01 5 
6.41 115.30 5’ 
6.37 117.74 6 
6.27 109.33 2 
6.23 122.03 2’ 
6.20 112.23 6’ 
4.54 73.72  
4.23 71.3 9 4.14 
3.41 55.15 OCH3-OCH3’ 
2.64 34.94 7’ 2.33 
2.50 42.35 8 
2.40 44.94 8’ 
 
 
1H C  
7.26 137.50 5 
7.20 130.00 8 
7.05 115.94 4 
6.65 111.60 12 
4.95 100.07 1’ 
4.17 53.11  
3.71 56.71 6-OCH3 
3.70 60.64 6’ 3.49 
3.68 61.8 2-OCH3 
3.36-3.43 72.99-75.95 Overlap, 2’,3’,4’ 
3.34 61.62 3-OCH3 
3.26 69.51 5’ 
2.32 28.72 10 1.68 











































1H C  
5.32 94.04 A1 
5.22 125.52 12 
4.79 101.00 R1 
4.47 101.97 B1 
3.95 69.13 R5 
3.89 70.41 R2 
3.74 68.62 2 
3.66 70.24 R3 
3.63 76.48 A3 
3.48 77.28 n.d. 
3.47 75.69 n.d. 
3.48 74.73 n.d. 
3.43 68.95 A 
3.40 71.87 R4 
3.34 75.17 n.d. 
3.30 76.66 n.d. 
3.21 73.44 B2 
2.09 52.64 18 
1.57 47.07 9 
1.36 38.56 20 
1.14 46.70 5 
0.90 38.60 19 
 
-CH2: 
1H C  
4.02 
3.85 67.57 A6 
3.80 
3.64 60.00 B6 
3.40 
3.30 64.16 23 
2.09 
1.64 23.90 16 
1.93 
0.89 46.10 1 
1.91 23.00 11 
1.68 
1.47 36.50 22 
1.63 
1.07 27.80 15 
1.48 
1.20 32.10 7 
1.47 
1.31 30.00 21 
1.33 17.70 6 
 
-CH3: 
1H C  
1.20 16.59 R6 
1.06 22.89 27 
0.98 16.63 25 
0.90 20.46 30 
0.83 16.59 29 
0.70 16.87 26 






































Predicted binding modes 








Combined STD NMR-Docking histograms for all interacting compounds 
The following histograms plot the number of interactions and related HuR residue (as seen 
through molecular modeling) and absolute STD% for each interacting proton (as determined 





























































































































































































































































































































































































































































































































































































































































































































































































































* values over 1%: 7’= 3.6% 
 
 



























































































































































































































































































































STD NMR spectra of selected natural compounds acquired with differential solvent 
conditions (DEEP-STD experiment) 
Reference spectra; (b) STD spectrum in D2O; (c) STD spectrum in H2O:D2O 90:10. 
§ DEEP-STD spectra of 5  
 
 



















































Chapter 5: Structure-based approach to obtain new HuR ligands 
Design of the new scaffolds, docking and optimization: methods, structures of the originally 
designed compounds, and docking poses of selected examples 
Methods 
Protein HuR (PDB code: 4ED5) and uracil residues 8 or 9 (anchors U8-U9, PDB code: 4ED5) 
were individually uploaded into AnchorQuery. The anchor was modified by PyMol so as to 
bear an additional aromatic group to allow a π−π interaction with Tyr63, not naturally present 
between RNA and HuR. The pharmacophore features were edited maintaining the aromatic 
character of the uracil ring as well as the hydrogen-bond acceptor features of the carboxylic 
moiety. 
The query characteristics were selected under the filters tab. The maximum total hits value was 
set to 200 and ranking was done according to molecular weight (lower to higher). In our case, 
a total of four queries were submitted. 
The resulting hit compounds were downloaded and their energy optimized by MOLOC. Further 
visual inspection allowed us to evaluate intermolecular clashes with the protein. The final 
selection of 17 molecules was carried out through a docking study performed by LeadIT and 







Structures of the originally designed compounds 
The anchors are highlighted in light blue ovals. The different scaffold class is identified by 
color code: blue for piperidinones, red for aromatic heterocycles, green for N,N-disubstituted 









Docking poses of selected exemplary compounds 
Selected docking pose of one compound per scaffold class (II, VII, XII, XVII). Compounds are 
shown as gray sticks, HuR residues as gray lines. Green rectangles show additional interactions 
compared to those established by U8–U9, and the yellow rectangle highlights Tyr63, which 
new compounds are designed to target. 
Synthesis: general methods and experimental procedures 
General methods 
Reagents and solvents for synthesis were purchased from Sigma-Aldrich (Italy, The 
Netherlands), Acros, Alpha Aesar or Apollo Scientific. Unless otherwise specified, 
commercially available reagents were used as received from the supplier. Solvents were 
purified according to the guidelines in Purification of Laboratory Chemicals. Microwave 
dielectric heating was performed in a Discover® LabMate instrument (CEM Corporation) 
specifically designed for organic synthesis and following an appropriate microwave program. 
Melting points were measured on SMP3 Stuart Scientific apparatus. Analytical thin-layer-






Kieselgel 60 F254, Merck) and visualized by ultra-violet (UV) radiation, acidic ammonium 
molybdate (IV), or potassium permanganate. Flash chromatography (FC) was performed on 
Silica Gel 60 (particle size 230–400 mesh, purchased from Nova Chimica). IR spectra were 
recorded on a Jasco FT/IR-4100 spectrophotometer with ATR module; only noteworthy 
absorptions are reported. Unless otherwise specified, 1H and 13C nuclear magnetic resonance 
(NMR) spectra were recorded on a Bruker Avance 400 MHz spectrometer and Bruker Avance 
500 MHz spectrometer at 25°C. 
Proton chemical shifts (δ) are reported in ppm with the solvent reference relative to 
tetramethylsilane (TMS) employed as internal standard (CDCl3, δ = 7.26 ppm; CD2Cl2, δ = 5.32 
ppm; acetone-d6, δ = 2.05 ppm). The coupling constant values are reported in Hz. 13C-NMR 
spectra were recorded with complete proton decoupling. Carbon chemical shifts (δ) are reported 
in ppm relative to TMS with the respective solvent resonance as internal standard (CDCl3, δ = 
77.23 ppm; CD2Cl2, δ = 54.00 ppm; acetone-d6, δ = 29.84 ppm). 
The compounds purity was determined by Ultra High Pressure Liquid Chromatography 
(UHPLC) coupled with UV-ESI/MS. The analyses were carried out on an Acquity UPLC 
Waters LCQ FLEET system using an ESI source operating in positive ion mode, controlled by 
ACQUITY PDA and 4 MICRO (Waters). Analyses were run on an Acquity BEH Shield RP18 
(50 x 2,1 mm;1,7 μm) column, at room temperature, with gradient elution (solvent A: water 
containing 0.1% of formic acid; solvent B: methanol containing 0.1% of formic acid; gradient: 
10% B in A to 100% B in 3 minutes, followed by isocratic elution 100% B for 1.5 minutes, 
return to the initial conditions in 0.2 minutes) at a flow rate of 0.5 mL/min. All final compounds 
had a purity suitable for our purposes. 
Exact mass analyses (HRMS) were performed using a Thermo Scientific LTQ Orbitrap-XL 
mass spectrometer. 
Experimental procedures 
2-(3,5-Dimethoxyphenyl)-1-isobutyl-6-oxopiperidine-3-carboxylic acid (9)  
 
To a solution of aldehyde 6 (100 mg, 0.60 mmol) in acetonitrile (2 mL) at room temperature 
(rt), isobutylamine 7 (60 μL, 0.60 mmol) and two drops of formic acid were sequentially added. 
The reaction mixture was irradiated with a microwave power of 140 W at 120 °C for 30 minutes. 






(2 mL) and then glutaric anhydride 8 was added (54 mg, 0.60 mmol). The suspension was 
refluxed overnight under stirring. The solvent was decanted and the remaining brown solid was 
washed with ether affording a beige solid. The crude was further purified by flash 
chromatography eluting with DCM/MeOH (9:1, v/v), giving (±)-9 as a white solid (125 mg, 
62%). 
Mp=176−179 °C. 1H-NMR (400 MHz, CDCl3): δ 9.76 (s, 1H), 6.31 (t, J = 2.2 Hz, 1H), 6.24 
(d, J = 2.2 Hz, 2H), 5.02 (d, J = 2.9 Hz, 1H), 3.88 (dd, J = 13.6, 8.8 Hz, 1H), 3.71 (s, 6H), 2.80 
(dd, J = 7.5, 4.2 Hz, 1H), 2.64 (ddd, J = 17.7, 10.5, 6.9 Hz, 1H), 2.48 (ddd, J = 18.1, 6.0, 3.4 
Hz, 1H), 2.19 (dd, J = 13.5, 6.1 Hz, 1H), 1.96 (t, J = 22.9 Hz, 1H), 1.85 (d, J = 35.1 Hz, 1H), 





To a solution of (±)-9 (100 mg, 0.30 mmol) dissolved in THF (3 mL), TBTU (115,3 mg, 0.36 
mmol) and DIPEA (0.109 mL, 0.62 mmol) were subsequently added. The reaction mixture was 
stirred at room temperature for 30 minutes. N-benzylethylendiamine (10) (0.045 mL, 0.30 
mmol) was added and the solution was stirred overnight at room temperature. The reaction 
mixture was concentrated in vacuo, dissolved in DCM (10 mL) and washed with water (20 
mL). The organic layers were dried over Na2SO4, filtered and the solvent evaporated in vacuo. 
The crude was purified by FC eluting with DCM/MeOH (8:2, v/v), giving 1 as yellow oil (99.6 
mg, 71%) 
1H-NMR (400 MHz, CDCl3): δ 7.25 (ddd, J = 7.4, 4.5, 1.5 Hz, 2H), 7.22-7.15 (m, 3H), 6.30-
6.27 (m, 1H), 6.25 (d, J = 2.2 Hz, 2H), 5.96 (s, 1H), 4.75 (d, J = 7.5 Hz, 1H), 3.87-3.80 (m, 
1H), 3.67 (d, J = 3.0 Hz, 6H), 3.62 (d, J = 4.5 Hz, 2H), 3.23 (ddd, J = 16.9, 11.9, 5.1 Hz, 1H), 
3.18-3.08 (m, 1H), 2.61 (dq, J = 8.7, 4.9 Hz, 1H), 2.57-2.49 (m, 2H), 2.46−2.34 (m, 2H), 2.15 
(dd, J = 13.6, 6.2 Hz, 1H), 2.02-1.83 (m, 4H), 0.78 (d, J = 5.4 Hz, 3H), 0.76 (s, 3H). 13C-NMR 
(101 MHz, CDCl3): δ 175.26, 171.13, 161.21, 142.42, 104.53, 99.23, 61.68, 55.31, 52.91, 
45.75, 28.78, 26.41, 20.18, 19.97, 18.50. IR (νmax/cm-1): 836.9, 910.4, 991, 1061.62, 1156.12, 
1203.36, 1607.38, 1746.23, 3002.62, 3027.69, 3381.57. UHPLC-ESI-MS: ABS tR = 1.55 min, 









The synthesis was carried out according to the reported procedure. Benzyl-2-(aminomethyl) 
carbamate (11) (500 mg, 2.57 mmol) was dissolved in ethyl formiate and the suspension was 
refluxed overnight. The reaction mixture was concentrated in vacuo giving the corresponding 
N-formylcarbamate as a white solid without further purification. Subsequently, to a solution of 
the carbamate thus prepared (530 mg, 2.38 mmol) and TEA (2 mL, 14.35 mmol) in DCM 
(10 mL) cooled to 0°C under stirring, POCl3 (0.25 mL, 2.68 mmol) was dropwise added 
keeping the internal reaction temperature below 5°C. After the POCl3 addition was complete, 
the reaction was left at rt for 4 hours. The change in color for the reaction mixture, from yellow 
to dark brown, was indicative of the end of the reaction (further confirmed by TLC). The 
reaction was thus purged in a 5% NaHCO3 aq solution and icy-water, then extracted with DCM 
(40 mL) and the organic layer washed with a 5% NaHCO3 aq solution. The collected organic 
layers were dried on dry MgSO4, filtrated and the solvent evaporated in vacuo. The crude was 
re-dissolved in DCM and filtered on silica pad. The filtrate was evaporated once more in vacuo 
yielding isocyanide 12 as a brown oil (271 mg, 52 %). 1H NMR (500 MHz, CDCl3): δ 7.43-
7.28 (m, 5H), 5.35 (s, 1H), 5.14 (s, 2H), 3.52 (d, J = 10.6 Hz, 2H), 3.47-3.36 (m, 2H).  
 
Benzyl-2-((6-(3,5-dimethoxyphenyl)-imidazo[2,1-b]thiazol-5-yl)amino)ethyl) carbamate (2) 
 
Aldehyde 6 (100 mg, 0.60 mmol) and amine 13 (49 mg, 0.60 mmol) were dissolved in ACN (2 
mL) in a microwave vessel and added two drops of formic acid. The reaction mixture was 
irradiated with a microwave power of 200 W, at 120 °C for 30 minutes. Then, zirconium 
chloride (10 mg, 0.07 mmol) and isocyanide 12 (120 mg, 0.60 mmol) were sequentially added. 
The reaction mixture was then quickly warmed in an oil bath at 70-80°C and stirred overnight. 
Successively, the reaction was concentrated in vacuo, dissolved in DCM (25 mL) and washed 
with a HCl aq solution (1 M). The aqueous layer was basified with a NaOH aq solution (1 M) 






and then filtered; the solvent was evaporated in vacuo. The crude was purified by FC eluting 
with DCM/MeOH (97:3, v/v) affording 2 as a yellow oil (57.5 mg, 21 %). 1H NMR (400 MHz, 
CDCl3): δ 7.42 (d, J = 2.3 Hz, 1H), 7.27 (s, 5H), 6.97 (d, J = 2.2 Hz, 2H), 6.67 (d, J = 4.4 Hz, 
1H), 6.31 (t, J = 2.1 Hz, 1H), 5.01 (s, 2H), 3.73 (s, 6H), 3.47 (d, J = 5.2 Hz, 1H), 3.21 (dd, J = 
11.1, 5.6 Hz, 2H), 3.14-3.07 (m, 2H). 13C-NMR (101 MHz, CDCl3): δ 161.03, 156.70, 144.90, 
136.43, 136.19, 135.70, 128.55, 128.18, 128.09, 116.83, 112.66, 108.58, 104.30, 99.56, 66.99, 
55.43, 48.60, 41.23. IR (νmax/cm-1): 926.62, 992.19, 1204.33, 1295.93, 1318.111510.95, 
1596.77, 1738.51, 2837.74, 2935.13, 3001.66, 3181.01, 3333.36. UHPLC-ESI-MS: ABS 




A solution of sodium p-toluenesulfinate (4.45 g, 25 mmol) in water (30 mL) was stirred for 30 
minutes until a clear solution was obtained. Methyl tert-butyl ether (MTBE, 30 mL) was added, 
followed by the slow addition of HCl (37%, 2.1 mL, 25 mmol). The reaction mixture was stirred 
for an additional 30 minutes, and the aqueous layer was removed. The organic layer was diluted 
with toluene (30 mL) and concentrated under reduced pressure until approximately 80% of the 
solvent was removed. Heptane (10 mL) was added, and the precipitate white solid was collected 
by filtration, rinsed with heptane (10 mL) and dried in vacuo for 4 hours to give p-
toluenesulfinic acid (14) (2.46 g, 63% yield). 
A solution of 3-phenoxybenzaldehyde (15) (1.70 mL, 9.83 mmol), formamide (16) (1 mL, 25 
mmol) and chlorotrimethylsilane (1.40 mL, 11.00 mmol), in acetonitrile (5 mL) and toluene (5 
mL), was stirred under a nitrogen atmosphere at 50 °C for 5 hours. Then, p-toluenesulfinic acid 
(14) (2.46 g, 15.80 mmol) was added, and the reaction mixture was stirred at 50 °C for 16 hours. 
The reaction was cooled to rt, and then MTBE (5 mL) was added. After 5 minutes stirring, 
water (30 mL) was added. The collected organic phases were dried over dry MgSO4, filtered 
and concentrated in vacuo, affording the crude. MTBE (10 mL) was added, and the resulting 
mixture was cooled to 0 °C for 1 hour, and the precipitated white solid was collected by 
filtration, rinsed with MTBE (2 x 5 mL) and dried in vacuo at 60 °C for 5 hours. Compound 






purification.  1H-NMR (400 MHz, CDCl3): δ 8.12 (s, 1H), 7.71 (d, J = 7.8, 2H), 7.39-7.29 (m, 




A solution of intermediate 17p (2.00 mg, 5.25 mmol) and phosphorus oxychloride (1.1 mL, 
10.74 mmol) in THF (20 mL) was stirred at rt for 5 minutes. After cooling the reaction mixture 
to 0°C, triethylamine (4.4 mL, 31.50 mmol) was added dropwise over 45 minutes whilst 
keeping the internal reaction temperature below 10 °C. Afterwards, the reaction was warmed 
to 10 °C for 45 minutes. EtOAc (15 mL) and water (15 mL) were added, and the reaction 
mixture was stirred at rt for 5 minutes. The organic layer was washed with water (2 x 15 mL), 
saturated NaHCO3 solution (15 mL) and a saturated NaCl solution (10 mL). The collected 
organic phases were dried over dry MgSO4, filtered and concentrated in vacuo to afford 
compound 17 as a brown oil (1.62 g, 85%), which was used in the next step without further 
purification. 
1H-NMR (400 MHz, CDCl3): δ 7.64 (d, J = 8.2, 2H), 7.38−7.33 (m, 5H), 7.18−7.06 (m, 4H), 
6.98−6.96 (m, 2H), 5.59 (s, 1H), 2.46 (s, 3H). 
 
5-(1-Isobutyl-4-(3-phenoxyphenyl)-1H-imidazol-5-yl)106mylose106-2(1H)-one (3)  
 
A solution of isobutyl amine (7) (0.33 mL, 3.30 mmol) and 6-oxo-1,6-dihydropyridine-3-
carbaldehyde (18) (440 mg, 3.58 mmol) in anhydrous DMF (10 mL) was stirred under a 
nitrogen atmosphere at rt for 4 hours. Then, a solution of intermediate 17 (1.00 g, 2.75 mmol) 
in anhydrous DMF (5 mL) and K2CO3 (760 mg, 5.50 mmol) were added. The reaction mixture 
was stirred at rt for 72 hours. EtOAc (20 mL) and water (20 mL) were added, and the mixture 
was stirred for 10 minutes and extracted with EtOAc (3 x 10 mL). The combined organic layers 






organic phase was dried over dry MgSO4, filtered and concentrated in vacuo. The crude was 
purified by silica gel column chromatography (DCM/MeOH, 96:4, v/v) giving 3 as a yellow 
solid (159 mg, 15%). 
1H-NMR (400 MHz, CDCl3): δ 7.65 (s, 1H), 7.39−7.21 (m, 6H), 7.13-7.08 (m, 1H), 7.05 (t, J 
= 7.4, 1H), 6.95 (d, J = 7.8, 2H), 6.87 (dd, J = 8.0, 1.5, 1H), 6.62 (d, J = 9.8, 1H), 3.58 (d, J = 
7.5, 2H), 1.84 (dp, J = 13.7, 6.7, 1H), 0.84 (d, J = 6.7, 6H). 13C-NMR (101 MHz, CDCl3): δ 
164.65, 157.81, 156.90, 144.25, 139.00, 137.91, 136.52, 135.64, 129.95, 129.83, 123.69, 
123.53, 121.45, 121.31, 119.47, 117.35, 116.49, 109.99, 52.79, 29.79, 20.02. IR (νmax/cm-1): 
3060, 2960, 2926, 2871, 1678, 1658, 1623, 1581, 1542, 1488, 1434, 1332, 1312, 1231, 1163, 
1126, 1102, 1073, 997, 885, 838, 812, 790, 757, 736, 694, 639, 485, 461, 440. HRMS (ESI): 
calculated for C24H24N3O2 [M+H]+ 386.18685, found 386.18630.  
 
Methyl 2-(3,5-bis((tetrahydro-2H-pyran-2-yl)oxy)phenyl)acetate (20p) 
 
To solution of of methyl-2-(3,5-dihydroxyphenyl)acetate (19) (500 mg, 2.74 mmol) and 
pyridinium p-toluenesulfonate (22 mg, 0.087 mmol), in dry DCM (7 mL), was added dropwise 
dihydropyran (2.2 mL, 24.10 mmol) dissolved dry DCM (3 mL). The mixture became 
homogeneous at the end of the addition of the last reagent. After the end of reaction (3 h, TLC), 
the mixture was washed with water (2x), dried over MgSO4, filtered and evaporated in vacuo. 
Compound 20p was obtained as a yellow oil as a mixture of diastereoisomers and used in the 
next step without further purification (948 mg, 98%). 
1H-NMR (400 MHz, CDCl3): δ 6.69 (q, J = 1.8 Hz, 1H), 6.61 (t, J = 2.3 Hz, 2H), 5.39 (dt, J = 
6.1, 3.2 Hz, 2H), 3.89 (td, J = 11.3, 9.9, 3.0 Hz, 2H), 3.67 (s, 3H), 3.59 (dtd, J = 7.9, 4.0, 2.4 




A solution of ester 20p (900 mg, 2.57 mmol) in anhydrous DCM (10 mL) was stirred under a 
nitrogen atmosphere and cooled to −78°C; DIBAL-H dissolved in DCM (1 M, 4.13 mL, 3.86 






was quenched with a NH4Cl aq solution (20 mL), followed by addition of water (20 mL) and 
extraction with EtOAc (3 x 20 mL). The combined organic layers were washed with water (50 
mL) and an aqueous saturated NaCl solution (25 mL). The collected organic phases were dried 
over dry MgSO4, filtered and concentrated in vacuo. The crude so obtained was purified by FC 
(pentane/EtOAc, 8:2) affording aldehyde (20) as a mixture of diastereoisomers as a yellow oil 
(403 mg, 49% yield). 
1H-NMR (400 MHz, CDCl3): δ 9.68 (t, J = 2.4, 1H), 6.71 (d, J = 2.1, 1H), 6.55 (t, J = 2.1, 2H), 
5.38 (dt, J = 6.3, 3.1, 2H), 3.93−3.83 (m, 2H), 3.63-3.53 (m, 4H), 2.00−1.58 (m, 12H). 
 
2-(3,5-Bis((tetrahydro-2H-pyran-2-yl)oxy)phenyl)-N-(3-chlorobenzyl)ethanamine (22)  
 
Under a nitrogen atmosphere, a solution of aldehyde 20 (350 mg, 1.09 mmol) and 3-
chlorobenzylamine (21) (134 µL, 1.09 mmol) in anhydrous THF (20 mL) was refluxed for 15 
minutes. After cooling to 0°C, sodium triacetoxyborohydride (693 mg, 3.27 mmol) was slowly 
added to prevent the formation of foam. After stirring at rt for 24-hour, the reaction was 
quenched with a saturated NaHCO3 solution (40 mL) and extracted with EtOAc (3 x 20 mL). 
The combined organic layers were washed with water (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. Compound 22 was obtained as a mixture of diastereoisomers as a yellow 
oil (413 mg, 85% yield) and used in the next step without further purification. 
1H-NMR (400 MHz, CDCl3): δ 7.29 (s, 1H), 7.25–7.09 (m, 3H), 6.66–6.47 (m, 3H), 5.39–5.33 
(m, 2H), 3.93–3.83 (m, 2H), 3.77 (s, 2H), 3.56 (d, J = 9.9 Hz, 2H), 2.94–2.65 (m, 4H), 2.00–
1.58 (m, 12H). 
 
4-((Tetrahydro-2H-pyran-2-yl)oxy)benzoic acid (23) 
 
A solution of 4-hydroxybenzoic acid (1.00 g, 7.24 mmol) and pyridinium p-toluenesulfonate 
(64 mg, 0.25 mmol) in anhydrous DCM (12 mL) was treated dropwise with a solution of 3,4-
dihydro-2H-pyran (0.80 mL, 8.77 mmol) in anhydrous DCM (3 mL). The reaction mixture was 






of starting material. The organic layer was washed with water (2 x 15 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The crude was further purified by FC (DCM/MeOH, 99:1 
to 96:4 v/v) afforded 23 as a white solid (441 mg, 27% yield).  
1H-NMR (400 MHz, CDCl3): δ 8.06 (d, J = 8.8, 2H), 7.10 (d, J = 8.8, 2H), 5.53 (t, J = 3.0, 1H), 





A solution of carboxylic acid 23 (150 mg, 0.63 mmol) in anhydrous DMF (3.5 mL) was cooled 
to 0 °C, and HOBt (102 mg, 0.76 mmol), EDC·HCl (144 mg, 0.76mmol) were subsequently 
added. The solution was stirred under a nitrogen atmosphere at rt for 30 minutes. Then, a 
solution of amine 22 (280 mg, 0.63 mmol) and DIPEA (275 µL, 1.58 mmol) in anhydrous DMF 
(3.5 mL) was added. The reaction was stirred at rt for 24 hours. Successively, the reaction was 
quenched with water (10 mL) and extracted with EtOAc (2 x 15 mL). The combined organic 
layers were washed with water (30 mL) and a saturated NaCl solution (30 mL). The collected 
organic phases were dried over MgSO4, filtered and concentrated in vacuo. The crude was 
further purified by FC (pentane/EtOAc, 80:20 to 70:30, v/v), affording amide 4p as a colorless 
oil (245 mg, 60% yield). 
1H-NMR (400 MHz, CDCl3): δ 7.40−7.28 (m, 3H), 7.24−6.90 (m, 5H), 6.71–6.49 (m, 2H), 6.30 
(s, 1H), 5.43 (s, 1H), 5.35 (s, 2H), 4.71 (s, 1H), 4.28 (s, 1H), 3.95−3.80 (m, 3H), 3.67−3.54 (m, 









A solution of intermediate 4p (100 mg, 0.15 mmol) and pyridinium p-toluenesulfonate 
(17.3 mg, 0.068 mmol) in EtOH (7 mL) was stirred at 55 °C for 16 hours. The reaction solvent 
was evaporated under reduced pressure, and the reaction mixture was dissolved in EtOAc (10 
mL). The organic layer was washed with a saturated NaCl solution (2 x 10 mL) and water (10 
mL). The collected organic phases were dried over MgSO4, filtered and concentrated in vacuo. 
The obtained crude was purified by FC (DCM/MeOH, 97:3 to 96:4 v/v) yielding the final amide 
4 as a white solid (45 mg, 75%).  
1H-NMR (500 MHz, CD3OD at –50°C) [mixture of conformers]: δ 7.44–7.26 (m, 8H), 7.15–
7.04 (m, 4H), 6.79 (d, J=8.4, 4H), 6.18–6.07 (m, 4H), 5.93 (d, J=1.6, 2H), 4.79 (s, 2H), 4.36 (s, 
2H), 3.51 (t, J=6.7, 2H), 3.41 (t, J=6.7, 2H), 2.78 (t, J=6.7, 2H), 2.67 (t, J=6.7, 2H).13C-NMR 
(125 MHz, CD3OD at –50°C) [mixture of conformers] : δ 175.15, 174.58, 160.80, 160.36, 
159.79, 159.76, 159.48, 142.52, 141.47, 141.20, 140.71, 135.70, 135.41, 131.66, 131.44, 
129.84, 129.59, 128.83, 128.64, 127.93, 127.35, 127.25, 127.11, 126.30, 116.13, 115.98, 
108.09, 108.00, 101.36, 54.15, 51.75, 48.49, 47.92, 35.21, 34.14. IR (νmax/cm-1): 3307, 2927, 
1600, 1516, 1471, 1426, 1345, 1274, 1160, 1079, 1043, 994, 842, 767, 691, 592, 444. HRMS 
(ESI): calculated for C22H21ClNO4 [M+H]+ 398.1200, found 398.1154. 
 
STD NMR: methods and spectra (compounds 1 and 3) 
Methods 
All protein−ligand samples were prepared in a 1000:1 ligand/protein ratio. Typically, the final 
concentration of the samples was 400 μM of ligand and 0.4 μM of HuR, and the final volume 
was 200 μL. The buffer used is a 20 μM deuterated phosphate buffer pH 7.4. 
Prior to STD-NMR experiments compounds 1 and 3 were converted to the corresponding 
hydrochloride salt according to the following procedures. 
37% HCl (4 μL, 0.128 mmol) was added to a solution of (±)-1 (30 mg, 0.064 mmol) in methanol 
(500 μL)  under stirring. The solvent was then evaporated in vacuo obtaining final compound 






0.066 mmol) in methanol (500 μL) under stirring. The solvent was then evaporated in vacuo 
obtaining final compound 3 HCl as a light-yellow solid. 
1H-STD-NMR experiments were performed on a 600 MHz Bruker Avance spectrometer. The 
probe temperature was maintained at 283 K. In the STD experiments, water suppression was 
achieved by the WATERGATE 3-9-19 pulse sequence. The on-resonance irradiation of the 
protein was performed at −0.05 ppm. Off-resonance irradiation was applied at 200 ppm, where 
no protein signals are visible. Selective presaturation of the protein was achieved by a train of 
Gauss-shaped pulses of 49 ms length each. The STD-NMR spectra were acquired with an 
optimized total length of saturation train of 2.94 s. Blank experiments were conducted in 
absence of protein in order to avoid artefacts. 
Intensities of all STD effects (absolute STD) were calculated by division through integrals over 
the respective signals in STD-NMR reference spectra. The different signal intensities of the 
individual protons are best analyzed from the integral values in the reference and STD spectra, 
respectively. (I0−Isat)/I0 is the fractional STD effect, expressing the signal intensity in the STD 
spectrum as a fraction of the intensity of an unsaturated reference spectrum. In this equation, I0 
is the intensity of one signal in the off-resonance or reference NMR spectrum, Isat is the intensity 








Full NMR characterization in phosphate buffer (1, 3 and 4) and STD-NMR spectra (1 and 
3) 
Chemical shift assignment of compound 1 in phosphate buffer 20 mM pH = 7.4 at 283 K. 
  
  1H (ppm) 13C (ppm) Mult., J (Hz) N.O.E. STD % 
Ring A 
7.12 129.28 bs - 0.27 
0.19 7.25 129.42 bs - 
Ring B 
6.20 99.93 d, J = 1.8 OCH3 
0.03 
6.20 105.83 d, J = 1.8 OCH3-6-5-7°-8 
OCH3 3.50 55.50 s 12-11-13 0.15 
3 2.45 30.60 t, J = 6.8 4-5 0.20 
4 1.70 22.00 m 3-5-6   
5 2.52 49.30 m 4-6-12-11 0.27 
6 4.65 63.50 -  12-11-5-7°-8-9-10-4 - 
7° 2.05 51.40 
dd, J = 6.52; 
14.40 7b 0.33 
7b 3.37 51.40 m 7°-9-10-8 - 
8 1.62 25.40 m 9-10-6-7b - 
9-10 0.50 19.11 d, J = 3.35 8-7°-7b-6 0.40 
14 3.10 36.20 m 15 - 
15 2.6−2.55 45.80 m 14-16 - 
















Chemical shift assignment of compound 3 in phosphate buffer 20 mM pH = 7.4 at 283 K. 
 
  1H (ppm) 13C (ppm) Mult., J (Hz) N.O.E. STD % 
ring A 
7.26 (18) 131.1  m   
- 7.04 (17) 121.3 
 
d, J = 8.26   
6.96 (19) 119.5 m   
ring B 
6.67 (24-28) 115.4 d , J = 8.6   
0.30 7.09 (25-27) 119.6  t , J = 8.6   
6.96 (26) 129.9  m   
3 6.30 124.7 d, J = 9.4Hz    - 
4 7.23 
120.5  dd, J = 2.54; 
9.4 
  1.20 
6 7.29 144.1 d, J = 2.54   1.10 
9 8.64 138.1 s   0.20 
12 3.60 134.7  d, J = 7.8   - 
13 1.59 54.0  m   - 
14-15 0.53 28.3  d, J = 6.8   0.30 















Chemical shift assignment of compound 4 in phosphate buffer 20 mM pH = 7.4 at 283 K. 
 
  1H (ppm) 13C (ppm) Mult., J (Hz) N.O.E. STD% 
Ring A 
6.10 108.11 d, J = 2.03  6, 5 
0.40 5.98 100.86 s 4, 6, 5 
5.74 108.30 s 6, 5 
Ring B 
7.16 127.40 s 5, 4, 6 
0.36 7.13 126.32 m 5, 4, 6 
7.05 128.30 m 6 
Ring C 
6.72 128.74 d, J = 8.42  6, 5, 4 
0.25 
6.58 115.24 d, J = 8.42  6, 5, 4 
4 2.58 33.50  - 
Ring B, 
ring C, 
ring A, 5, 
6 
- 
5 3.57 50.70 bs 
Ring B, 
ring C, 
ring A, 4 
- 
6 4.30 52.90  - 











In silico studies: Methods and docking  
Methods 
Modeling simulations were performed starting from the crystal structure of the two N-terminal 
RRM domains of HuR complexed with RNA (PDB code: 4ED5). The complex was prepared 
using the Protein Preparation Wizard implemented in Maestro, using OLPS-2005 as force field. 
The Prime module allowed us to add all missing side chains; residual crystallographic buffer 
components and water molecules were removed and hydrogen atoms were added; side chain 
protonation states at pH 7.4 were assigned. 
The HuR-RNA complex was submitted to 10000 MacroModel minimization steps, using 
OPLS_2005 as force field. 
In order to consider the protein as ensembles of conformational states, we submitted the 
HuR−mRNA complex to 500 ns of molecular dynamics simulations (MDs). MDs were run 
using the Desmond package v. 3.8 at 300 K temperature and ensemble NPT class; the system 
was immersed in an orthorhombic box of TIP4P water molecules, extending at least 10 Å from 
the protein and counter ions were added to neutralize the system charge. The resulting trajectory 
was clustered with respect to RMSD (Root Mean Square Deviation), in order to explore all the 
structures obtained, getting ten representative structures, which were submitted to 10.000 
Macromodel minimization steps, using OLPS-2005 as force field. 
In detail, according to the Prime calculate Energy tool, the lowest- and highest-energy 
structures, were selected for molecular recognition studies. Furthermore, the two selected HuR 
states correspond to “open” and “closed” protein conformations. For our docking studies, we 
chose the “closed” HuR conformations. 
Compounds 1, 3 and 4 were prepared by means of LigPrep Tools at pH 7.4 and were submitted 
to 10000 MacroModel minimization steps, using OPLS_2005 as force field. Docking 
simulations were carried out exploiting the Glide software; by using SP v. 6.7 (standard 
precision) algorithm, 100 poses were generated for each ligand. 
RMSD values for each analyzed compound with respect to U8 











Selected docking poses and reported interactions (compounds 1 and 3) 
 
3D representation of HuR–1 interactions. Hydrogen bonds and hydrophobic interactions are 
displayed as yellow and dark dashed lines, respectively. RNA and HuR are represented as a 
brown and yellow cartoon, respectively. Compound 1 is shown in green sticks.  
We report the main interactions as follows: the benzyl ring is involved in hydrophobic 
interactions with Tyr63, Ile23, Asn25 and Leu61 of HuR. The carboxyl group of the piperidone 
ring establishes a double hydrogen bond with Arg97 and hydrophobic interactions with the 
same residues. The isopropyl group (that has the strongest STD signal) establishes strong 
hydrophobic interactions with HuR (specifically, residues Ile103, Phe154, Asp155, Arg153 and 
Ile133). The anchor moiety establishes hydrophobic interactions with Tyr26, Asn25, Ile23, 











3D representation of HuR–3 interactions. Hydrogen bonds and hydrophobic interactions are 
displayed as yellow and dark dashed lines, respectively; a π–π stacking interaction is shown as 
blue dashed line. RNA and HuR are represented as a brown and yellow cartoon, respectively. 
Compound 3 is shown in green sticks.  
We report the main interactions as follows: the external phenyl ring establishes a hydrophobic 
interaction with Phe65, while the phenyl directly bound to the imidazole ring establishes a π-
cation interaction with Arg153 and hydrophobic interactions with Ile133, Asn25 and Ile23. The 
imidazole ring is involved in hydrophobic interactions with Ser94, Lys92, Val93, Ile23 and 







Chiral resolution via enantioselective HPLC 
General Methods 
HPLC analyses were performed on a JASCO system: pump (PU 1580), degasser (DG-2080-
53) and mixer (LG-1580-02); PDA (photo array detector, MD 1510), injection system 
Rheodyne valve 7125 equipped with a 10 μL loop. Semi-preparative methods were conducted 
on the same system equipped with a 1mL loop. Specific rotations were determined on a DIP 
100 JASCO polarimeter, equipped with sodium (λ = 589 nm) and mercury (λ = 405 nm) lamps. 
A Laborota 4000 Efficient (Heidolph) rotary evaporator was exploited for solvent evaporation 
of each fraction. 
HPLC solvents (n-hexane, 2-propanol, ethanol, methanol), were acquired from Sigma Aldrich 
and VWR. 
Chromatographic analyses were performed on immobilized polysaccharide chiral columns: 
Regispack IA [tris-(3,5-dimethylphenyl carbamate) of 120mylose , 4.6 mm I.D. x 150 mm, s-
5μm] Regis Technologies, and Chiralpak IC [tris-(3,5-dichlorophenyl carbamate) of cellulose, 
4.6 mm I.D. x 250 mm, s-5μm]. 
Semi-preparative chromatography was carried out on Chiralpak IC (1 cm I.D. x 25 cm, s-5µm). 
Screening protocol for eluent mixtures to separate (±) 1 on REGISPACK IA and 
CHIRALPAK IC columns. 
Eluent Composition (v/v) Flow DEA 
1 n-Hex/EtOH (90:10) 1 mL/min 0.1% 
2 n-Hex /EtOH (85:15) 1 mL/min 0.1% 
3 n-Hex /EtOH (80:20) 1 mL/min 0.1% 
4 n-Hex /IPA (90:10) 1 mL/min 0.1% 
5 n-Hex /IPA (85:15) 1 mL/min 0.1% 
6 n-Hex /IPA (80:20) 1 mL/min 0.1% 
7 n-Hex /IPA (75:25) 1 mL/min 0.1% 
8 n-Hex /IPA (70:30) 1 mL/min 0.1% 
9 n-Hex /IPA (50:50) 1 mL/min 0.1% 


















The flow rate was determined as follows: 





Fsp =  flow rate on semi-preparative scale 
Fa  =  flow rate on analytical scale 
Lsp and La = column length 







21.16	𝑚𝑚A = 4	𝑚𝐿/𝑚𝑖𝑛 
The theoretical flow rate value was optimized according to the column operational pressure 
(flow = 2 mL/min). 
Results of the screening The most interesting conditions are highlighted in bold.  
Eluent REGISPACK IA CHIRALPAK IC K1 K2 α Rs K1 K2 α Rs 
1 6.906 8.402 1.217 1.204     
2 1.859 2.107 1.133 0.776     
3     3.775 - N/A N/A 
4 7.017 8.436 1.200 1.324     
5 3.209 3.825 1.192 0.762     
6 1.983 2.295 1.157 N/A 8.786 10.818 1.231 2.530 
7     4.974 5.890 1.184 1.896 
8 0.983 1.115 1.134 0.812 3.621 4.401 1.215 1.891 
9 0.564 - N/A N/A 1.482 1.837 1.239 1.460 








Semi-preparative chiral separation of (±) 1 enantiomers performed using Chiralpak IC 
(1 cm I.D. x 25 cm, s-5µm), n-Hex:IPA:DEA 75:25:0.1 (v/v/v), flow: 2 mL/min, 25°C, 
λ = 220 nm. Injection volume 1 mL x 4 (10 mg/ml in n-Hex:IPA 75:25).  
 
Interaction studies with HuR of (+) 1 and (–) 1 by STD NMR, and solvent- DEEP-STD 
STD NMR spectra 
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Solvent DEEP-STD spectra of of compound (+) 1: (a) Reference spectra; (b) STD spectrum in 





















Chapter 6: Design of new derivatives of synthetic hit 4 via fragment-based approach 
Screening of halogen-enriched fragment library on native HuR 
Screening of the 146-fragment library by SPR 
SPR experiments were performed using a Reichert SR7500DC surface plasmon resonance 
spectrometer (Reichert Technologies, Depew, NY, USA) equipped with a medium density 
carboxymethyl dextran hydrogel CMD500 sensor chip (Xantec Bioanalytics, Düsseldorf, 
Germany). HuR (37 kDa) was immobilized using amine coupling chemistry. The surface of the 
flow cells on the sensor chip were activated with a 100 μl injection of a 1:1 mixture of 0.1 M 
NHS (N-hydroxysuccinimide) and 0.1 M EDC (3-(N,N-dimethylamino)propyl-N-
ethylcarbodiimide) at a flow rate of 10 μl/min. HuR protein was applied to the flow cells at a 
concentration of 50 μg/ml in 10 mM acetate buffer pH 4.0 for immobilization at a flow rate of 
5 μl/min. The adjacent flow cell was left blank to use as reference channel. All surfaces were 
blocked with a 100 μl injection of 1 M ethanolamine•HCl pH 8.5 at a flow rate of 25 μL/min; 
the final signal (difference between protein channel and reference) corresponded to a density 
of 2000 RU (response units). Integrity of the binding site was confirmed by injecting 
epigallocatechin gallate (EGCG, see chapter 4, compound 1) as reference compound prior to 
the screening. To perform the screening and collect binding data, all fragments in 20 mM 
HEPES buffer pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% p20 (v/v), 5% DMSO (v/v), were 
injected over the flow cells at a flow rate of 50 μl/min at 20°C. Association was allowed for 1 
minute and dissociation for 2 minutes. A three-concentration-point screening was performed in 
duplicates (250−500−1000 μM) allowing to select 10 fragments for KD determination; the 
following curves were built with 10 concentration points (15 μM to 2 mM). Ethylene glycol 
80% in the running buffer was used for regeneration of the surface. Differences in the bulk 
refractive index due to DMSO were corrected by 7-concentration-point DMSO calibration 
(3.5%−6.5%) and blanks (running buffer) were injected for the following data fitting. 
Processing of the experimentally observed sensorgrams was obtained by successive subtraction 
of signals obtained for the protein and reference channels injected with the fragments under the 
same conditions, as well as DMSO and blank correction, exploiting Scrubber (Version 2.0c, 







Confirmation of binding for the 3 hit fragments by STD NMR 
Hit fragments were characterized by 1H NMR and assigned prior to the STD NMR experiments. 
1H NMR spectra were acquired on a 400 MHz Bruker Avance spectrometer using a 1 mM 
solution of each fragment in a 20 mM deuterated phosphate buffer pH 7.4, 5% DMSO-d6 at 
303K.  
One sample of protein HuR−hit fragment mix (a+b+c) was prepared in a 1000:1 
fragment/protein ratio. The final concentration of the samples was 800 μM for the ligands and 
0.8 μM of HuR, and the final volume was 500 μL. The buffer used is a 20 mM deuterated 
phosphate buffer pH 7.4. 
1H-STD NMR experiments were performed on a 600 MHz Bruker Avance spectrometer. The 
probe temperature was maintained at 283 K. Water suppression was achieved by the 
WATERGATE 3-9-19 pulse sequence. The on-resonance irradiation of the protein was 
performed at −0.05 ppm. Off-resonance irradiation was applied at 200 ppm, where no protein 
signals are visible. Selective presaturation of the protein was achieved by a train of Gauss-
shaped pulses of 49 ms length each. The STD NMR spectra were acquired with an optimized 
total length of saturation train of 2.94 s. A blank experiment was conducted in absence of 








Chapter 7: Fragment linking by protein templated dynamic combinatorial chemistry 
to identify new HuR ligands 
Thermal shift assay to study new protein constructs 
Both constructs were tested in a thermal shift assay (TSA) in their native buffer (20 mM 
Phosphate buffer pH 7.0) at six protein concentrations (0.25−10 μM). A 96-well plate was 
prepared for the experiment, each well was prepared in duplicate as reported in the table. The 
dye used is SyproOrange (Thermo Fischer Scientific) at the final concentration 4x. 
The plate was subjected to a thermal cycle (21 to 95°C, incremental temperature ramp of 0.5°C 
per minute) on a real-time PCR instrument (Step one 2.3).  
RRM1+2 (125 μM) 
final protein μM 10 5 2.5 1 0.5 0.25 
μL protein 2 1 0.5 2.5 1.25 0.625 
μL dye 2.5 2.5 2.5 2.5 2.5 2.5 
μL buffer 19.25 20.25 20.75 18.75 20 20.625 
μL DMSO 1.25 1.25 1.25 1.25 1.25 1.25 
 
RRM1+2+3_GGS (27 μM) 
final protein μM 10 5 2.5 1 0.5 0.25 
μL protein 9.26 4.63 2.32 2.5 1.25 0.625 
μL dye 2.5 2.5 2.5 2.5 2.5 2.5 
μL buffer 11.99 16.62 18.93 18.75 20 20.625 
μL DMSO 1.25 1.25 1.25 1.25 1.25 1.25 
 








Screening of halogen-enriched fragment library on native HuR 
Screening of the 146-fragment library by SPR 
SPR experiments were performed using a Reichert SR7500DC surface plasmon resonance 
spectrometer (Reichert Technologies, Depew, NY, USA) equipped with a medium density 
carboxymethyl dextran hydrogel CMD500 sensor chip (Xantec Bioanalytics, Düsseldorf, 
Germany). RRM1+2+3_GGS (37 kDa) and RRM1+2 (20 KDa) were immobilized using amine 
coupling chemistry. The surface of the flow cells on the sensor chip were activated with a 
100 μL injection of a 1:1 mixture of 0.1 M NHS (N-hydroxysuccinimide) and 0.1 M EDC (3-
(N,N-dimethylamino)propyl-N-ethylcarbodiimide) at a flow rate of 10 μL/min. The constructs 
were applied to the flow cells at a concentration of 50 μg/mL in 10 mM acetate buffer pH 4.5 
for immobilization at a flow rate of 5 μL/min. The adjacent flow cell was left blank to use as 
reference channel. All surfaces were blocked with a 100 μL injection of 1 M ethanolamine•HCl 
pH 8.5 at a flow rate of 25 μL/min; the final signal (difference between protein channel and 
reference) corresponded to a density of 3000 and 2000 RU respectively. Integrity of the binding 
site was confirmed by injecting epigallocatechin gallate (EGCG, see chapter 4, compound 1) 
as reference compound prior to the screening. To perform the screening and collect binding 
data, all fragments in 20 mM HEPES buffer pH 7.4, 150 mM NaCl, 3 mM EDTA, 
0.05% p20 (v/v), 5% DMSO (v/v), were injected over the flow cells at a flow rate of 50 μl/min 
at 20°C. Association was allowed for 1 minute and dissociation for 2 minutes. A three-
concentration-point screening was performed in duplicates (250−500−1000 μM) allowing to 
select 20 fragments for KD estimation; the following curves were built with 5 concentration 
points (125 μM to 2 μM). Ethylene glycol 80% in the running buffer was used for regeneration 
of the surface. Differences in the bulk refractive index due to DMSO were corrected by 
7-concentration-point DMSO calibration (3.5%−6.5%) and blanks (running buffer) were 
injected for the following data fitting. Processing of the experimentally observed sensorgrams 
was obtained by successive subtraction of signals obtained for the protein and reference 
channels injected with the fragments under the same conditions, as well as DMSO and blank 







Experimental conditions for the pt-DCC experiment 
Buffer selection by TSA 
A 96-well plate, containing seventeen 10 μM solutions of protein in sixteen buffers and H2O 
and 5% DMSO, (each solution prepared in duplicate) was stored at room temperature for four 
days, and sampled every day (day 0 to day 3) for TSA experiments. Blank and negative control 
wells were added to each TSA run. The solutions were sampled daily and tranfered in a TSA 
96-well plate prepared as described in the table.  
The dye used is SyproOrange (Thermo Fischer Scientific) at the final concentration 4x. 
The plate was subjected to a thermal cycle (21 to 95°C, incremental temperature ramp of 0.5°C 
per minute) on a real-time PCR instrument (Step one 2.3). 
 The buffers used are reported in the table 
Buffer Type pH 
Acetate 10 mM 5–5.5–6  
MES 20 mM 5.5–6–6.5 
Bis-TRIS 
20 mM 5.5–6–6.5–7 
Phosphate 
50 mM 5.5–6–6.5–7–7.5 
The final content of each well is reported in the table 
μL protein 2 
μL dye 2.5 
μL buffer 19.25 
μL DMSO 1.25 







The melting curves were analyzed using the Protein Thermal Shift 1.3 software and the Tm 
recorded for each sample was plotted against time. 
 
pt-DCC experiment 
Experimental setup  
The four reaction mixtures (two for each buffer type) were prepared as reported in the 
corresponding table.  
Blank Amount Final concentration 





Hydrazides 200 μM 
Aniline 1 mM 
DMSO 5% 
Total 200 μL  
 
pt-DCC Amount Final concentration 





Hydrazides 200 μM 
Aniline 1 mM 
DMSO 5% 
RRM1+2  
(125 μM) 64 μL 40 μM 


















RRM 1+2 Stability in Buffer
Acetate pH5 Acetate pH5.5 Acetate pH6
MES pH5.5 MES pH6 MES pH6.5
Bis-Tris pH5.5 Bis-Tris pH6 Bis-Tris pH6.5
Bis-Tris pH7 Phosphate pH5.5 Phosphate pH6
Phosphate pH6.5 Phosphate pH7 Phosphate pH7.5



















Aldehydes (100 mM) 1 μLx 2 2 mM 
Hydrazides (100 mM) 2 μL x 8 4 mM 
Aniline (1 M) 1 μL 20 mM 
DMSO 31 μL - 
Total 50 μL  
# The preparation of the pre-mixed solution followed a precise order to avoid triggering the 
reaction: 1) Hydrazides; 2) Aldehydes; 3) Aniline. The premixed solution was then added last 
to the reaction mixture.  
The four reactions were then left rotating for 36h and sampled at regular intervals starting from 
hour 0. The samples for HPLC-UV-MS monitoring were prepared as follows: 5 μL of each 
sample were added to a Eppendorf containing 44 μL ACN analytical grade (precipitates 
protein) and 1 μL NaOH 1 M (stops reaction reversibility). The vial was vortexed for 10 s and 
centrifuged for 5 min x 14000 RPM, 4°C, after which the supernatant was transferred to a HPLC 
vial for analysis. All analysis were performed on the same day at the end of the experiment. All 
samples previously collected were stored at 4°C. 
HPLC method 
HPLC-UV-MS analyses were performed on a ThermoScientific Dionex Ultimate 3000 UHPLC 
System coupled to a ThermoScientific Q Exactive Focus with an electrospray ion source. An 
Acquity Waters Column (BEH, C8 1.7 µm, 2.1 x 150 mm, Waters, Germany) equipped with a 
VanGuard Pre-Column (BEH C8, 5 x 2.1 mm, 1,7 µm, Waters, Germany) was used for 
separation. The mass spectrum was measured in positive mode in a range from 100 – 700 m/z. 
At a flow rate of 0.250 mL/min, the elution was performed in a gradient as reported in the table:  
(A = ACN + 0.1% HCOOH; B = H2O + 0.1% HCOOH) 
min %B %A 
0 90 10 
1 90 10 
17 5 95 
18.5 5 95 
18.6 90 10 
20.5 90 10 







Determination of equilibrium and quantification of product amplification 
Products were identified univocally by high resolution mass and the area of the attributed peak 
was integrated through the Excalibur software at the selected wavelength of 272 nm. 
To assess that equilibrium was reached, the area of each peak was plotted against time for each 
blank sample collected. Once the area reaches a value stable in time, the equilibrium is 
considered reached and the amplification can be investigated in pt-DCC samples.  
Amplification is calculated for each peak by attributing the arbitrary value of 100% to the area 
in the blank. According to the following proportion for each peak:  
AreaDCC : x = Areablank : 100. Then, x = (AreaDCC * 100) / Area blank.  
The amplification % is then calculated as A% = x – 100.  
There is no standard cut-off for selecting amplified products, since this depends on the amount 
of protein used and on the product affinity for the template. Nonetheless, in general, low values 
of A% (calculated as reported) could be attributed to small integration differences rather than 
actual amplification. If low amplifications are seen, a systematic study on a single library to 







DCL1 – Acetate buffer 
The equilibrium was reached after 10 h.  
 
The amplification was measured at 10, 24 and 30 h, and significant values were found for 10 
and 24 h for compound P10 (1): amplification 83% (10h), 107% (24h); Rt 12.86 min (indicated 









0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Blanks DCL-1 Acetate
P7 P15 P4 P3 P3 P11 P8






RT: 4.01 - 13.48






















RT: 11.98RT: 8.81RT: 7.21 RT: 12.61RT: 8.03
RT: 9.93 RT: 11.81 RT: 12.64RT: 8.46
RT: 10.85
RT: 12.67RT: 6.47
RT: 11.29RT: 9.90 RT: 12.91RT: 8.01
RT: 8.88RT: 6.44
RT: 6.56
RT: 5.00 RT: 7.32
RT: 4.30 RT: 8.99RT: 6.06
NL:
7.10E8




RT: 3.98 - 13.40




















RT: 3.98 - 13.40






















RT: 3.98 - 13.40





















RT: 3.98 - 13.40































DCL1 – Phosphate buffer 
The equilibrium was reached after 12 h. 
 
The amplification was measured at 12, 24 and 30 h, and significant values were found for 10 
and 24 h for compound P10 (1): amplification 121% (12h), 328% (24h); Rt 12.85 min (indicated 








0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Blanks DCL-1 Phosphate
P7 P15 P4 P3 P3 P11 P8
P16 P6 P14 P2 P13 P10
d:\ms-data\jmk\serena\dcc_008\dcc8_24h 06/13/19 21:20:41
RT: 3.97 - 13.51






















RT: 8.04 RT: 8.80 RT: 9.91 RT: 12.60
RT: 11.96RT: 7.20
RT: 8.45 RT: 8.82 RT: 11.79RT: 8.01 RT: 0.85
RT: 10.37
RT: 10.86RT: 6.46 RT: 9.88
RT: 12.89RT: 4.98
RT: 6.55









RT: 3.98 - 13.50




















RT: 3.98 - 13.50






















RT: 3.98 - 13.50




















RT: 3.98 - 13.50



































DCL2 – Acetate Buffer 
The equilibrium was reached after 10 h.  
 
The amplification was measured at 10, 24 and 30 h, and significant values were found for 
10 h for compounds P9 (5) and P11 (6): Hit P9 (5), amplification 121% (10h); Rt 12.82 min; 














0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Blanks DCL-2 Acetate
P11 P14 P13 P6 P5 P10
P2 P4 P7 P9 P1
d:\ms-data\jmk\serena\dcc_009\dcc9_10h 06/14/19 06:32:31
RT: 5.97 - 14.00








































RT: 5.97 - 14.00






















RT: 6.00 - 13.99




















RT: 6.00 - 13.99






















RT: 6.00 - 13.99

































DCL2 – Phosphate Buffer 
The equilibrium was reached after 10 h.  
 
The amplification was measured at 10, 24 and 30 h, and significant values were found for 




General synthetic procedure 
An equimolar amount of aldehyde (~50 mg) and hydrazide were dissolved in dry MeOH under 
a N2 atmosphere, and the reaction was heated to reflux and stirred overnight. The final 
compounds often precipitated as white/yellowish solids. The solids were washed with cold 
methanol (3 x 3 mL) and centrifuged three times, finally the solvent was evaporated under 
reduced pressure. The purity and confirmation of Rt was assessed by HPLC, and the compounds 












0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
Blanks DCL-2 Phosphate
P11 P14 P13 P6 P5 P10
P2 P4 P7 P9 P1
d:\ms-data\jmk\serena\dcc_010\dcc10_10h 06/14/19 13:41:50
RT: 5.97 - 14.00























RT: 11.60RT: 7.51 RT: 13.06
RT: 8.77
RT: 13.38
RT: 7.49 RT: 12.87RT: 10.68 RT: 12.12RT: 7.54
RT: 12.45
RT: 8.91RT: 7.26 RT: 8.29 RT: 9.56
RT: 7.21 RT: 10.05RT: 7.62RT: 6.45
NL:
5.18E8




RT: 5.97 - 14.00




















RT: 6.00 - 13.99
















RT: 6.00 - 13.99






















RT: 6.00 - 13.99
































Characterization of synthesized compounds 
1H NMR spectra were measured in DMSO-d6 (D) or CDCl3 (Cl) on a Bruker Fourier 500 
spectrometer (500 MHz). The chemical shifts are reported in parts per million (ppm) relative to 
the corresponding solvent peak. The coupling constants of the splitting patterns were reported 
in Hz and were indicated as singlet (s), doublet (d), triplet (t) and multiplet (m). Due to the 
presence of isomers for acylhydrazones, some of the signals are doubled (minor form in grey). 
Compound Structure 1H NMR (ppm)§§§§ 
1 (D) 
 
11.69 (NH, s); 8.01 (CH, s); 
7.72 (2H, 2,6 B, o/l); 7.59 (1H, 3 A s); 
7.45 (3H, 3,4,5 B, d, J = 5.84); 
7.34 (1H, 5 A, d, J = 9.35); 
7.09 (1H, 6 A d, J = 9.35); 
5.32 (2H, CH2, s). 
11.65 (NH, s); 8.27 (CH, s); 
7.71 (2H, 2,6 B, o/l); 7.63 (1H, 3 A, s); 
7.45 (3H, 3,4,5 B, o/l); 
7.40 (1H, 5 A, d, J = 9.35); 
7.12 (1H, 6 A d, J = 9.35); 
4.82 (2H, CH2, s). ratio ~3:1 
2 (D) 
 
11.64 (NH, s); 8.02 (CH, s); 
7.72 (2H, 2,6 B, o/l); 
7.45 (4H, 3,4,5 B, o/l; 3 A o/l); 
7.27 (1H, 5 A, t, J = 7.72); 
7.03 (1H, 6 A d, J = 8.37); 
6.96 (1H, 4 A, t, J = 7.72); 
5.32 (2H, CH2, s). 
11.67 (NH, s); 8.28 (CH, s); 
7.73 (2H, 2,6 B, o/l); 
7.45 (4H, 3,4,5 B, o/l; 3 A o/l); 
7.31 (1H, 5 A, t, J = 7.72); 
7.09 (1H, 6 A d, J = 8.37); 
7.01 (1H, 4 A, t, J = 7.72); 
4.82 (2H, CH2, s). ratio ~2.5:1 
 

























11.78 (NH, s); 8.16 (5 B, s); 
8.04(CH, s); 7.59 (1H, 3 A, d, J = 2.4); 
7.33 (1H, 5 A, dd, J = 2.4; 8.7); 
7.06 (1H, 6 A, d, J = 8.7); 
5.27 (CH2, s). 
11.75 (NH, s); 8.28 (5 B, s); 
8.12 (CH, s); 7.62 (1H, 3 A, d, J = 2.4); 
7.41 (1H, 5 A, dd, J = 2.4; 8.7); 




11.64 (NH, s); 8.02 (CH, s); 
7.71-7.45 (5H, 3,4,5 B; 2,6 B, o/l); 
7.33 (2H, 3,5 A, dt); 
6.97 (2H, 2,6 A dt); 5.17 (2H, CH2, s). 
11.59 (NH, s); 8.34 (CH, s);  
7.71-7.45 (5H, 3,4,5 B; 2,6 B, o/l); 
7.38 (2H, 3,5 A, dt); 




13.28 (NH B1, s); 11.84 (NH, s); 
8.50 (CH, s); 8.13 (1H, 2 B, d); 
7.83 (1H, 5 B, d, J = 8.31); 
7.79 (1H, 3 B1, s); 
7.56 (1H, 6 B d, J = 8.31); 
7.19 (1H, 5 A1, t, J = 7.72); 
7.06 (1H, 6 A1, d, J = 7.72); 
6.98 (1H, 2 A1 s); 6.96 (1H, 5 A s); 
6.90 (1H, 4 A1, d, J = 7.72); 
5.68 (2H, CH2, s); 2.28 (3H, CH3, s), 
1.31 (9H, (CH3)3, s). 
6 (D) 
 
13.26 (NH B1, s); 11.90 (NH, s); 
9.29 (1H, s); 8.89 (2H, s); 8.15 (1H, s); 
8.09 (1H, s); 7.74 (2H, m); 
7.50 (1H, d); 
6.96 (1H, 4 A, t, J = 7.72); 
4.64 (2H, CH2, s). 
13.28 (NH B1, s); 11.98 (NH, s); 
8.90 (1H, s); 8.87 (2H, s); 8.36 (1H, s); 
8.12 (1H, s); 7.85 (1H, s); 
7.82 (1H, d); 7.57 (1H, d); 













































11.61 (NH, B, s); 11.48 (NH, s, o/l); 
8.55 (1H, s); 8.26 (1H, d); 
7.83 (1H, s); 7.44 (1H, d);  
7.23–7.13 (3H, m; o/l);  
7.06–6.98 (2H, m; o/l);  
6.94–6.90 (2H, m; o/l); 
5.70 (CH2, s); 2.26 (CH3, s); 
1.31 ((CH3)3, s); 
11.48 (NH, s, o/l); 8.07 (1H, d); 
7.81 (1H, s); 7.23–7.13 (3H, m; o/l); 
7.06–6.98 (2H, m; o/l);  
6.94–6.90 (2H, m; o/l); 
5.63 ((CH3)3, s); 2.17 (CH3, s); 
1.35 ((CH3)3, s); 
ratio ~5:1 (full assignment pending 2D 
spectra due to overlap) 
8 (Cl) 
 
13.19 (NH, s); 7.53 (1H, 5 B, s); 
7.32 (CH, s); 7.15 (1H, 2 A1, s); 
7.09 (2H, 4,6 A1, d, J = 6.93); 
6.96 (1H, d, 5 A1, J = 6.93); 
6.64 (1H, 5 A, s); 
5.74 (CH2, s); 2.23 (CH3, s); 


























SECTION 2: Application of Dynamic Combinatorial Chemistry approach to 
obtain Bacterial Metalloprotease LasB ligands potentially acting as inhibitors 
1. Introduction and Aim 
The present chapter describes the first application of Dynamic Combinatorial Chemistry 
performed during the research work of my thesis. Motivated to learn this strategy for ligand 
discovery, I participated in a project whose target is the extracellular metalloprotease (LasB), 
an anti-infective target studied in the group of Prof. Hirsch at the Helmholtz Institute for 
Pharmaceutical Research Saarland, where I spent three stays abroad. This research project aims 
at developing new compounds to address the increasing emergence of resistant bacteria, in 
particular Gram-negative species176,177 such as Pseudomonas aeruginosa, one of the three most 
problematic pathogens on the WHO priority list.176 In this study field, a promising new 
approach is to target bacterial virulence to disarm pathogens rather than killing them. 
Pseudomonas aeruginosa produces several virulence factors, which contribute to disease 
progression, some of which represent interesting anti-infective targets.178,179 LasB is a major 
virulence factor, with a key role in the pathogenicity of P. aeruginosa. This enzyme is a zinc-
metalloprotease with high structural similarity to thermolysin.180 Among its main functions is 
the cleavage of connective tissue components such as elastin and collagen, thus allowing the 
bacteria to colonize in the host.181 Moreover, LasB allows P. aeruginosa to evade the human 
immune response by cleaving selected immunoglobulins and cytokines.182 For this reason, this 
protease represents an attractive anti-infective target, also due to its extracellular localization 
which facilitates drug discovery as permeation of the Gram-negative cell wall is not needed.183  
LasB belongs to the thermolysin (M4) family of enzymes and within this class, the rather open 
active site cleft of the protease can close through conformational changes upon binding of 
inhibitor.184 To date, several zinc-chelating inhibitors of LasB have been described,185,186 
including compounds bearing a mercaptoacetamide, a thiol, or a hydroxamic acid motif 
attached either to small peptides187 or to aniline.188 Additional derivatives are currently under 
study in the group.  
The application of a dynamic combinatorial chemistry approach could allow for the discovery 
of new scaffolds able to bind LasB which could be improved to act as enzyme inhibitors. 
Different groups and moieties with the potential for zinc-chelation were included in the 
building-block libraries. Moreover, given the similarity of binding site with other collagenases, 






research group) on the collagenase ColH from the Gram-positive pathogen Clostridium 
histolyticum.189 The same four DCL libraries were utilized for experiments, and the hits are 
currently being evaluated for inhibition of both enzymes. In case of lack of inhibition, all hits 
will be tested to assess binding to both targets.  
2. Protein-templated DCC to obtain new LasB ligands 
Establishment of the experimental conditions 
For LasB, experimental conditions were established by applying the protocol of the LasB 
enzyme-activity assay, where the degradation of a fluorogenic substrate is monitored over the 
experimental timeframes. With high activity of the enzyme, the fluorescence increases over 
time, while if the enzyme is inhibited, or has lost activity due to a loss in stability, the 
fluorescence remains constant during the experiment; plotting the fluorescence against 
experimental time gives a measure of activity. This way, by testing the protein stored in 
different buffers, for different periods of time, it is possible to plot slopes against storage time, 
building a curve which shows how the activity changes during the period of storage.  
The same 16 buffers plus water were exploited to establish the experimental conditions, and the 
activity was followed for 4 days for all buffers. Selected buffers were studied until day 8, finally 
allowing to choose phosphate buffer pH 6. 
Optimization of the pt-DCC experiment 
A total of six pt-DCC experiments were performed to progressively solve issues related to low 
amplification, slow equilibration and ill choice of building blocks. The final conditions chosen 
regarding protein concentration (to afford determination of significant amplification) and 
equilibrium (reached in reasonable timeframes) involve the use of 40% protein (over .  
As for building blocks, the most sensitive component was identified in the aldehydes; in fact, 
the use of deactivated aldehydes (i.e., in this specific case, few aldehydes were tried directly 
linked to a EDG) did not afford the corresponding acylhydrazones in the dynamic combinatorial 
library, supposedly due to their low reactivity, not compatible with the timeframes of the pt-
DCC experiment. This should be taken into consideration when building a DCL, to avoid false 
negatives. Another issue was found with building blocks sensitive to the drastic pH changes 
applied to freeze the reaction at each sampling. Since detection is done by mass, if the final 
compounds have a different mass than expected, due to instability of one portion of the 
molecule (i.e., in this specific case, a catechol-like portion), the impossibility to unequivocally 
identify the products and thus the related amplification, could once again lead to false negatives. 






the suspected building blocks to the same treatment done at each sampling followed by injection 
in the HPLC-UV-MS, and comparison with the profile of the building blocks as such.  
Such building blocks were thus removed from the libraries and replaced. The final compounds 
bearing the same portion could still be synthesized and tested, if considered necessary, without 
involving them in a pt-DCC experiment. 
Dynamic combinatorial libraries 
Four dynamic combinatorial libraries were designed to exploit the chemistry of acylhydrazones, 
based on commercially available aldehydes and hydrazides (the structures are reported in figure 
39). The blank and pt-DCC experiments were conducted in parallel and monitored via HPLC-
UV-MS upon protein precipitation (by adding ACN) and pH-induced “freezing” of the reaction. 
As reported in paragraph 3.4.4, this is essential to separate, identify and quantify the amount of 
each DCL member formed unequivocally and without any artifacts to determine both 
equilibrium and pt-amplification.  
 
Figure 39. Building-block libraries subjected to the pt-DCC study for target protein LasB. 
Within the four libraries, five hits were selected from the first three libraries, while no 
significant amplification was determined for library 4. A pool of derivatives were chosen for 
synthesis and testing (also after comparison with the results obtain by Dr Konstantinovic for 
the corresponding DCC experiments with ColH), for a total of ~15 final compounds (only the  













































































































































































































Figure 40. Structures of the compounds synthesized for evaluation against LasB. *The correct 
amplification of compounds 1 and 3, and 6 and 8 could not be univocally calculated due to peak overlap 
within the same experiment; thus both couples were synthesized for testing. §Compound 10 showed 
lower amplification compared to pt-DCC hits 9 and 11. 
3. Conclusion 
A dynamic combinatorial chemistry approach was exploited to discover new scaffolds able to 
bind LasB, a zinc-metalloprotease involved in the virulence of Gram negative P. aeruginosa, 
and potentially act as enzyme inhibitors. Given the nature of the LasB active site which we are 
targeting, different groups and moieties with the potential for zinc-chelation were included in 
the building block libraries. Four DCL were designed and subjected to pt-DCC experiments, 
finally affording five pt-DCC hits that were synthesized for biological testing. Along with these, 
additional derivatives and compounds that were not amplified serving as negative controls were 
synthesized, leading to a total of ~15 final compounds. Given the similarity of binding site with 
other collagenases, the same approach was carried out in parallel by Dr Jelena Konstantinovic 
(in the same research group – DDOP at HIPS) on Gram-positive collagenase ColH.189 The 
pooled hits, derivatives and negatives synthesized are currently being evaluated for inhibition 
of both enzymes. In case of lack of inhibition, all hits will be tested to assess binding to both 
targets, to elucidate the relevance of the pt-DCC approach in the discovery of new compounds 
as LasB ligands able to act as enzyme inhibitors. Positive results will open the way to the 
development of novel compounds useful as anti-infective agents according to a novel, 
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Experimental section 2 
Experimental conditions for the pt-DCC experiment 
Buffer selection by Enzyme Activity Assay 
A 96-well plate, containing seventeen 10 μM solutions of protein in sixteen buffers and H2O 
and 5% DMSO, (each solution prepared in duplicate) was stored at room temperature for four 
days, and sampled every day (day 0 to day 3) for activity assays. Blank and negative control 
wells were added to each assay run. The solutions were sampled daily and tranfered in a 
384-well plate prepared as described in the procedure. 
The buffers used (all containing 150 mM NaCl) are reported in the table: 
Buffer Type pH 
Acetate 10 mM 5–5.5–6  
MES 20 mM 5.5–6–6.5 
Bis-TRIS 20 mM 5.5–6–6.5–7 
Phosphate 50 mM 5.5–6–6.5–7–7.5 
Purified elastase prepared according to the published procedure was used.181 The fluorogenic 
substrate 2-aminobenzoyl-Ala-Gly-Leu-Ala-4-nitrobenzylamide was purchased from Peptides 
International (Louisville, KY, USA). Fluorescence intensity was measured for 60 min at 37 °C 
in black 384-well microtiter plates (Greiner BioOne, Kremsmünster, Austria) using a 
CLARIOstar microplate reader (BMG Labtech, Ortenberg, Germany) with an excitation 
wavelength of 340 ± 15 nm and an emission wavelength of 415 ± 20 nm. The assay was 
performed in a final volume of 50 μL of assay buffer (50 mM Tris, pH 7.2, 2.5 mM CaCl2, 
5% DMSO) containing LasB at a final concentration of 0.3 nM and the substrate at 150 μM. 
Before substrate addition, the enzyme was preincubated with the buffers for 15 min at 37 °C. 
After blank subtraction the fluorescence slope recorded for each sample (activity) was plotted 









Experimental setup  
Experiment 0 was performed without aniline. All other components of the reaction mixture 
were added as for experiments 1 (including the use of the same DCL). 
The reaction mixtures were prepared as reported in the following tables for experiments 1, 2 
and 3a***** (on the respective DCLs) 









Hydrazides 200 μM 
Aniline 1 mM 
DMSO 5% 
Total 200 μL  
  
 
***** DCL 3a was originally built in place of DCL 3, and the building blocks included a catechol-aldehyde 
(3,4-dihydroxybenzaldehyde). The latter was then removed (producing building-block library 3) to avoid 


















LasB stability in buffer
control - degraded Acetate pH5 Acetate pH5.5
Acetate pH6 MES pH5.5 MES pH6
MES pH6.5 Bis-Tris pH5.5 Bis-Tris pH6
Bis-Tris pH6.5 Bis-Tris pH7 Phosphate pH5.5
Phosphate pH6 Phosphate pH6.5 Phosphate pH7























Hydrazides 200 μM 
Aniline 1 mM 
DMSO 5% 
LasB 
(121 μM) 66.12 μL 40 μM 






Aldehydes (100 mM) 1 μL x 2 2 mM 
Hydrazides (100 mM) 2 μL x 8 4 mM 
Aniline (1 M) 1 μL 20 mM 
DMSO 31 μL - 
Total 50 μL  
# The preparation of the pre-mixed solution followed a precise order to avoid triggering the 
reaction: 1) Hydrazides; 2) Aldehydes; 3) Aniline. The premixed solution was then added last 
to the reaction mixture. The four reactions were then left rotating for 36h and sampled at regular 
intervals starting from hour 0. The samples for HPLC-UV-MS monitoring were prepared as 
follows: 5 μL of each sample were added to a Eppendorf containing 44 μL ACN analytical 
grade (precipitates protein) and 1 μL NaOH 1 M (stops reaction reversibility). The vial was 
vortexed for 10 s and centrifuged for 5 min x 14000 RPM, 4°C, after which the supernatant was 
transferred to a HPLC vial for analysis. All analysis were performed on the same day at the end 
of the experiment. All samples previously collected were stored at 4°C. 
The reaction mixtures were prepared as reported in the following tables for experiments 3 and 
4 (on the respective DCLs) 









Hydrazides 200 μM 
Aniline 1 mM 
DMSO 5% 
Total 200 μL  























Hydrazides 200 μM 
Aniline 1 mM 
DMSO 5% 
LasB 
(121 μM) 16.53 μL 10 μM 
Total 200 μL  
 
HPLC method 
HPLC-UV-MS analyses were performed on a ThermoScientific Dionex Ultimate 3000 UHPLC 
System coupled to a ThermoScientific Q Exactive Focus with an electrospray ion source. An 
Acquity Waters Column (BEH, C8 1.7 µm, 2.1 x 150 mm, Waters, Germany) equipped with a 
VanGuard Pre-Column (BEH C8, 5 x 2.1 mm, 1,7 µm, Waters, Germany) was used for 
separation. The mass spectrum was measured in positive mode in a range from 100–700 m/z. 
At a flow rate of 0.250 mL/min, the elution was performed in a gradient as reported in the table:  
(A = ACN + 0.1% HCOOH; B = H2O + 0.1% HCOOH) 
min %B %A 
0 90 10 
1 90 10 
17 5 95 
18.5 5 95 
18.6 90 10 
20.5 90 10 
After each run, a 8-minute wash was performed on the column.  
Determination of equilibrium and quantification of product amplification 
Products were identified univocally by high resolution mass and the area of the attributed peak 
was integrated through the Excalibur software at the selected wavelength of 272 nm. 
To assess that equilibrium was reached, the area of each peak was plotted against time for each 
blank sample collected. Once the area reaches a value stable in time, the equilibrium is 
considered reached and the amplification can be investigated in pt-DCC samples.  
Amplification is calculated for each peak by attributing the arbitrary value of 100% to the area 
in the blank. According to the following proportion for each peak:  






The amplification % is then calculated as A% = x – 100.  
There is no standard cut-off for selecting amplified products, since this depends on the amount 
of protein used and on the product affinity for the template. Nonetheless, in general, low values 
of A% (calculated as reported) could be attributed to small integration differences rather than 
actual amplification. If low amplifications are seen, a systematic study on a single library to 
enhance amplification and understand the significance of low values can be performed.  
Experiment 0 (DCL1) 
Given the demonstrated protein stability over 8 days in the chosen buffer, the first experiment 
was tried without aniline. The reactions (blank and pt-DCC) were monitored at time 0 and then 
once daily for 8 days. The area of each product peak was plotted against time to assess the 
moment equilibrium was reached. While for some products this appears to be after two days 
(~50 h), several others still showed variations after 3 days (~70 h) and equilibrium could not be 
ascertained by the end of the experiment. To reduce timeframes, all the following experiments 








Experiment 1 (DCL1) 
The equilibrium was reached after 6 h. 
 
The amplification was measured at 6, 21 and 26 h, and significant values were found for for 
compound P4 (2): amplification 32% (6h), ~50% (21 and 26h) Rt 11.43 min (indicated with a 
star). Compounds P5 (3) and P6††††† (1) showed peak overlap at Rt 13.67 min (indicated with 
a star); the amplification of the peak was 45% (6h) and ~35% (21 and 26h) both were 
synthesized as potential pt-DCC hits for testing. 
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Experiment 2 (DCL2) 
The equilibrium was reached after 8h. 
 
The amplification was measured at 8 and 24 h, and significant values were found for compound 








0 5 10 15 20 25 30
Blanks DCL-2
P10+P13 P15 P9 P1 P7 P3+P11 P5
d:\ms-data\jmk\serena\dcc_003\dcc3_24h 03/07/19 20:50:21
RT: 5.97 - 12.46
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Experiment 3 (DCL3) 
The equilibrium was reached after 10 h. 
 
The amplification was measured at 10 and 24 h, and significant values were found for 
compound P3 (9) and P11 (11): amplification 211% (10h) and 81 and 179% (10 and 24h), 
respectively; Rt 9.50 min and 10.77 min, respectively (indicated with a star). Lower 
amplification was observed for compound P8 (10) 80% (24h), Rt 13.08 min (indicated with §). 
Compounds P1 and P7 (6 and 8) showed peak overlap at Rt 13.89 min, amplified 101% (24h, 









0 5 10 15 20 25 30 35 40
Blanks DCL-3
P4+P14 P16 P10 P3
P9+P12+P15 P9+P13 P11 P6
P8 P2+P5 P1+P7
d:\ms-data\jmk\serena\dcc_005\dcc5_24h 03/28/19 16:13:59
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Experiment 4 (DCL4) 
No significant amplification was observed for this library. 
General synthetic procedure 
An equimolar amount of aldehyde (~50 mg) and hydrazide were dissolved in dry MeOH under 
a N2 atmosphere, and the reaction was heated to reflux and stirred overnight. The final 
compounds often precipitated as white/yellowish solids. The solids were washed with cold 
methanol (3 x 3 mL) and centrifuged three times, finally the solvent was evaporated under 
reduced pressure. The purity and confirmation of Rt was assessed by HPLC, and the compounds  
were characterized by HRMS and 1H NMR to confirm their identity (Average yield 65-80%). 
Characterization of synthesized compounds 
1H NMR spectra were measured in DMSO-d6 (D) or CDCl3 (Cl) on a Bruker Fourier 500 
spectrometer (500 MHz). The chemical shifts are reported in parts per million (ppm) relative to 
the corresponding solvent peak. Due to the presence of isomers for acylhydrazones, some of 
the signals are doubled (minor form in grey) and/or partially overlapped (o/l). 
1 (Cl) 13.19 (1H, s); 7.53 (1H, s); 7.32 (1H, s); 7.15 (1H, s); 7.09 (2H, d); 6.96 (1H, s); 
6.64 (1H,  s); 5.74 (2H, s); 2.23 (3H, s); 1.31 (9H, s). 
2 (D) 11.82 (1H, s); 8.12 (1H, s); 7.90 (2H, s); 2.78 (2H, t); 2.61 (2H, t); 1.81–1.74 (4H, m). 
3 (D) 11.61 (NH, B, s); 11.48 (NH, s, o/l); 8.55 (1H, s); 8.26 (1H, d); 
7.83 (1H, s); 7.44 (1H, d); 7.23–7.13 (3H, m; o/l); 7.06–6.98 (2H, m; o/l); 6.94–6.90 (2H, m; 
o/l); 5.70 (CH2, s); 2.26 (CH3, s); 1.31 ((CH3)3, s); 
11.48 (NH, s, o/l); 8.07 (1H, d); 7.81 (1H, s); 7.23–7.13 (3H, m; o/l); 7.06–6.98 (2H, m; o/l);  
6.94–6.90 (2H, m; o/l); 5.63 ((CH3)3, s); 2.17 (CH3, s); 1.35 ((CH3)3, s); 
ratio ~5:1  
4 (D) 11.78 (1H, s); 8.16 (1H, s); 8.04(1H, s); 7.59 (1H, d); 7.33 (1H, dd); 7.06 (1H, d); 5.27 
(2H, s). 
11.75 (1H, s); 8.28 (1H, s); 8.12 (1H, s); 7.62 (1H, d); 7.41 (1H, dd,); 7.1 (1H, d); 4.84 (2H, s). 
ratio ~3:1. 
5 (D) 11.64 (1H, s); 8.02 (1H, s); 7.71–7.45 (5H, m); 7.33 (2H, dt); 6.97 (2H, dt); 5.17 (2H, s).  
11.59 (1H, s); 8.34 (1H, s); 7.71–7.45 (5H, m); 7.38 (2H, dt); 7.03 (2H, dt); 4.69 (2H, s).  
ratio ~1.8:1 
6 (D) 11.43 (1H, s); 8.25 (1H, s); 7.96 (1H, d); 7.58 (1H, m; o/l); 7.33–7.28 (4H m; o/l); 7.21–






11.68 (1H, s); 8.46 (1H, s); 7.87 (1H, d); 7.58 (1H, m; o/l);  7.33–7.28 (4H m; o/l); 7.21–7.19 
(2H, m); 7.1 (1H, dd, o/l); 4.16 (1H, m) 3.87 (3H, s); 2.97–2.75 (2H, m; o/l); 1.32 (9H, s).  
ratio ~1.7:1 
7 (D) 11.66 (1H, s); 8.26 (1H, s); 7.95 (1H, d); 7.35 (3H, dd); 6.99 (3H, dd); 5.19 (2H, s); 
3.86 (3H, s). 
11.73 (1H, s); 8.61 (1H, s); 7.88 (1H, d); 7.57 (3H, td); 7.1 (3H, t); 4.67 (2H, s); 3.87 (3H, s). 
ratio ~2:1 
8 (D) 11.87 (1H, s); 8.67 (1H, s); 7.91 (1H, s); 7.58 (2H, dd); 7.12 (1H, d); 3.88 (3H, s); 
2.77 (2H, s); 2.60 (2H, t); 1.8–1.74 (4H, m). 
9 (D) 11.54 (1H, s); 8.69 (1H, s); 7.86 (1H, d); 7.58 (1H, dd); 7.09 (1H, d); 4.20 (1H, dd); 3.90 
(1H, dd); 3.87 (3H, s); 3.72–3.66 (2H, m); 3.58–3.52 (2H, m).  
10 (D) 11.86 (1H, s); 8.56 (1H, s); 7.67 (2H, d); 7.29 (1H, m); 3.96 (3H, s); 2.79 (2H, s); 2.61 
(2H,t); 1.80–1.74 (4H, m). 
11 (D) 11.46 (1H, s);  8.25 (1H, s);  7.87 (1H, m; o/l);  7.59–7.55 (1H, m; o/l);  7.09 (1H, t; o/l); 
3.84 (3H, s); 3.60 (2H, s); 2.15 (3H, s). 
11.65 (1H, s); 8.46 (1H, s); 7.87 (1H, m; o/l);  7.59–7.55 (1H, m; o/l);  7.09 (1H, t; o/l); 3.86  
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Exploration of ligand binding 
modes towards the identification 
of compounds targeting HuR: a 
combined STD-NMR and Molecular 
Modelling approach
Francesca Vasile  1, Serena Della Volpe1,2, Francesca Alessandra Ambrosio3, Giosuè Costa  3, 
M. Yagiz Unver4, Chiara Zucal5, Daniela Rossi2, Emanuela Martino6, Alessandro Provenzani5, 
Anna K. H. Hirsch4,7, Stefano Alcaro  3, Donatella Potenza1 & Simona Collina  2
Post-transcriptional processes have been recognised as pivotal in the control of gene expression, 
and impairments in RNA processing are reported in several pathologies (i.e., cancer and 
neurodegeneration). Focusing on RNA-binding proteins (RBPs), the involvement of Embryonic Lethal 
Abnormal Vision (ELAV) or Hu proteins and their complexes with target mRNAs in the aetiology of 
various dysfunctions, has suggested the great potential of compounds able to interfere with the 
complex stability as an innovative pharmacological strategy for the treatment of numerous diseases. 
Here, we present a rational follow-up investigation of the interaction between ELAV isoform HuR 
and structurally-related compounds (i.e., flavonoids and coumarins), naturally decorated with 
different functional groups, by means of STD-NMR and Molecular Modelling. Our results represent 
the foundation for the development of potent and selective ligands able to interfere with ELAV–RNA 
complexes.
Post-transcriptional modifications have a crucial role in regulating gene expression by shaping the fate of RNA 
transcripts in their journey from the nucleus (i.e., alternative splicing, poly-adenylation, nuclear export) to the 
ribosome (i.e., cytoplasmic localisation, stability, translation rate). Dysfunctions within these routes may be 
directly involved in several pathologies, such as neurodegenerative diseases, inflammation and cancer1–5.
In this context, RNA-binding proteins (RBPs), have been recognised to be play a prominent role as they affect 
the fate of target messenger RNAs (mRNAs) coding for proteins pivotal in key cellular functions1–5.
Embryonic Lethal Abnormal Vision (ELAV) or Hu proteins are among the better characterised RBPs with 4 
human mammalian isoforms: ubiquitous HuR, and HuB, HuC and HuD prevalently expressed in the nervous 
system (nELAVs)6. These proteins share a high degree of sequence homology (70–85%): they contain three RNA 
recognition motif-type (RRM) domains, each approximately 90 amino-acid in length7; the first two consecutive 
domains (RRM1 and RRM2) are near the N-terminus and link to the third domain (RRM3) by an unconserved 
hinge region, responsible for the nuclear/cytoplasmic shuttling occurring after protein activation8–10. RRM1 and 
RRM2 directly interact with target transcripts through highly conserved ribonucleoprotein (RNP) sequences 1 
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and 2, formed by 8 and 6 amino acids, respectively11,12 while RRM3, aside from binding the poly(A) tail of target 
mRNAs, has a crucial role in the homo- and heteromultimerisation of ELAV proteins (Fig. 1)13–15.
The interaction of the four mammalian ELAV proteins with many mRNAs, gives rise to various ELAV pro-
tein−RNA complexes, characterised by different physiological roles. As a consequence, ELAV proteins have a 
potential as pharmacological targets in several pathologies and compounds able to interfere with ELAV–RNA 
complexes may lead to different effects.
Particularly, it has been demonstrated that the RNA-binding protein HuR is highly abundant in many cancers 
and it may either be a marker for malignancy or have an oncogenic role in numerous tumor systems including 
breast, ovarian, and colon16–18. In fact, numerous HuR‐regulated mRNAs encode proteins implicated in carcino-
genesis19. For this reason, HuR can be considered a promising candidate target for governing gene regulatory 
mechanisms. Specifically, it was shown that HuR is upregulated and dysregulated in cancer cells, in part, through 
post-transcriptional gene regulation19,20. Among the small natural products that have been reported to inhibit 
HuR function, it is worth mentioning MS-444, since it has been shown to prevent translocation of HuR (and its 
associated mRNA cargos) to the cytoplasm. In a number of tumor cells, HuR inhibition by MS-444 leads to a 
dose-dependent reduction in cell proliferation by promoting apoptosis21. The majority of compounds interact-
ing/interfering with HuR−RNA complexes have been discovered by screening a large number (or a library) of 
commercially available compounds with high-throughput screening (HTS) approaches and using various bio-
logical assays based on different detection technologies21,22. Among them, dihydrotanshinone (DHTS), which 
is a nanomolar disruptor of HuR–RNA binding23, has potent HuR-dependent antitumor activity in vivo and is 
able to inhibit HuR multimerization24,25. Starting from the DHTS scaffold, medicinal-chemistry efforts led to the 
discovery of a series of small molecules called Tanshinone Mimics (TMs) with improved affinity and potency 
compared to DHTS26. Summing up, and going beyond the state of the art of HuR modulators available so far, the 
identification of the key druggable pockets on the surface of HuR is the essential milestone for discovering new 
molecular scaffolds.
As a part of our ongoing efforts in this field, we had already demonstrated the importance of the four RNP 
sequences in binding and stabilising a target transcript RNA by means of real-time quantitative PCR27, molec-
ular modelling28 and advanced NMR techniques (Saturation-Transfer Difference, STD, and Diffusion-Ordered 
Spectroscopy, DOSY)29.
In the present work, we set out to study the interaction between HuR and a number of compounds performing 
a systematic study which combines a ligand-based NMR technique, namely STD-NMR, with a molecular model-
ling study. It is well known that STD-NMR can be used as an epitope mapping device to describe the target–ligand 
interactions30–32 and it can be applied to weak and transient protein–ligand complexes that are difficult to study by 
other structural methods33,34. We compared results of STD-NMR with molecular dynamics and docking simula-
tions, thus affording an improved understanding of ligand–HuR interactions. Despite the high protein mobility 
and width of the protein–RNA interface, the combination of NMR and in silico studies resulted to be a reliable 
tool for understanding HuR-ligand binding modes35,36. The exploitation of these interactions lays the foundation 
for the design of ad hoc molecules endowed with HuR–RNA complex interfering properties.
Results
Selection of compounds, solubility and stability assessment. Our previous docking results 
had revealed that a series of natural products, i.e. epigallogatechin gallate, quercetin, okicenone, myricetyn, 
DHTS, MS-444 and others (described in SI), interact with HuR in the same regions as the target RNAs, more 
specifically with the RNP1 and RNP2 sequences of the RRM1 and RRM2 domains of the protein22. Based on these 
preliminary data, with the aim to study the ligand-HuR interaction, we collected a small series of compounds of 
natural origin, namely flavones, flavonols, flavan-3-ols and coumarins, naturally decorated with different func-
tional groups, as well as some unrelated compounds with similar features and a high degree of structural diversity 
(Figs 2, 3). We then tested their solubility and stability in the buffer and time-ranges required by STD-NMR 
experiments (24–48 hours). In detail, a 1 mM solution of each compound was dissolved in a 20 mM deuterated 
phosphate buffer within a 5.0–7.4 pH range (where necessary, a DMSO-d6 percentage ≤10% was added), at a 
283–303 K temperature range and studied by preliminary 1H-NMR experiments.
Among the tested molecules, we selected 13 soluble and stable compounds (Fig. 3) and used them in 
STD-NMR experiments to explore the ligand-protein interaction mode.
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NMR interaction studies with HuR. Prior to the interaction study with HuR, 1H, COSY, TOCSY, HSQC 
and NOESY spectra of the selected compounds were recorded in the proper deuterated phosphate buffer solution 
(pH range 5.8–7.4) at 298 K and 283 K. The assignment of all compounds is reported in SI.
STD-NMR is one of the most widespread NMR techniques used to study the interactions between small lig-
ands and macromolecules37,38. This method is based on the transfer of saturation from the protein to the bound 
ligand which in turn, by exchange, is moved into solution where it is detected. During the period of saturation 
(saturation time), the magnetisation gradually moves from the protein to the protons of the ligand when it binds 
to the target. The saturation time is chosen taking into account the efficiency of saturation transfer from protein 
protons during the bound state (intermolecular protein–ligand NOEs) and the rate of accumulation of saturated 
ligand molecules in the free state. Long saturation times permit to map all ligand contacts. This saturation pro-
cess is very efficient, so the modulation of the ligand signal induced by the protein is readily detected, even in 
the presence of a large excess of ligand. The ligand protons nearest to the protein are most likely to be saturated 
to the highest degree, and therefore have the strongest signal in the one-dimensional STD spectrum. The ligand 
protons located further away are saturated to a lower degree, and their STD intensities are weaker. Therefore, the 
degree of saturation of individual ligand protons (expressed as absolute-STD %) reflects their proximity to the 
protein surface and can be used as an epitope-mapping method to describe the target–ligand interactions39,40. 
STD-NMR spectra were initially acquired with varying saturation times from 0.98 s to 2.94 s and using different 
ligand–protein ratios (from about 500:1 to 1000:1). This large molar excess of ligand was employed in order to 
preclude the perturbations of absolute STD intensities due to rebinding effects, which would impede the correct 
determination of the group epitope mapping. Additionally, negative controls were performed to avoid artefacts 
due to the presence of signals in the blank. The optimal conditions found entail the use of 2.94 s, with high ligand/
protein ratios (around 1000:1) for all compounds and exploiting the Watergate sequence for water suppression.
The absolute STD percentages of each ligand protons were quantified in order to analyse their proximity to the 
protein surface (short protein–ligand distances produce a strong intensity of the corresponding STD signal). On 
the other hand, also relative STD percentages were calculated for each compound, by normalising all measured 
STD intensities against the most intense signal (which is arbitrarily assigned a value of 100%). The obtained group 
epitope mapping then illustrates which chemical moieties of the ligand are key for molecular recognition in the 
binding site.
STD-NMR spectra were acquired and processed accordingly for all 13 compounds and showed that 12 out of 
the 13 compounds studied interact with HuR displaying different intensities and epitopes of interaction. Given 
the difficulty of determining KD values for each compound with STD-NMR experiments due to the compounds 
poor solubility, we analysed the absolute STD data following two different keys: (a) the intensity of the STD sig-
nals (indicative of the proximity to the protein) and (b) the number of interactions for each ligand.
By reporting the number of the signals and related intensity of each compound, Table 1 gives a picture of their 
interaction with target HuR. Most of the compounds studied are characterised by a weak interaction with the 
protein within the absolute STD range of 0.4–0.1% and only a few ligands present STD signals exceeding the unit 
value (Table 1). Remarkably, compound 9 gives the highest number of interactions, while 6 is characterised by 
fewer and weaker interactions with the protein.
Moreover, compound 5 has the highest number of very strong interactions and several of medium and low 
intensity. On the other hand, the STD-NMR spectra for 13 and HuR showed absence of signal, indicative of lack 
of interaction between the two entities.
In addition to absolute STD% to evaluate the binding epitope of each compound, we calculated relative STD% 
as shown in Fig. 4 conveyed by colour code; black dots are used to indicate the most intense signal arbitrarily 
assigned the value of 100% relative STD. Subsequently, dark red dots represent relative STD over 80%, orange 
dots over 40%, and lime green dots under 40%; all are relative to the most intense STD signal. Additionally, in 
Fig. 5, we report the 1H and STD spectra for compound 5 and the corresponding coloured dots for relative STD% 
according to the colour code just described.
In silico studies on HuR protein. For the preliminary selection of the compounds to be used in our study, 
we utilised the rigid docking approach previously published22, which allowed us to quickly evaluate their poten-
tial. In order to better characterise the results obtained through STD-NMR, we decided to exploit a complemen-
tary in silico approach, which is computationally more demanding but enables a more detailed description of the 
ligand–protein behaviour in solution.
The protein crystal structure represents one of the many possible substates of the protein and, in most cases, 
the overall topology of the folded state is conserved, but a different orientation of even a single side chain in the 
binding site can significantly influence docking results41. Thus, in order to consider all conformational states of 
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HuR and to investigate potential protein rearrangement, we submitted the HuR RRM domain–RNAc-fos complex 
(PDB code: 4ED5) to 500 ns of Molecular Dynamics simulations (MDs)42. The result trajectory was clustered 
with respect to the Root Mean Square Deviation (RMSD), affording ten representative structures, which we used 
for the following docking studies. By applying this approach, we were able to reproduce the results previously 
reported on the two main conformational states of the HuR RRM domains, “open” and “closed”24,43. We analysed 
how the ligands can bind the two states and we observed that the STD contacts better fit with the “closed” state 
of HuR. Here, we will describe the interaction of each ligand with a HuR snapshot corresponding to the “closed” 
conformation. Molecular-recognition studies revealed that 12 of the 13 considered compounds interact with the 
same region in the HuR interaction site (Figs 6b and 7), in a deep pocket of domains RRM1 and RRM2, while 
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Compound
Number of interacting protons
Absolute STD % ranges
>1 1.0–0.9 0.8–0.7 0.6–0.5 0.4–0.2 <0.2
1 2 4
2 2 3 2
3 2 1 5
4 1 3 1
5 3 5 1
6 1 6
7 1 2 2
8 2 2
9 2 2 1 1 7
10 1 1 5
11 1 2 5 5
12 1 2 1 3
13 no signal shown
Table 1. Compound and related number of interacting protons within listed absolute STD range.
Figure 4. Group epitope mapping is highlighted for each compound. Relative STD percentages are conveyed 
by colour code: black dots indicate the most intense signal (100% relative STD), dark red dots over 80%, orange 
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compound 13 appears to interact with their external surface (docking poses divided by class of compound are 
reported in Fig. 7, while poses for single compounds are reported in SI). All contacts between the HuR binding 
site and ligands will be identified and catalogued in terms of hydrophobic contacts, hydrogen bonds and cation-π 
interactions.
Furthermore, it is worth noting that the HuR “closed” form thus explained could exceed the sole descriptive 
purpose and be exploited as a model for future structure-based virtual screening (SBVS) studies using different 
compound libraries, as already implemented on different targets in our previous investigations44,45, in order to 
identify new ligands interfering with the HuR–RNA complex.
Discussion
STD-NMR and molecular modelling results have been compared to gain a more detailed picture of the ligand–
protein interactions. As previously mentioned, MD simulations of HuR clearly showed that the protein can exist 
in two prevalent structural conformations: the “open” conformation and the “closed” one; the comparison of 
experimental STD-NMR and theoretical docking results, led us to hypothesise that the “closed” conformation is 
predominant in presence of interacting ligands.
For simplicity purposes, we present all the following considerations in the next section as a comparison of 
the results divided by class of compound. Combined NMR and docking data for all interacting compounds are 
Figure 5. 1H and STD spectrum of compound 5; coloured dots convey relative STD % according to the 
following colour code, black dots indicate the most intense signal arbitrarily assigned the value of 100% relative 
STD; dark red dots represent relative STD over 80%, orange dots over 40%, and lime green dots under 40%; all 
relative to the most intense STD signal.
Figure 6. (a) 3D representation of HuR RRM1 and RRM2 domain–RNAc-fos complex in its “closed” 
conformation; (b) Superimposition of all studied compounds in the “closed” conformation of the HuR–
RNA interaction site. HuR and RNAc-fos are represented as light-orange and orange cartoon, respectively; all 
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reported in supporting information, where for each compound, the intensity of the STD signal of each proton is 
compared with the number of the interactions observed in silico.
Concerning Flavan-3-ols or catechins (1–3), the three compounds considered differ only in the substitution 
and stereochemistry of the carbon atom in position 3; in particular, 2 and 3 only differ in the configuration of 
carbon 3 (respectively, (R) and (S)), while 1 (R) hosts an additional aromatic ring. STD experiments showed that 
the protons in positions 6 and 8 of the chroman-3-ol nucleus (structures in Figs 4a and SI) are mainly involved in 
their interaction with HuR. For all compounds, the aromatic nucleus in position 2, and the additional aromatic 
ring (gallate ester) in position 3 for compound 1, participate in the interaction, even though to a lesser degree. 
Docking results show that all compounds interact in the same region of the HuR interaction site (Fig. 7a); in par-
ticular, we observed that all aromatic rings in position 2 overlap and are involved in a cation-π interaction with 
Arg97. On the other hand, the chroman-3-ol nucleus of 1 does not show overlapping interactions with the same 
nucleus of compounds 2 and 3, as it projects towards Phe65, establishing hydrophobic interactions, whereas, the 
chroman-3-ol nucleus of compounds 2 and 3 overlaps with the gallate ester moiety of 1. Moreover, considering 
the evidence that 2 and 3 show very similar interactions, it is fair to assume that, within their scaffold, the absolute 
configuration at carbon 3 does not play a relevant role in the interaction with target HuR.
Within the flavonol compound class (4 and 5), the chromone-3-ol nucleus and the aromatic ring in position 
2 are highlighted as interacting regions (Figs 4b and SI), in line with the STD results obtained with the previous 
class (Flavan-3-ols). Furthermore, in both cases, the additional sugar rings in position 3 reinforce the interaction 
with the protein. In silico results show compounds 4 and 5 bind to HuR by interacting with the same residues 
(Arg153, Tyr63, Arg97, Pro98). However, the second sugar moiety of compound 5 (rhamnose) establishes addi-
tional hydrophobic interactions with Lys55 and Ile52 and a hydrogen bond with Tyr63 of RRM1, justifying a 
slight deviation from the binding site for compound 5 (Fig. 7b); this is also in accordance with the strong STD 
signals seen for this sugar moiety.
Different to the first two classes of flavonoids, the chromone nucleus of Flavones (6 and 7) shows almost com-
plete absence of STD peaks (Figs 4c and SI), which denotes a scarce contact with the protein, while, albeit weak, 
the interaction of the phenols in position 2 is still observed. The sugar moieties interact with the target protein 
HuR with different intensities, namely 1% absolute STD for the proton in position 2″ of 7, and 0.25% abso-
lute STD for 4′′′ of 6. Accordingly, 6 and 7 show different binding poses and very limited common interactions 
(Fig. 7c), as compound 7 elongates in the site forming hydrogen bonds with Asn82, Asn 25, Arg97 and Pro98, 
while compound 6 adopts a rather closed conformation and interacts with Arg153 and Ile103 of RRM2 and Tyr63 
and Lys55 of RRM1.
Focusing on coumarins (8 and 9), within STD experiments, compound 8 displayed few and weak interactions 
with HuR, presumably due to its small size. Furthermore, the sugar ring in position 6 does not improve its contact 
with HuR (Figs 4d and SI). In contrast, the STD spectrum of 9 showed a large number of intense peaks relative to 
both the coumarin nucleus and the conjugated moiety on the right-hand side (Figs 4d and SI). Moreover, the STD 
peaks relative to the noviose moiety, although weaker, convey its contribution to increasing the interaction with 
Figure 7. 3D representation of compounds divided by compound class in the HuR–RNA interaction site: (a) 
compounds 1, 2, 3 (blue, green and yellow sticks, respectively); (b) compounds 4 and 5 (green and violet sticks 
respectively); (c) compounds 6 and 7 (blue and green, respectively); (d) compounds 8 and 9 (violet and green 
sticks); (e) compounds 10, 11 and 12 (yellow, green, blue sticks, respectively); (f) compound 13 shown as green 
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the target HuR. Accordingly, docking studies reveal compounds 8 and 9 fit differently into the HuR interaction 
site, most likely due to their different size (Fig. 7d). In particular, the unsaturated conjugated regions of 9 protrude 
all along the considered interaction site, establishing hydrophobic interactions with Ile132 and Ile133 of RRM2 
and Lys92, Val93 and Ser94 of RRM1 and hydrogen bonds with Arg153 of RRM2 and Asn25 of RRM1 with the 
sugar portion projecting towards the solvent, providing additional interactions with Lys55 of RRM1.
As mentioned above, compounds 10–13 (Fig. 4e) are structurally different to both the original ones and the 
others involved in the study. For all of them, STD-NMR spectra show that the main interactions are achieved 
through the presence of unsaturated conjugated regions. Related docking results show compounds 10–12 occupy 
the deep part of the interaction site (Fig. 7e), as they appear to be involved in hydrogen-bond interactions with 
amino acids lining the deep part of the pocket such as Arg97, Arg131, Arg153, Asp105.
Finally, the STD spectrum of compound 13 in presence of HuR shows no signals indicating the absence of 
interactions. Within docking studies against the “closed” conformation of the protein, compound 13 only appears 
to interact with the external surface of the HuR–RNA interacting site probably due to steric hindrance, and does 
not overlap with the same region interacting with all other molecules. As a consequence, the in vitro interaction 
may be too weak to fall in the detection range of STD-NMR.
In addition to the considerations reported and discussed inside each compound class, it is worth remarking 
that recurring patterns can be recognised within the entirety of the compound collection investigated or wider 
subgroups.
Particularly, among flavonoid derivatives, flavan-3-ols and flavonols (Figs 4a,b, 7a,b and SI), both STD-NMR 
epitopes and in silico data show similar data, while flavones (Figs 4c, 7c and SI) show different behaviours. This 
has been attributed to both the difference in substitution positions (position 3 for the first two classes, versus 6 
and 8 for flavones) and in sugar linking (O- and C-glycoside, respectively), which increase the rigidity of the 
flavone scaffold.
Moving on to comment on the whole library, the importance of unsaturated conjugated regions as well as 
aromatic rings in the interaction with HuR has been noted throughout both STD-NMR and molecular modelling; 
additionally, these moieties seem to fit in repeated regions, and thus show hydrophobic interactions with repeated 
residues, namely Ile23, Asn25, Ser94, Ile133 and Arg153. Moreover, concerning the sugar moiety counterparts, 
we observed that the sugar rings directly attached to the aromatic ring of compounds 4, 5, 6, 7 and 8 and the 
quinic acid moiety of 10, overlap in the same region of the HuR binding site, establishing contacts with repeated 
residues (Arg97, Pro98, Ser99 and Ile 103).
To sum up, the results we obtained thus far evidenced that all interacting compounds interact with repeated 
residues of RNP1 and RNP2 of RRM1 domain; compounds 1–12 interact deep in the interaction site, while 13 
protrudes more outwardly towards the solvent. Furthermore, our study corroborates the already reported obser-
vation that interacting compounds could stabilise a closed conformation of the HuR binding site22,26,46.
Conclusions
The acknowledgement of the crucial role of post-transcriptional processes in the control of gene expression and 
their connection to various diseases has opened up a new fascinating route for discovering new drugs. RNA 
binding proteins, and particularly those belonging to the ELAV family, can affect the fate of target mRNAs whose 
coded proteins are fundamental for key cellular functions22,47. Interfering compounds may specifically affect 
the fate of ELAV protein−mRNA complexes at various levels, in both the nucleus and the cytoplasm, and also 
depending on the transcript targeted, as well as on other modulating factors (i.e., other RBPs and miRNAs). 
Since compounds interfering with all ELAV proteins may give rise to several effects, the tailored design and 
tissue-targeted delivery of selective compounds will be essential. To date, little structural information are available 
and a rational drug-design approach is difficult to employ at this stage and this is still considered a challenging 
research. In this manuscript, by focussing on HuR, owing to its high potential in cancer therapy and diagnosis48,49 
and in line with this observation, we studied the molecular recognition between natural ligands and the protein at 
the atomic level. We followed a systematic medicinal-chemistry approach based on structural biophysical studies 
by STD-NMR combined with molecular modelling. To properly explore the chemical space, we collected and 
selected a library of compounds of natural origin, applying structural diversity criteria.
The combined STD-NMR/molecular modelling approach allowed us to study the direct interactions between 
HuR and small molecules. By defining the ligand epitope of interaction and corroborating useful aspects about 
the protein conformational changes and HuR–ligand interactions, our findings represent a pivotal starting point 
to drive a drug discovery program. The preliminary SAR considerations drawn in this work will drive the design 
of a new ad hoc small focused compound library. In the near future, our efforts will be directed along this long 
and winding road.
Methods
Preliminary docking studies. The preliminary docking investigation on all 28 selected compounds was 
carried out as already described22.
Characterisation of the natural compounds, solubility and stability assessment. To assess the 
compound stability and solubility, 1H-NMR spectra were acquired on a 400 MHz Bruker Avance spectrometer 
using a 1 mM solution of each compound in a 20 mM deuterated phosphate buffer within a 5.0–7.4 pH range, and 
a 283–303 K temperature range; all occurring peak variations due to instability or solubility issues were monitored 
over time within a 48 h time period by acquiring 1H spectra at regular intervals; a DMSO-d6 percentage ≤10% 
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The full compound characterisation at the optimised conditions (pH 5.8 or 7.4, DMSO-d6% and 283 K) was 
performed for the final 13 selected compounds and required the further acquisition and assignment of COSY, 
TOCSY, HSQC and NOESY spectra.
Protein expression and purification. Protein expression, purification and purity assessment for HuR 
aliquots utilised in the STD-NMR study were performed as already described23,50.
STD-NMR. All protein/ligand samples were prepared in a 1000:1 ligand/protein ratio. Typically, the final con-
centration of the samples was 400 µM of ligand and 0.4 µM of HuR, and the final volume was 500 µL. The buffer 
used is a 20 µM deuterated phosphate buffer with 10% H2O, pH 5.8 for compounds 1–3, 9, 10; pH 7.4 for 4–8, 
11–13; an additional amount of DMSO-d6 ≤ 10% was used to aid the solubility of compounds 4, 5, 7, 11 and 13.
1H–STD-NMR experiments were performed at 600 MHz on a Bruker Avance spectrometer. The probe tem-
perature was maintained at 283 K. In the STD experiments, water suppression was achieved by WATERGATE 
3–9–19 pulse sequence. The on-resonance irradiation of the protein was performed at a chemical shift of −0.05 
ppm for all compounds with the exception of compound 13 which was irradiated at –2.00 ppm to avoid artefacts. 
Off-resonance irradiation was applied at 200 ppm, where no protein signals are visible. Selective presaturation 
of the protein was achieved by a train of Gauss-shaped pulses of 49 ms length each. The STD-NMR spectra were 
acquired with varying saturation times from 0.98 s to 2.94 s; the optimised total length of the saturation train was 
2.94 s for all compounds except for compound 1 for which we analysed the STD experiment at 0.98 s due to its 
instability observed after longer experimental timeframes.
Intensities of all STD effects (absolute STD) were calculated by division through integrals over the respective 
signals in STD-NMR reference spectra. The different signal intensities of the individual protons are best analysed 
from the integral values in the reference and STD spectra, respectively. (I0 − Isat)/I0 is the fractional STD effect, 
expressing the signal intensity in the STD spectrum as a fraction of the intensity of an unsaturated reference spec-
trum. In this equation, I0 is the intensity of one signal in the off-resonance or reference NMR spectrum, Isat is the 
intensity of a signal in the on-resonance NMR spectrum, and I0 − Isat represents the intensity of the STD-NMR 
spectrum.
Molecular Dynamics and Docking simulations. Starting from the crystal structure of the two 
N-terminal RRM domains of HuR complexed with RNA, deposited in the Protein Data Bank (PDB) with 4ED5 
PDB code51, we performed our modelling simulations. The HuR-RNA complex was prepared through Protein 
Preparation Wizard implemented in Maestro using OLPS-2005 as force field52–54. Residual crystallographic buffer 
components and water molecules were removed, missing side chains were built using the Prime module55, hydro-
gen atoms were added, side chains protonation states at pH 7.4 were assigned. The structure was then submitted 
to 10000 of MacroModel minimisation steps using OPLS-2005 as force field54,56. Molecular Dynamics (MD) 
simulations were run using Desmond package v. 3.8 at 300 K temperature and ensamble NPT class57,58. The system 
was immersed in an orthorhombic box of TIP4P water molecules, extending at least 10 Å from the protein, and 
counter ions were added to neutralise the system charge. The resulting trajectory was clustered with respect to 
Root Mean Square Deviation (RMSD), in order to explore all the collection structures obtained, getting ten repre-
sentative structures, which were submitted to 10.000 MacroModel minimisation steps, using OLPS-2005 as force 
field. Docking studies were carried out with Glide, software by using SP v. 6.7 (standard precision) algorithm and 
the binding pocket was identified by placing a cube centred on the mRNA, 10 poses for ligand were generated59.
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ABSTRACT: The key role of RNA-binding proteins (RBPs) in regulating
post-transcriptional processes and their involvement in several pathologies
(i.e., cancer and neurodegeneration) have highlighted their potential as
therapeutic targets. In this scenario, Embryonic Lethal Abnormal Vision
(ELAV) or Hu proteins and their complexes with target mRNAs have been
gaining growing attention. Compounds able to modulate the complex
stability could constitute an innovative pharmacological strategy for the
treatment of numerous diseases. Nevertheless, medicinal-chemistry efforts
aimed at developing such compounds are still at an early stage. As part of our
ongoing research in this field, we hereby present the rational design and
synthesis of structurally novel HuR ligands, potentially acting as HuR−RNA
interferers. The following assessment of the structural features of their
interaction with HuR, combining saturation-transfer difference NMR and in
silico studies, provides a guide for further research on the development of
new effective interfering compounds of the HuR−RNA complex.
KEYWORDS: RNA-binding protein, HuR−RNA complexes, STD-NMR, virtual screening, multicomponent reactions
RNA is an important regulatory element of many cellularprocesses, and thus, so-called RNA-binding proteins
(RBPs), play a prominent role in affecting the fate of target
mRNAs coding for proteins pivotal in key cellular functions.1−5
Therefore, a dysregulation of RBPs may be related to the
pathogenesis of several diseases.2,4,6 In 2018, the first candidate
drug targeting RBPs, called H3B-8800, reached the clinical
phase for the treatment of acute myelogenous leukemia and
chronic myelomonocytic leukemia.7 Among RBPs, the family
of ELAV (Embryonic Lethal Abnormal Vision) proteins is
involved in controlling the functional activities of diverse RNA
populations. In particular, HuR regulates splicing, stability, and
translation of thousands of coding and noncoding RNAs and is
therefore considered a valid drug target for anticancer therapy.8
HuR is a nuclear protein, but upon cell stress such as DNA
damage, it shuttles into the cytoplasm where it regulates the
fate of cargo mRNAs and determines the abundance of the
encoded proteins. Overexpression of HuR is associated with
tumor progression and poor prognosis in various cancer types.8
For this reason, compounds able to bind HuR and to inhibit
the formation of the HuR−RNA complex may have anticancer
properties. So far, various high-throughput screening cam-
paigns afforded several natural products.9−12
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After studying the concept of druggability of ELAV proteins
and related complexes with mRNA,13−15 we analyzed the
literature concerning the main findings on the ELAV−RNA
complexes from a medicinal-chemistry standpoint and defined
the interaction features of HuR and a small series of natural
products.16,17 In this Letter, we report on the structure-based
design and the synthesis of compounds with different “core
structures” and the investigation of their interactions with HuR
using a combination of saturation-transfer difference (STD)-
NMR and in silico studies. While on the RNA side the
interaction of HuR and RNA is mediated by AU-rich elements
(AREs), on the protein side two consecutive RNA recognition
motif-type (RRM1 and RRM2) domains are involved; these
interact directly with target RNAs through highly conserved
ribonucleoprotein (RNP1 and RNP2) sequences.18,19 For the
design of new compounds, we focused on a pocket-like region
hosting small HuR ligands, formed by the two asymmetric
units of the protein, which belong to RNP1 and RNP2 of
RRM1. Inspection of the cocrystal structure of the HuR RRM1
and RRM2 domains in complex with the ARE sequence of
RNAc‑fos (PDB code 4ED5) confirms that this region
corresponds to binding site of RNA uridine residues 8 and 9
(U8−U9) (Figure 1a).
We based our search for new scaffolds for HuR ligands on
the key interactions shown in Figure 1a and employed the free
web-based virtual screening platform AnchorQuery.21−24 This
program is specifically designed for targeting protein−protein
interactions (PPIs) with small molecules by combining the
anchor concept with one-pot multicomponent reaction
(MCR) chemistry. Briefly, PPI inhibitors are characterized
by specific moieties able to mimic amino acid side chains of the
donor protein, called “anchor motifs”. Since the contact
surfaces involved in PPIs are typically large and flat, similar to
protein−RNA interactions, we used NucleoQuery, a nucleo-
side derivative of the web application AnchorQuery, for the
rational structure-based design of HuR−RNA targeting
compounds. We selected U8 and U9 as anchors and
investigated whether one of the two nucleotides may be a
pharmacophore in terms of occupied position and interactions.
To increase the probability of discovering new ligands, the
anchors were modified so as to bear an additional phenyl
group to establish a π−π-stacking interaction with Tyr63
(Figure 1b). As a result of four runs in NucleoQuery, a large
library (800 molecules) featuring a wide range of structurally
diverse derivatives was obtained. To select the candidates for
synthesis, we relied on visual inspection and molecular-
recognition studies. This way, we selected 17 compounds
featuring piperidinones, aromatic heterocycles, N,N-disubsti-
tuted amides, and sulfonamides as scaffolds (see SI, S1.2). For
all compounds, the anchor shows good overlap with the
corresponding uracil ring, preserving the same hydrogen bonds
with Arg97 and Lys92, while the additional aromatic rings
should afford the desired interaction with Tyr63. Moreover,
selected compounds are engaged in additional interactions
with the protein, including hydrophobic interactions with
residues Ile23, Asn25, Phe65, Ile103, and Ile133 (docking
poses of exemplary compounds for each scaffold can be found
in SI, S1.3). Taking into account the synthetic feasibility and
commercial availability of the corresponding starting materials,
we selected the most promising scaffolds and replaced the
uracil moiety with an easy-to-handle starting material. We
evaluated several hydrophobic/aromatic portions as anchors,
potentially able to interact with HuR in the position occupied
by U8 and preserving its main contacts. Thus, we designed and
synthesized compounds 1−4 (Figure 2), characterized by
different scaffolds.
The computationally predicted structures can be easily
prepared by a short synthesis using MCR or equally efficient
processes.
Thus, compound 1 was synthesized by a Castagnoli−
Cushman reaction (CC-3CR)25 followed by amidation; 2 by a
Groebke−Blackburn−Bienayme ́ (GBB-2CR);26 3 by a Van
Figure 1. (a) HuR−RNA contacts (PDB code 4ED5) for U8−U9. Red lines show side-chain contacts; green lines show main-chain contacts.
Distances are expressed in Å.20 (b) Modification applied to the anchor to increase the predicted affinity. Dashed blue rectangles indicate hydrogen-
bond acceptors and dashed green rectangles hydrogen-bond donors on both the original and modified anchor, while the dashed orange circle shows
the anchor modification potentially allowing for additional hydrophobic interactions with the selected Tyr63 residue.
Figure 2. Structures of the four compounds selected for the
experimental study. The modified anchors are highlighted with light
blue circles. The different scaffolds (piperidinones, heterocycles, N,N-
disubstituted amides) are highlighted in bold.
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Leusen reaction (vL-3CR),27 and 4 by a reductive amination28
followed by acylation. Herein, we will briefly describe the
synthetic strategies adopted to obtain compounds 1−4.
Further details on protocols employed and compound
characterization are reported in the Supporting Information
(SI, S2).
Amidation of the acid intermediate trans (±)-9 with amine
10 afforded compound (±)-1 as racemate.29 The key
intermediate trans-6-oxopiperidine-3-carboxylic acid (9) was
obtained in good yield and diastereoselectivity, applying a
microwave-aided one-pot CC-3CR on benzaldehyde (6),
isobutylamine (7), and glutaric anhydride (8) (Scheme
1a).25 A microwave-assisted GBB-2CR,26,30 involving isocya-
nide 12, aldehyde 6, and amino-thiazole 13 produced
compound 2. Isocyanide 12 was obtained starting from
amine 11, which was converted into the corresponding
formamide and subsequently dehydrated (Scheme 1b). A vL-
3CR27 on commercially available aldehyde 18, isobutylamine
(7), and substituted TosMIC derivative 17 led to compound 3.
This MCR allows access to functionally rich imidazoles in a
single pot via cycloaddition of TosMIC reagents on imines,
generated in situ from an aldehyde and an amine under mildly
basic conditions. We synthesized 17 starting from p-
toluenesulfinic acid (14), which afforded the intermediate
formamide derivative upon reaction with commercially
available 3-phenoxybenzaldehyde (15), formamide (16), and
chlorotrimethylsilane; subsequent dehydration furnished iso-
cyanide 17 (Scheme 1c).31 Compound 4 was obtained by
reductive amination of aldehyde 20 followed by an amide
coupling with acid 23 followed by removal of the THP
protecting groups (Scheme 1d).28 Prior to the interaction
study, compounds 1−3 were converted into the corresponding
hydrochloride salts, and their solubility in both the buffer and
time-ranges required for STD-NMR experiments was
evaluated. Under these conditions, compound 2 proved to
be poorly soluble and had to be excluded from the interaction
study.
The interaction of compounds 1, 3, and 4 with HuR was
studied by STD-NMR spectroscopy. This technique, based on
the nuclear Overhauser effect, is a well-established epitope-
mapping methodology for studying the target−ligand inter-
actions.32 Briefly, the method relies on the selective irradiation
of the protein, which allows magnetization to be transferred to
the bound ligand; the observation of the ligand signals in the
NMR spectrum provides an indication of the interaction.
Those ligand protons that are nearest to the protein are more
likely to become highly saturated and therefore show the
strongest signal in the monodimensional STD spectrum.
Therefore, the intensity of the STD signal (expressed as
absolute STD percentage) reflects the proximity of the ligand
to the protein surface.33−38 The group epitope mapping
illustrates which chemical moieties of the ligand are key for
molecular recognition in the binding site. The analysis of STD
data shows that compounds 1 (Figure S3.2.1 and Table
S3.2.1), 3 (Figure S3.2.2 and Table S3.2.2), and 4 (Figure 3
and Table S3.2.3) interact with the protein.
For ligand 1, the isopropyl group shows the strongest
interaction (0.40 STD %), while the STD signal related to ring
B is the least intense (0.03 STD %); ring A contributes to the
interaction (0.20 STD %), while the protons of the amino
chain (H14, H15, and H16) do not give STD signals. The
binding of compound 3 to HuR is mediated by the pyridone
Scheme 1. Synthetic Pathways of Compounds 1−4a
aReagents and conditions: (a) Compound (±)-1: (i) 6, 7, HCOOH,
ACN, mw 120 °C, 50 W, 30 min; (ii) 8, p-xylene, reflux, 10 h, yield
62%; (iii) TBTU, DIPEA, THF, rt, 12 h, yield 71%. (b) Compound
2: (i) Ethyl formiate, 10 h; (ii) TEA, POCl3, DCM, rt, 4 h, yield 62%;
(iii) 6, 13, HCOOH, ACN, mw 120 °C, 30 min; (iv) 12, ZrCl4, 80
°C, 10 h, yield 21%. (c) Compound 3: (i) H2O, 30 min; (ii) HCl,
MTBE, 30 min; (iii) 15, 16 Me3SiCl, ACN, toluene, N2, 50 °C, 5 h;
(iv) 14, 16 h, yield 62%; (v) POCl3, triethylamine, THF, 10°C, 45
min, yield 85%; (vi) 18, 7 dry DMF, rt, 4 h; (vii) 17, K2CO3, rt, 72 h,
yield 15%.
Figure 3. STD-NMR spectrum (bottom) and 1H-NMR (top) of
compound 4. The strong interaction observed for aromatic rings A, B,
and C is evidenced.
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anchor (1.20 STD %) and by the isopropyl moiety (0.30 STD
%). For compound 4, we observed STD signals of similar
intensity for the three aromatic rings (0.40% for ring A, 0.36%
for ring B, and 0.25% for ring C, respectively), suggesting that
they are positioned within a protein pocket.
In parallel, we performed docking studies on the crystal
structure of HuR RRM1-2 domains according to the approach
we published.17 We used STD-NMR in combination with in
silico studies (applied to the “closed” HuR conformations, see
SI) to enable a more detailed description of the ligand−protein
behavior in solution. Molecular docking simulations were
performed to elucidate the binding mode and the interactions
between compounds 1 , 3 , and 4 with HuR protein, using
Maestro tools.39 We observed that the anchor moiety of each
compound is predicted to be superimposed with U8,
establishing pivotal interactions with the HuR protein. The
interactions of compounds 1 and 3 with HuR is described in
the SI (Section S4.3, Figures S4.3.1 and S4.3.2). As for
compound 4, we report strong hydrophobic interactions for all
aromatic rings as evidenced by STD data. The amide carbonyl
group establishes double hydrogen bonds with Arg97 and
hydrophobic interactions with the same residue and Ile103
(Figure 4). Regarding ring B, it establishes a π−π-stacking
interaction with Phe65 and hydrophobic interactions with
Arg97, Pro98, and Phe65. Ring C is involved in a double
hydrogen bond with Arg153 and Ile103 and different
hydrophobic interactions. The zoomed-in view in Figure 4
highlights the full overlap of U8 and the anchor motif (ring A)
of compound 4.
In this Letter, we report for the first time on the structure-
based design and synthesis of potential HuR ligands. The
structure-based design strategy used in the present study
enabled the identification of three novel compounds that
interact with HuR, establishing contacts with the RNP regions
of RRM1 and RRM2 domains of the protein. Targeting this
region is pivotal for the inhibition of the protein activity, and
so the identification of compounds able to bind to this site
plays a critical role in the development of new potential HuR
inhibitors. Biophysical experiments (STD-NMR) are in
agreement with computational results, confirming that the
designed compounds 1 , 3 , and 4 are indeed binders of HuR.
Furthermore, theoretical experiments carried out by molecular
dynamics and docking studies confirm that compound 4 is the
best binder of HuR protein, in terms of theoretical binding
affinity (SI, S4.2). The identified hit compounds will be further
optimized in forthcoming studies, building an in silico focused
library. Our findings represent a step forward in discovering
novel compounds potentially useful to counteract several
pathologies such as cancer, inflammation, and neurodegenera-
tion, in which ELAV−RNA complexes play a pivotal role.
■ EXPERIMENTAL PROCEDURES
Design of New Scaffolds. We report all protocols in the SI, S1.
Compound Synthesis. Procedures are reported in the SI, S2.
Protein Expression and Purification. HuR aliquots utilized in
the STD-NMR study were prepared as already described.10,40
Interaction Study with HuR. STD-NMR experiments, molecular
dynamics simulations, and docking studies were carried out as
reported in the SI (S3 and S4, respectively).
■ ASSOCIATED CONTENT
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Figure 4. 3D representation of HuR−4 interactions. Hydrogen bonds
and hydrophobic interactions are displayed as yellow and dark dashed
lines, respectively; a π−π-stacking interaction is shown as a blue
dashed line. RNA and HuR are represented as a brown and yellow
cartoon, respectively. Compound 4 is shown in green sticks.
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ELAV, embryonic lethal abnormal vision; RBP, RNA-binding
protein; STD-NMR, saturation transfer difference-NMR;
RRM, RNA recognition motif-type; RNP, ribonucleoprotein;
MCR, multicomponent reaction; CC-3CR, Castagnoli−Cush-
man reaction; GBB-2CR, Groebke−Blackburn−Bienayme ́
reaction; vL-3CR, Van Leusen reaction.
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Abstract: Leishmaniosis is a neglected tropical disease which affects several millions of people
worldwide. The current drug therapies are expensive and often lack efficacy, mainly due to the
development of parasite resistance. Hence, there is an urgent need for new drugs effective against
Leishmania infections. As a part of our ongoing study on the phytochemical characterization
and biological investigation of plants used in the traditional medicine of western and central
Asia, in the present study, we focused on Eremurus persicus root extract in order to evaluate its
potential in the treatment of leishmaniosis. As a result of our study, aloesaponol III 8-methyl
ether (ASME) was isolated for the first time from Eremurus persicus root extract, its chemical
structure elucidated by means of IR and NMR experiments and the (R) configuration assigned
by optical activity measurements: chiroptical aspects were investigated with vibrational circular
dichroism (VCD) and electronic circular dichroism (ECD) spectroscopies and DFT (density functional
theory) quantum mechanical calculations. Concerning biological investigations, our results clearly
proved that (R)-ASME inhibits Leishmania infantum promastigotes viability (IC50 73 µg/mL),
inducing morphological alterations and mitochondrial potential deregulation. Moreover, it is not
toxic on macrophages at the concentration tested, thus representing a promising molecule against
Leishmania infections.
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1. Introduction
Leishmaniosis, a neglected tropical disease (NTD), continues to be a major health problem,
affecting 12 million people worldwide [1]. This disease is caused by the Leishmania species,
and is generally classified into three different clinical forms: visceral leishmaniosis (VL),
cutaneous leishmaniosis (CL) and mucocutaneous leishmaniosis (MCL). These forms differ in the
pattern and clinical manifestations of the infection. VL can be fatal if left untreated, CL is localized and
frequently self-heals within 3–18 months, while MCL leaves disfiguring scars. Although new drugs,
such as paromycin, miltefosine and liposomal amphotericin B, are available as antileishmanial therapy
in several countries, currently pentavalent antimonials and amphotericin B are the most used drugs for
such purpose. Still, they induce toxic effects, produce development of parasite resistance and, no less
important, they are expensive [2]. For these reasons, the need for new chemotherapeutic drugs is still
strongly felt. Among different approaches proposed to fulfill this primary need, the investigation
of medicinal plants with evidence of traditional use against Leishmania infections represents one of
the most promising strategies. In fact, several plants and plant-derived natural products have been
investigated so far as antileishmanial drug candidates [3,4].
Our nature-aided drug discovery research takes place as a response to this situation. As part of
our ongoing study on the phytochemical characterization and biological investigation of plants used
in western central Asia traditional medicine [5], we addressed our attention to plants belonging to
genus Eremurus (Xanthorrhoeaceae), which includes forty species mainly found in western and central
Asia. In the present work, we focused on Eremurus persicus (Jaub & Spach) Boiss. as source of potential
antiprotozoal drugs. Eremurus persicus has a widespread usage in Kurdistan for both food purposes
and to cure diseases related to inflammation [6] and infections; it has been demonstrated that aerial
parts possess antibacterial and cytotoxic properties [7] and that root extracts show anti-inflammatory
properties [8]. Nonetheless, so far, no scientific evaluation of the antileishmanial properties of
Eremurus persicus had been carried out. Therefore, we herein report the preparation of Eremurus persicus
roots ethanolic extract, the bioassay-guided fractionation of the extract in order to identify constituents
with antileishmanial potential and the isolation, structural elucidation and biological investigation of
its most abundant secondary metabolite.
2. Results and Discussion
Maceration using ethanol is a generally employed method in selective extraction of secondary
metabolites from plant tissues, and we had already utilized such a procedure in our previous works on
Eremurus Persicus [8]. Given the long timeframes (overnight maceration) and generally low and hardly
reproducible yields (3.9%–7.6%) of maceration, on the basis of our previous experience, we studied
the applicability of microwave-assisted solvent extraction (MASE) to the extraction of E. Persicus and
compared it with dynamic maceration. Pilot extraction procedures with dynamic maceration and
microwave-assisted extraction were investigated keeping the ratio sample weight/solvent volume
constant with a value of about 0.05 g/mL.
The maceration procedure substantially followed the one described in our previous work [8],
while for MASE, the extractions were effected in closed vessel system, under controlled pressure and
temperature, to minimize the losses of components due to volatilization.
Through our study, we found that a rather short extraction time (20 min) afforded the ethanolic
extract (EE) in higher yields (21.2%) compared to dynamic maceration. The EE obtained from both
approaches showed a superimposable chromatographic profile at HPLC-UV performed according to
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Following the assessment of scale-up applicability, the root ethanolic extract of E. Persicus was
then prepared according to the optimized MASE procedure (see Section 3.3).
To obtain a preliminary phytochemical fingerprint, the HPLC-UV/PAD method from [9] was
exploited. The HPLC method was then slightly modified to afford faster analyses (see Section 3.4).
The optimized method involves a switch in solvent from acetonitrile to methanol, which allowed to
reduce chromatographic run times from 60 to 30 min without compromising the resulting information.
The same method was consequently applied to both HPLC-UV/PAD and HPLC-ESI-MS analysis,
with optimized MS experimental parameters for positive and negative ion modes. The HPLC-MS
analysis unambiguously showed the presence of a preponderant secondary metabolite characterized
by a molecular weight of 272 Da, given that the corresponding MS spectrum clearly displays an
[M + H]+ at 273 m/z, [M + Na]+ at 295 m/z and a dimeric ion [2M + Na]+ at 567 m/z (Figure 1).
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Fig re 1. ESI- S (positive ion ode, full scan) of the most abundant metabolite of EE.
With the aim to speed up the identification of new potential antiprotozoal compounds we
adopted a bioassay-guided approach. The extract was fractionated by flash chromatography on silica
gel (see Section 3.5) and analyzed applying the optimized HPLC method (see Section 3.4).
Flash chromatography allowed the isolation of six fractions which underwent a preliminary
cytotoxicity screening. Only one fraction resulted active against Leishmania infantum in our initial
screening whose structure matches, as shown by HPLC analysis, to the most abundant metabolite
(Figure 2).
In order to obtain the compound of interest in the amount and chemical purity adequate for
structural characterization as well as for in depth biological in vitro investigation, liquid–liquid
extraction of the crude extract using water/dichloromethane (see Section 3.6) was then experimented.
This procedure allowed for the isolation of the compound of interest with higher process yields in
shorter timeframes.
The structure of the isolated compound was elucidated by mono and bidimensional NMR
(1H-NMR, 13C-NMR, 1H-1H COSY, 1H-13C HSQC, 1H-13C HMBC), as well as IR spectroscopy and
polarimetric analysis. Overall, spectroscopic data were consistent with those reported in literature for
( )-1-oxo-4,9-dihydroxy-8-methoxy-6-methyl-1,2,3,4-tetrahydroanthracene or aloesaponol III 8-methyl
ether, from now on called ( )-ASME [10–12].
The absolute configuration of ( )-ASME (Figure 3) was unambiguously assigned through VCD
(vibrational circular dichroism) and ECD (electronic circular dichroism) spectroscopies and DFT
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and also already employed in instances relevant to the present case [16–19]. In Figure 4, we report
the comparison of the spectra obtained with the computations performed for the assumed (R)
configuration. The major features were correctly predicted by calculations conducted on the basis of
the assumed configuration.Molecules 2017, 22, 519 4 of 15 
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Fi . e ical structure of (R)-aloesaponol I - 8 ethyl ether ((R)-AS E).
Even the weak features of the ECD spectra presented in the insets of Figure 4 are accounted for in
the specific case of chloroform measurement: these weak features come from the subtle balance of the
relative statistical weights of the ECD spectra associated to the various conformers (see Table S1 and
Figure S9) and we verified experimentally that, switching to acetonitrile as solvent, a change in sign
occurs as shown in Figure 4, inset. In passing, we note that, for the best prediction of most VCD and
ECD data, it is crucial that the hydroxyl group on C4 be axial, as already noted in [16,17].
The minor n!⇡* feature at ca. 290 nm is crucially dependent on the population of conformers with
the OH groups in the axial vs. equatorial position; in parallel, the 1Lb feature at 380 nm [20] depends
on which fraction of the OCH3 groups is either below or above the naphthalene plane (d instead of
u), as defined in Figure S9; such conformations are overall approximately 58–56% vs. 42–44% in the
first case or 51–50% vs. 49–50% in the second case and might reverse with solvent change (see Table 1).
The specific OR might accordingly change and we do not consider them here, since the latter data are
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trace) and experimental (blue trace) ECD (top) and UV (bottom) spectra of 1 in acetonitrile. In the
inset, we repeat the magnified portions of spectra between 280 and 450 nm; in this region, we also
report experimental ECD and UV data for chloroform solution (red trace). The calculations are in the
PC /C Cl3 approximation (see text).
The antileishmanial potential of EE and (R)-ASME was finally examined through in vitro
biological investigation, in particular their antiparasitic effects were evaluated on L. infantum
promastigotes through MTT test. The results of our study clearly suggested that EE does not
possess any effect on viability of L. infantum promastigotes, whereas (R)-ASME showed an interesting
anti-Leishmania activity (Figure 5), its IC50 value being equal to 73 µg/mL.
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The treatment of L. infantum promastigotes with (R)-ASME at the IC50 concentration induced a
decrease of cell number, as clearly stated in Figure 6. This effect was particularly evident after 24 h of
treatment, although evidence suggests that it occurred even earlier, i.e., after five and seven hours of
incubation. The decrease of cell number was probably due to the inhibition of proliferation or/and
lysis of promastigotes by (R)-ASME.
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To investigate the mechanisms of action responsible for the biological activity observed for
(R)-ASME, its effects on (i) morphology; (ii) apoptosis/necrosis events; (iii) DNA integrity and (iv) cell
cycle of L. infa tum promastigotes were studied.
Concerning the effect of (R)-ASME on L. infantum pro astigotes morphology, modificatio s were
evaluated by optical icroscopy using direct examination f live micr organism (hanging drop) and
after Giemsa stain. The orphological observations pointed out a change in the shap and mobility of
L. infantum cells treated with (R)-ASME at the IC50 concentration (Figure 7). In details, control cells
were very mobile with characteristic fusiform shape. After Giemsa staining, it was possible to observe
the characteristic shape, long flagellum emerging from the anterior region of the parasite, nucleus and
kinetoplast, posterior to the nucleus. In contrast, treated cells did not show the typical elongated shape
since they became rounder and smaller, losing their mobility.
This evidence suggested that cytoskeletal disorganization and/or alterations on mitochondrial
bioenergetics activity occur in treated cells.
Table 1. Effects of (R)-ASME (IC50 concentration) on mitochondrial transmembrane potential of
L. infantum promastigotes.
L. infantum Intracellular Entities (% of Cells)
JC1Ag JC1Mon MIF aAgreg/MIFMon
2 h 4 h 6 h 24 h 2 h 4 h 6 h 24 h 2 h 4 h 6 h 24 h
Control 98 88 91.6 93.7 2 11.2 8.2 6.2 4 7.4 2.7 2.2
(R)-ASME 97 81.4 88.2 90.5 2.9 18.5 11.4 9.5 5.6 6 2.2 1.5
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and to DMSO (control cells) (B); for 4 h (1); and 24 h (2). Hanging drop in phase contrast (magnification
100⇥ and 200⇥) and Giemsa staining (magnification 1000⇥).
Alterations in the mitochondrial transmembrane potential were then studied by flow cytometry,
using JC-1 as a probe. In healthy cells characterized by a high mitochondrial membrane potential,
JC-1 tends to form aggregates; in impaired cells, with a low membrane potential, it is found as
monomers. Cell treatment with (R)-ASME at IC50 concentration caused a loss of potential after four
hours of incubation (Table 1), suggesting an early event of apoptosis mechanisms that could be
associated with impaired cellular function.
To investigate the effect of (R)-ASME on apoptosis/necrosis events of L. infantum cells,
the annexin-V/PI double staining method was employed. Annexin-V was used to mark early apoptotic
cells, while PI, a non-permeable stain with affinity for nucleic acid, was used to distinguish necrotic
cells. Our results revealed that apoptosis could be seen on treated cells after four hours of incubation
and that necrosis mechanism did not occur at this time of incubation, being the percentage of cell
positive to annexin-V and PI equal to 8.5 and 0.1, respectively (Table 2). After 24 h of treatment,
neither annexin-V nor PI were positive, pointing out that the apoptosis/necrosis process was not
maintained at this time of incubation.
Table 2. Flow cytometry analysis of L. infantum promastigotes treated with (R)-ASME showing the
percentage of PI and annexin-V positive cells.
L. infantum Intracellular Entities (% of Cells)
Annexin-V PI Annexin/PI
2 h 4 h 6 h 24 h 2 h 4 h 6 h 24 h 2 h 4 h 6 h 24 h
Control 18.8 6.3 3.3 2.4 0.4 0.3 0 0.4 3.7 1.5 0.4 0.7
(R)-ASME 2.8 8.5 4.5 4.3 0.5 0.1 0.1 0.4 1.2 2 0.1 0.6
Since the degradation of nuclear DNA is one of the hallmarks of apoptotic cell death, the DNA
integrity of L. infantum promastigotes treated with (R)-ASME at the IC50 concentration was then
investigated by means of gel electrophoresis DNA analysis. Interestingly, similarly to control cells,
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Finally, the effects of (R)-ASME (IC50 concentration) on the cell cycle of L. infantum promastigotes
were investigated by flow cytometry. (Table 3). After six hours of incubation the treated parasite cells
were on G0/G1 phase (88.6%) and S phase (11%) of the cell cycle. Comparatively, in non-treated cells
the number of cells on G0/G1 and S phases was 71.4% and 29%, respectively. This means that, at this
time of incubation, (R)-ASME promoted retention of L. infantum promastigotes in the G0/G1 phase of
the cell cycle, thus suggesting an arrest of the cycle at this stage. Interestingly, this evidence seem to be
correlated with the effects of (R)-ASME on cell number.
Table 3. Effects of (R)-ASME on the cellular cycle of L. infantum promastigotes.
L. infantum Intracellular Entities (% of Cells)
Phase G0/G1 Phase S Phase G2/M
2 h 4 h 6 h 24 h 2 h 4 h 6 h 24 h 2 h 4 h 6 h 24 h
Control 83.3 87.1 71.4 47.7 16 13 29 36 0.3 0 0 16.4
(R)-ASME 83.9 87.1 88.6 44.9 15 13 11 38 1.1 0 0 17.6
Altogether, the results of our study focused on the mechanism of action of (R)-ASME suggest
that initially (R)-ASME induced apoptosis events and arrest on G0/G1 phase cell cycle. Proliferation
inhibition together with cell death were responsible for the rapid effects of (R)-ASME on cell number
and morphological alterations (four to seven hours). After these events, the surviving cells are healthy;
thus, at 24 h no differences in the apoptosis/necrosis parameters, DNA fragmentation and cell cycle
were noticed.
Since the evaluation of cytotoxicity is a highly important issue in the drug discovery process, as the
last step of our study we evaluated the toxicity of (R)-ASME in a macrophage cell line (RAW 264.7).
Indeed, it is mandatory that a molecule with anti-Leishmania activity does not produce significant
toxicity in the host cells. In detail, (R)-ASME was tested at high concentrations (until two folds the
IC50 against L. infantum) on mammalian cells. Results showed that (R)-ASME seems to be safe for
mammalian cells at tested concentrations, since only a slight decrease in macrophages viability was
observed (Figure 8).
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3. Materials and Methods
3.1. General
Solvents for extraction, purification (analytical grade), and high performance liquid
chromatography analysis—HPLC-(HPLC grade) were supplied by Carlo Erba (Milan, Italy).
Polyvinylpyrrolidone (PVP), gallic acid, deuterated solvent for NMR spectroscopy, RPMI-1640
Medium, Phosphate Buffered Saline (PBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), dimethylsulfoxide (DMSO) were purchased from Sigma Aldrich (Milan, Italy).
Fetal bovine serum (FBS; GibcoR) was purchased from ThermoFisher Scientific (Lisbon, Portugal).
All solvents were evaporated under reduced pressure using a Heidolph Laborota 4000 instrument
(Heidolph Instruments GmbH & Co., Schwabach, Germany).
Extractions were carried out a multimode Microwave apparatus using a closed-vessel system
(MARSX press, CEM Corporation, Matthews, NC, USA).
Melting points were measured on an SMP3 Stuart Scientific apparatus and are uncorrected.
Analytical thin-layer chromatography (TLC) was carried out on silica gel pre-coated glass-backed plates
(Fluka Kieselgel 60 F254, Merck, Darmstadt, Germany) and visualized by UV light, acidic ammonium
molybdate (IV), or potassium permanganate.
Flash chromatography was performed with silica gel 60 (particle size 230–400 mesh) purchased
from Nova Chimica (Cinisello Balsamo, Italy).
1H-NMR, 13C-NMR and bidimensional experiments were performed at 400.0 MHz and 100.6 MHz,
respectively, on the Bruker Avance 400 MHz FT NMR spectrometer (Bruker, Leipzig, Germany) with a
multinuclear BBO probe. CDCl3 was used as solvent. 1H chemical shift values were reported on the
  scale in ppm, relative to TMS (  = 0.0 ppm) and in 13C-NMR, chemical shift values were reported
posing CDCl3 (  = 77.36 ppm) as reference.
Optical rotation values were measured on a Jasco (Cremella, LC, Italy) photoelectric polarimeter
DIP 1000 with a 1 dm cell at the sodium D line (l = 589 nm); sample concentration values (c) are given
in 10 2 g·mL 1.
ECD spectra were run on a Jasco-815SE instrument (Jasco Corporation, Hachioji, Tokyo, Japan)
using 0.1 to 1 mm cuvettes with chloroform and acetonitrile solutions of various concentrations (from
0.002 M to 0.004 M). VCD spectra were obtained on a Jasco FVS 6000: a 0.200 mm BaF2 cell and
0.056 M/CDCl3 solutions were employed. DFT calculations ancillary to chiroptical spectroscopies
were run by use of Gaussian09 set of programs [21], preceded by Molecular Mechanics analysis of
possible conformers of assumed configuration.
3.2. Plant Material
Eremurus persicus (Jaub. & Spach) Boiss. was collected in a mountain area (Kūh-e Golestān,
Golpayegan) located 120 km from Isfahan/Iran, at an altitude of 3000–3200 m. The collected plant
materials were identified and classified by Dr. Abdulla Sa’ad at the Education Science Department,
Faculty of Biology, Salahaddin University, Hawler/Iraq. The voucher specimen (No. 6856) was
deposited at ESUH (Education Salahaddin University Herbarium), Hawler/Iraq. Freshly cut roots
were dried in a drying room with active ventilation at room temperature (about 20–22  C) until they
showed no further weight loss. The roots were cut to small size and grounded with a blade mill
(A10 IKA-Werke GmbH & Co. Staufen, Germany) to obtain a homogeneous fine powder. The plant
material so treated was stored in dark conditions.
3.3. Extraction Procedure
In our previous works [8,9], the ethanolic extract (EE) of Eremurus persicus was prepared through
a dynamic maceration procedure (extraction yield 7.6%).
In the present work, the extraction process was optimized through the application of a MASE
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were extracted by using ethanol (500 mL) in a multimode microwave apparatus at 120  C for 20 min,
with a power of 800 W. The extract was separated by Buchner filtration and solvent was evaporated to
dryness under vacuum, yielding a yellow oil (5.2 g, extraction yield 20.8%).
3.4. High Performance Liquid Chromatography Analyses
High performance liquid chromatography-photodiode array (HPLC-UV/PAD) analyses were
performed on a Jasco system (Cremella, LC, Italy) equipped with a Jasco AS-2055 plus autosampler,
a PU-2089 plus pump and a MD-2010 plus multi-wavelength detector. Experimental data were
acquired and processed by Jasco Borwin PDA and Borwin Chromatograph Software.
High performance liquid chromatography-electrospray-tandem mass spectrometry (HPLC-ESI-MS)
analyses were carried out on Finnigan LCQ fleet ion trap system, controlled by Xcalibur software 1.4
(ThermoFinnigan, San Jose, CA, USA). Mass spectra were generated both in positive and negative
ion mode under constant instrumental conditions. For positive ion mode: ion spray voltage 5 kV,
capillary voltage 46 V, capillary temperature 220  C, and tube lens voltage 120 V. For negative ion
mode: ion spray voltage 5 kV, capillary voltage  35 V, capillary temperature 220  C, and tube lens
voltage  100 V.
Reverse phase chromatographic analyses were carried out at room temperature (RT) under
gradient conditions, using a Chromolith SpeedROD RP-18 endcapped column (50 mm ⇥ 4.6 mm,
ID 3 mm, macropore size 2 µm, mesopore size 13 nm, Merck, Darmstadt, Germany).
The HPLC analysis conditions were properly optimized to monitor the extract fractionation.
The mobile phase was water containing 0.1% formic acid (A) and methanol containing 0.1%formic
acid (B), and the composition gradient was: from 30% to 39% of B in 7 min, 42% B until 4 min, 50% B
until 5 min followed by an isocratic elution for 2 min, 70% B until 5 min 30% B until 5 min, followed by
a re-equilibration step of 2 min; total run time 30 min.
For all analyses the flow rate was set at 1 mL/min. Samples were dissolved in methanol (3 mg/mL)
and filtered with a 0.45 µm GH Polypro (GHP) membrane before injection into the HPLC-system.
3.5. Bio-Guided Fractionation
The EE (1 g) was subjected to Flash Chromatography on Silica gel under gradient conditions
eluting with 50% ethyl acetate and 50% hexane to 70% and then 100% ethyl acetate. Six fractions
were collected on the basis of the TLC profile, analyzed according to described HPLC method and
evaluated with a preliminary biological assay (MTT test, Section 3.8.2). Fraction 2 (19 mg, yield 1.9%),
characterized by the presence of a single peak (HPLC: RT = 6.94 min, purity > 99%) corresponding to
the main peak of EE chromatogram, resulted the only effective.
3.6. Isolation of the Main Secondary Metabolite
The EE (3 g) was dissolved in water (900 mL) and extracted with dichloromethane (DCM, 900 mL)
under mechanical stirring for 3 h at RT. The organic fraction was then collected and the extraction
procedure repeated for three times. The combined organic phases, dried over sodium sulphate and
evaporated in vacuo furnished a yellow solid (210 mg, yield 7%, HPLC: RT 6.94 min, purity = 75%,
TLC Rf 0.87 EtAc/MeOH/H2O). Further purification of the solid via crystallization (acetone) allowed
the isolation of 135 mg of a pure compound 210 mg, m.p. 174–175  C, yield 4.5%, HPLC: RT 6.93 min,
purity > 99%). Nuclear Magnetic Resonance (1H- and 13C-NMR) and Mass Spectral (MS) techniques
were employed for the structure elucidation of the isolated compound. The structure was determined as
( )-1-oxo-4,9-dihydroxy-8-methoxy-6-methyl-1,2,3,4-tetrahydroanthracene or aloesaponol III 8-methyl
ether by comparison of the spectroscopic data with the previous reports.
[↵]20D  37.9 (c 0.04, CHCl3), [↵]
20
D  18.2 (c 0.2, Acetone), [↵]
20
D  18.5 (c 0.3, CH3OH); ESI-MS:
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1H-NMR (CDCl3, 300 MHz):   2.01 (1H, brs, OH), 2.28 (2H, m, H-3), 2.48 (3H, s, H-11), 2.69
(1H, m, H-2), 3.05 (1H, m, H-2), 4.02 (3H, s, OCH3), 4.94 (1H, dd, J = 5 Hz, H-4), 6.69 (1H, d, J = 2 Hz,
H-7 or H-5), 7.06 (1H, s, H-10), 7.14 (1H, d, J = 2 Hz, H-7 or H-5).
13C-NMR (CDCl3):   203.3 (C-1, s), 165.9 (C-9, s), 159.5 (C-8, s), 142.0 (C-6, s), 140.3 (C-5a, s),
139.9 (C-4a, s), 119.9 (C-5, d), 115.4 (C-10, d), 113.8 (C-8a, s), 109.2 (C-1a, s), 108.3 (C-7, d), 68.0 (C-4, d),
56.0 (OCH3, q), 34.0 (C-2, t), 30.7 (C-3, t), 22.1 (C-11, q).
3.7. ECD, VCD Spectra and DFT Calculations
ECD spectra were run using 0.1 to 1 mm cuvettes with chloroform and acetonitrile solutions at
different concentrations (from 0.002 M to 0.004 M) to accommodate the various spectroscopic regions.
Twenty scans were run to obtain data in the 500–180 nm range. The corresponding ECD spectra for the
solvent in the same conditions were run and subtracted from those of the solution. VCD spectra were
obtained employing a 0.200 mm BaF2 cell and 0.056 M/CDCl3 solutions. Five thousand scans were
taken and solvent subtraction was made with VCD spectra in the same condition. DFT calculations
ancillary to chiroptical spectroscopies were run by use of Gaussian09 set of programs [21], preceded by
Molecular Mechanics analysis of possible conformers of the assumed configuration (R): subsequent
quantum mechanical DFT calculations were conducted at B3LYP/TZVP level of theory in the PCM-IEF
modelization of solvent [22]. The computed VCD and IR spectra were obtained from calculated
rotational strengths and dipole strengths and wavenumbers by assigning Lorentzian bandshapes
with 16 cm 1 bandwidth; spectra were scaled by 0.98 in frequency and divided by 3 in intensity to
facilitate comparison with experimental spectra. The UV and ECD spectra were generated assigning
Gaussian bandshapes with 0.2 bandwidth. Computed spectra were shifted by 20 nm and intensities
were divided by 3.
3.8. Biological Evaluation
3.8.1. Parasites and Cultures
Promastigote forms of Leishmania infantum Nicolle (zymodeme MON-1) were maintained at 26  C
with weekly transfers in HEPES (25 mM)-buffered RPMI 1640 medium enriched with 10% inactivated
fetal bovine serum (FBS).
3.8.2. Viability Assay
The antiparasitic effect of EE and (R)-ASME was studied through MTT test, a colorimetric assay
of cell survival, following the method of [23]. Log phase L. infantum promastigotes were incubated
with increasing concentration of EE and (R)-ASME, in fresh medium for 2 h. After the incubation,
25 µL of MTT (5 mg·mL 1) was added to each well, incubated for 2 h at 37  C and centrifuged at
3000 rpm for 5 min. The supernatant was removed, the cells were washed in PBS, and the precipitated
formazan was dissolved in DMSO (250 µL). Cell viability was measured by absorbance at 530 nm on
an ELISA plate reader (Synergy HT, Bio-TEK, Winooski, VT, USA), and calculated using the following
formula: [(L2/L1) ⇥ 100], where L1 is the absorbance of control cells and L2 is the absorbance of
treated cells. Three separate experiments were performed for each sample and the concentration that
inhibited viability by 50% (IC50) was determined through dose-response regression analysis, plotted by
GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA).
3.8.3. Morphological Studies and Cell Counting
Parasites cells were exposed to (R)-ASME and morphological alterations were investigated by
optical microscopy using direct examination of live microorganisms (hanging drop) and after Giemsa
stain. Briefly, exponentially grown of L. infantum (2 ⇥ 106 cells mL 1) were treated with the compound
at IC50 concentrations for 2 h, 4 h, 6 h and 24 h at 26  C. After incubation, cells were pelleted by
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was suspended in fresh medium and approximately 10 µL were placed on a Koch slide and directly
observed under the optical microscope phase contrast (Eclipse E400, Nikon coupled with a digital
camera 165 DN100 Nikon, Nikon Europe B.V. Amsterdam, the Netherlands). In addition, a total cell
counting was performed using a haemocytometer and a smear was made which was submitted to
Giemsa stain. The smear was fixed with methanol for 5 min, stained with aqueous solution of Giemsa
(1/10, v/v) for 10 min at room temperature and finally washed with water and air dried. The stained
smear was observed under the microscope with a 100⇥ lens (Eclipse E400, coupled with Nikon digital
camera, Nikon DN100 165).
3.8.4. Cell Cycle Analysis
For the analysis of DNA content, exponentially grown L. infantum (2 ⇥ 106 cells mL 1) were
treated with (R)-ASME at IC50 concentration for 2 h, 4 h, 6 h and 24 h at 26  C. At each time point,
cells were fixed in 200 µL of 70% ethanol for 30 min. at 4  C. After washing cells with 2 mL of PBS,
enriched with 2% of bovine serum albumin (BSA), the pellets were suspended in 0.5 mL of propidium
iodide (PI) solution (PI/Rnase, Immunostep, Salamanca, Spain) and incubated for 15 min at 37  C [24].
Cells were then analyzed by flow cytometry (D Biosciences, San Jose, CA, USA). Results were treated
using ModFit LT V 2.0 programme (D Biosciences).
3.8.5. Phosphatidylserine Externalization
Double staining for annexin V-FITC and PI was performed as described previously [25]. Briefly,
L. infantum promastigotes (2 ⇥ 106 cells mL 1) were exposed to (R)-ASME at IC50 concentrations for
2 h, 4 h, 6 h, and 24 h at 26  C. Cells were then washed with PBS and re-suspended in binding buffer
(10 mM HEPES–NaOH, pH 7.4, 140 nM NaC1, 2.5 mM CaCl2). To 100 µL of this suspension were
added 5 µL of annexin V-FITC and 5 µL of PI (AnnexinV-FITC Apoptosis Detection Kit, Immunostep).
After 15 min incubation in the dark at room temperature, 400 µL of binding buffer were further added
and cells were analyzed by flow cytometry (FacsCalibur–Beckton–Dickinson). Data analysis was
carried out using the program Paint-a-gate, and values are expressed as a percentage of positive cells
for a given marker, relatively to the number of cells analyzed.
3.8.6. Measurement of Mitochondrial Membrane Potential
To assess mitochondrial membrane potential (D m), a cell-permeable cationic and lipophilic dye,
JC-1 (5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolcarbocyanine iodide), was used as previously
described [26]. This probe aggregates within mitochondria and fluoresces red (590 nm) at higher D m.
However, at lower D m, JC-1 cannot accumulate within the mitochondria and instead remains in the
cytosol as monomers, which fluoresces green (490 nm). Therefore, the ratio of red to green fluorescence
gives a measure of the transmembrane electrochemical gradient. L. infantum promastigotes (106 cells)
were exposed to (R)-ASME at the IC50 concentrations for 24 h at 26  C. Promastigotes were then
incubated with JC-1 (5 µg·mL 1) (Molecular Probes, Invitrogen) in the dark for 15 min at RT. Then,
cells were washed in PBS, suspended in 400 µL of PBS and analyzed by flow cytometry. Data analysis
was carried out using the program Paint-a-gate.
3.8.7. DNA Fragmentation Assay
Promastigotes of L. infantum (2 ⇥ 106 cells mL 1) were exposed to (R)-ASME at IC50 concentration
or to dissolution vehicle (DMSO), and incubated at 26  C for 24 h. The Leishmania DNA extraction
was carried out according to the procedure in DNeasy Blood & Tissue (Qiagen, Hilden, Germany).
DNA integrity analysis was done by electrophoresis, running DNA through an EtBr-treated agarose







Molecules 2017, 22, 519 13 of 15
3.8.8. Mammalian Cell Cytotoxicity
For cytotoxicity assays on mammalian cells, log phase of macrophages (RAW 264.7) were
trypsinized and incubated at 37  C in 24-well tissue culture plates in Dulbecco’s Modified Eagle
Medium (DMEM), enriched with Glutamax and supplemented with 10% FBS, under microaerophilic
conditions. As soon as the monolayers reached confluence, the medium was removed and cells were
incubated at 37  C for 24 h with fresh medium and (R)-ASME at IC50 concentrations. After incubation,
control and treated cells were washed with PBS, pH 7.2, and 450 µL of PBS and 50 µL MTT solution
(5 mg·mL 1) were added to each well and incubated at 37  C for 1 h. The cells were then washed with
PBS, 500 µL of DMSO were added to the wells and absorbance was measured at 530 nm on an ELISA
plate reader (Synergy HT, Bio-TEK). The percentage of viable cells was determined as described in the
viability assay.
3.9. Statistical Analysis
The results are expressed as mean ± SEM from at least three independent experiments; they were
analyzed by one-way analysis of variance (ANOVA), followed by Dunnett´s test, using GraphPad
Prism, version 6.0d (GraphPad Software, San Diego, CA, USA). The level of significance was * p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001 when compared to control.
4. Conclusions
In this work, we used a bioassay-guided fractionation as a strategic approach to natural
source product discovery and isolation. Liquid–liquid extraction of the ethanolic extract (EE) of
Eremurus persicus roots combined with biological evaluation led to the identification of an active
fraction with antileishmanial activity corresponding to the (R) enantiomer of Aloesaponol III 8-methyl
ether ((R)-ASME). Interestingly, this is the first time that the (R)-ASME has been isolated from
natural sources, while the (S) enantiomer had already been reported as found in Kniphofia foliosa [11],
Eremurus chinensis [12] and Asphodelus microcarpus [27].
(R)-ASME possesses a remarkable antiprotozoal effect against L. infantum. We demonstrated
that it is active with an IC50 of 73 µg/mL, it is able to induce alterations on both morphology and
mitochondrial potential of L. infantum promastigotes, and does not produce significant toxicity
in a macrophage cell line. Results showed that (R)-ASME seems to be safe for mammalian
cells at tested concentrations, since only a slight decrease in macrophages viability was observed.
These results strongly suggest that (R)-ASME may represent a valuable lead against Leishmania
infections. Although our preliminary results are encouraging, additional studies should be planned
both in vitro and in vivo to get further insight into the mechanisms of action behind the antileishmanial
activity of (R)-ASME.
Supplementary Materials: Supplementary materials are available online.
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Introduction: Marrubium vulgare is a herbal remedy presents in several European
Pharmacopoeias and commonly marketed as white horehound. The chemotaxonomic
marker of Marrubium genus is marrubiin and its content may change in response to
biotic and abiotic stress.
Objective: Development of a microwave‐assisted solvent extraction (MASE)
methodology suitable for exhaustively extracting marrubiin from M. vulgare leaves,
easily applicable to large sets of samples. Evaluation of the influence of copper(II)
on marrubiin production.
Material and methods: M. vulgare leaves were dried, extracted exploiting MASE
and analysed via high‐performance liquid chromatography ultraviolet photodiode
array detection (HPLC‐UV/PAD) system. A design of experiments approach was
adopted to select the best extraction conditions. Extraction parameters (solvent
composition, extraction time and temperature), were studied applying two full
factorial experimental designs in a sequential approach. To analyse samples, a rapid
HPLC‐UV/PAD method was set up.
Results: The best results in terms of marrubiin extraction yield were obtained
extracting samples at 120°C with 100% ethanol, for 15 min (3 × 5 min microwave
cycles). The developed methodology was successfully applied to matrices grown in
Greenhouse conditions and under stress induced by copper(II), selected as model
agent for abiotic stress. Progressively decreasing production of marrubiin was
evidenced in connection with treatment with 80, 200 and 300 mg/L copper sulphate.
Conclusion: An efficient methodology for the extraction and determination of the
amount of marrubiin in large sets of samples of M. vulgare plants was developed.
Results demonstrated that marrubiin is an easily detectable marker useful for evaluat-
ing M. vulgare reaction to stress.
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copper(II)‐induced stress, DoE, HPLC‐UV/PAD analysis, Marrubium vulgare L. leave extract, MASE
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Nature contributes greatly to the history and landscape of drugs.
Around half of the drugs currently in clinical use are of natural
origin, about 30% ofdrugs approved by the FDA (US Food and Drug
Administration) over the past three decades are nature‐inspired
and nearly one‐quarter derive from the vegetal kingdom.1 By their
very nature, plants protect themselves producing compounds
commonly known as secondary metabolites.2 These compounds are
characterised by a high degree of structural variability, including
terpenes, phenols, alkaloids, also in their glycosidic forms. Secondary
metabolites produced in nature have survival functions for producing
organisms and are able to set off physiological and pharmacological
effects within living cells. For this reason, on one hand, natural
compounds play a relevant role in the nature‐aided drug‐discovery
process and, on the other hand, given their involvement in the plant
defence system, they are useful markers for evaluating the plant
adaptation to environmental stress factors (i.e. growth, geographical
position, climate change, waste deposition or agricultural practices).
The extensive use of plants for millennia for healthcare purposes
has found renewed interest due to recent advances in modern biology,
pharmacology, chemistry and related disciplines.3 The integration of
traditional and modern medicine has given birth to “Green Medicine”;
which has been proven to be more effective with fewer side effects
on human beings. Within this context, we can mention white hore-
hound whose great interest as a herbal remedy is testified by its pres-
ence in Pharmacopoeias and the Merck Index of Phytotherapy since
1910. Recent literature has evidenced that Marrubium vulgare shows
several in vivo and in vitro activities including antihypertensive, antiox-
idant, antiinflammatory, antidiabetic, effects on respiratory system,
digestive stimulant, antiasthmatic, hypolipidemic, antibacterial, and
antifungal effects. Within this context, and as a part of our current
research in this field, in the present contribution we focused on M.
vulgare L. (white/common horehound), an annual herbaceous plant
belonging to Lamiaceae family, native to Eurasia and northern Africa
zones.4-17 Due to its biological activities, the European Medicines
Agency has published a monograph for M. vulgare in which all the tra-
ditional, non‐clinical and clinical data are reported.18 The main second-
ary metabolite of the plant is marrubiin, a furane labdane diterpenoid,
isolated for the first time from M. vulgare in 1930 and considered a
chemotaxonomic marker of Marrubium genus.19 During the last
20 years, a plethora of works has highlighted that marrubiin can be
related to pharmacological effects such as antinociceptive, antioxidant,
antigenotoxic, cardioprotective, vasorelaxant, gastroprotective, anti-
spasmodic, immunomodulating, antioedematogenic, analgesic, and
antidiabetic properties (Figure 1).10,12,20-29
Aim of our general project is to understand whether culture and
environmental conditions may affect the growth and quality of white
horehound. We have already demonstrated that copper(II)‐induced
stress reduced the uptake and translocation of cationic elements, like
iron(II), potassium(I) and calcium(II), whereas increased the content of
total phenols and flavonoids. It is worth noting that in connection with
waste deposition and agricultural practices, copper(II), commonly pres-
ent at low concentrations in the soil, tends to accumulate to high and
toxic concentrations, leading to an alteration of vital physiological or
biochemical functions. These effects may have a great impact on
human health, since M. vulgare is commonly used worldwide for its
medicinal properties. As a continuation of our research, the aim of
the herein presented work is to develop a rapid and reproducible
microwave‐assisted solvent extraction (MASE) methodology for
exhaustively extracting marrubiin from M. vulgare leaves. In the last
decades, MASE has gained increasing importance for isolation and
extraction of metabolites from vegetal matrices, since it entails low
solvent consumption, gives high and fast extraction performances
and offers protection to thermo‐labile constituents. To date, MASE
is considered a robust alternative to traditional extraction techniques,
especially for analytical purposes. 4-7
In detail, we herein describe the development of a MASE method-
ology easily applicable to the extraction of marrubiin from M. vulgare,
and the evaluation of the impact of copper(II) concentration in the
soil on the production of marrubiin. It is worth noting that in connec-
tion with waste deposition and agricultural practices, copper(II), com-
monly present at low concentration in the soil, tends to accumulate
to high and toxic concentrations, leading to an alteration of vital
physiological or biochemical functions. These effects may have a great
impact on human health, since M. vulgare is used worldwide for its
medicinal properties.
To set up the experimental conditions suitable to ensure the
exhaustive extraction of marrubiin from the vegetal matrix, a design
of experiments (DoE) approach was adopted. Moreover, a proper
high‐performance liquid chromatography (HPLC) method allowed the
rapid analysis of the samples. The proposed MASE methodology
allowed the exhaustive extraction of marrubiin from M. vulgare leaves
and may be successfully applied for evaluating the marrubiin content
in a wide number of samples. Until now, such approach for evaluating
the production of marrubiin in M. vulgare had not been reported.
FIGURE 1 Marrubiin natural source, chemical structure and biological activities [Colour figure can be viewed at wileyonlinelibrary.com]








2.1 | Plant material and copper treatment
Seeds of M. vulgare were issued from a non‐contaminated wild popu-
lation in the region of Béja (north‐westernTunisia; latitude 36°43′30″
(N), longitude 9°10′51″ (E), altitude 255 m). Voucher specimen of M.
vulgare was deposited in the herbarium unit for the research of Plant
Ecology, Department Biology, Faculty of Sciences of Tunisia, under
the registration number MV‐N‐20.
The experiments started in August 2014, and lasted four months.
Initially, three replicates of 20 seeds for each treatment were sown at
a depth of 2 cm in plastic pots (26 cm × 22 cm) fitted with commercial
peat and sand (1:2, v/v) and maintained under Greenhouse conditions
(naturally exposed to sunlight, with a temperature range 20–25°C, and
relative humidity range 50–80%). Seedlings were separately
transplanted into individual pots (18.2 cm × 14.2 cm) and treated with
0 (control), 80, 200 and 300 mg/L copper sulphate (CuSO4) for
eight weeks. Nutrient solutions were renewed every 4 days.3 At the
end of the treatment (in December), the fresh leaves were separated,
and dried in a drying room with active ventilation at room temperature
(about 26–28°C) until constant weight. The aerial parts were stored in
closed glass jars and preserved in dark conditions. The plant material
was thus ground with a blade‐mill (A10 IKA‐Werke GmbH & Co.,
Staufen, Germany) to obtain a homogenous powder, just before
performing the extractions.
2.2 | Chemicals and standards
Solvents for both HPLC (HPLC grade) and extraction procedures (ana-
lytical grade) were supplied by Carlo Erba (Milan, Italy). The reference
standard of marrubiin (> 98% purity) was obtained from Carbosynth,
while charcoal from Sigma Aldrich (Milan, Italy).
2.3 | Instruments and apparatus
All extraction experiments were conducted under microwave irradia-
tion in a microwave mono‐mode oven (Discover® Lab‐Mate instru-
ment, CEM Corporate, Buckingham, UK) equipped with a power and
temperature controller. Extract analyses were carried out on a Jasco
(Tokyo, Japan) high‐performance liquid chromatography ultraviolet
photodiode array detection (HPLC‐UV/PAD) system equipped with
a Jasco AS‐2055 plus autosampler, a PU‐2089 plus pump and a
‐2010 plus multi‐wavelength detector. Experimental data were
acquired and interpreted with Borwin PDA and Borwin chromato-
graph software (Tokyo, Japan).
2.4 | HPLC‐UV/PAD analysis
We prepared the hydroalcoholic leaves extract by applying the
MASE methodology we had previously developed and reported3
and analysed by HPLC‐UV/PAD, at 1 mL/min flow rate, at room
temperature using a Phenyl X‐Bridge endcapped column (50 mm
× 4.6 mm, length × inner diameter, 3 μm particle size, macropore size
2 μm, mesopore size 13 nm, Merck, Darmstadt, Germany). The
mobile phase consisted of water containing 0.1% (v/v) formic acid
(A) and methanol containing 0.1% (v/v) formic acid (B). The eluent
was applied onto the column in gradient mode from 10% to 90% B
in 14 min, followed by an isocratic elution step for 6 min.
Reconditioning of the column was accomplished by eluting the
column with the mobile phase from 90% B to 10% B in 5 min,
followed by a re‐equilibration step of 5 min under isocratic condi-
tions with 10% B. The analytical conditions reported earlier ensure
a good resolution of marrubiin (unequivocally identified comparing
its HPLC retention time and UV spectrum with those of the standard
analysed in the same conditions, Figure 2 and Supporting Information
Figure S1) with respect to the other analytes present in the extract.
A representative chromatographic profile of the extract is reported in
Figure 2. Quantitative determination of marrubiin was performed
using the external standard procedure by means of a six‐point cali-
bration curve with three replicate measurements for each calibration
point (Figure S1).
The limits of detection (LOD) and limits of quantification (LOQ)
were estimated using the calibration curves calculated during the
validation procedure, from which the average of slope (S) and the
standard deviation of intercept (δ) were calculated. LOD and LOQ
were obtained as follows: LOD = 3.3δ/S, LOQ = 10δ/S, thus the
values were 0.016 mg/mL and 0.032 mg/mL, respectively. The
calibration curve in the range 1.00–0.003 mg/mL was linear with a
correlation coefficient (R) of 0.9878 (y = 7E + 06x – 434459). The
statistical control of the method was assessed by performing
three injections of reference standard at the beginning of every
measurement session on different days. The method accuracy was
evaluated by assessing the marrubiin recovery by single‐point
standard addition method, spiking 0.30 g of samples with 3.2 mg of
marrubiin. The recovery found by comparison of the spiked amount
of marrubiin to the amount found in the non‐spiked samples was
as high as 99%.
FIGURE 2 High‐performance liquid chromatography ultraviolet
photodiode array detection (HPLC‐UV/PAD) profile at λ = 220 nm
of ethanol microwave‐assisted solvent extraction (MASE) obtained
from plant grown in Greenhouse conditions. The star * identifies the
marrubiin peak








2.5 | MASE parameters determination: DoE
The experimental extraction plan was designed to study three
responses, i.e. total extraction yield percentage (computed as milli-
grams of dried extract per milligrams of dried plant material × 100,
Y1), total area of the peaks recorded in the HPLC‐UV/PAD chromato-
grams (mAU‐s, Y2), and marrubiin yield (expressed in milligrams of
marrubiin per gram of dried plant material, Y3). Three experimental
parameters were evaluated in the first set of experiments; the
parameters were solvent composition (%volume of solvent/volume
of water, X1), time of extraction (in minutes, X2) and temperature
(in Celsius degrees, X3). All other parameters including the operator
were kept constant (e.g. amount of dried material, solvent volume,
type of vessel, etc.). The selected parameters were varied within
defined ranges according to Tables 1 and 2 for methanol and ethanol.
2.6 | Statistical analysis
All collected data were studied using Microsoft Excel 2010 and R for
Microsoft Windows version 3.2.3, Copyright© 2014. The R Founda-
tion for Statistical Computing R‐based chemometric software routines
were used for DoE calculations.
The R‐based software has been developed by the Group of
Chemometrics of the Italian Chemical Society (http://gruppochemiometria.
it/gruppo‐lavoro‐r‐inchemiometria.html).
2.7 | Sample extraction and analysis
2.7.1 | Marrubium vulgare matrices obtained from
plant grown in Greenhouse conditions
Here 0.30 g of matrix were dispersed in 10 mL of solvent (Tables 1
and 2) under magnetic stirring and subjected to microwave heating
(2 min ramping, maximum pressure 120 psi, maximum potency
100 W, temperature – Tables 1 and 2) for one to three cycles of
5 min with solvent renewal (Tables 1 and 2). The mixture was left to
cool at room temperature, charcoal (0.090 g) was added, stirred for
5 min and filtered over paper; the last procedure was repeated once
and the solvent was evaporated under reduced pressure to obtain a
yellow‐green oil (yield, Tables 1 and 2).
2.7.2 | Marrubium vulgare matrices from plants
treated with copper(II)
Here 0.30 g of matrix in 10 mL of ethanol under magnetic stirring
were subjected to microwave heating (2 min ramping, maximum
pressure 120 psi, maximum potency 100 W, temperature 120°C) for
three cycles of 5 min. The mixture was left to cool at room tempera-
ture, added with 0.090 g of charcoal, stirred for 5 min, and filtered
over paper; the filtration was repeated once and the solvent was
evaporated under reduced pressure to obtain a yellow‐green oil (yield,
Table 3).
All samples were analysed by HPLC‐UV/PAD. Each extract was
dissolved in a 90:10 methanol/water mixture (12.5 mg/mL) and
filtered with a 0.45 μm GH Polypro (GHP‐ PerkinElmer, China) mem-
brane before injection into the HPLC‐system. The different extracts
were analysed exploiting the chromatographic conditions described
earlier.
3 | RESULTS AND DISCUSSION
To establish a powerful approach for the determination of marrubiin in
M. vulgare leaves, the research activity was organised as follows:
i. a HPLC‐UV/PAD methodology for marrubiin quantitation was
properly set up, using marrubiin as external standard;
ii. the dried samples ofM. vulgare leaves were ground and extracted
using microwave irradiation; and a screening of the factors
relevant to the MASE procedure was conducted;
iii. the best MASE parameters were determined by DoE, quickly
allowing the identification of the best extraction conditions;
iv. samples of M. vulgare leaves grown under abiotic stress induced
by CuSO4 (80–200‐300 mg/L) were analysed;
every step is discussed hereinafter.
3.1 | Optimisation of the HPLC method
Relying on the results obtained in our previous work, a rapid and eco-
nomic chromatographic method suitable for the complete resolution












1 80:20 1 × 5 40 16.29 7831107 2.20
2 20:80 1 × 5 40 13.86 7706809 0.15
3 80:20 3 × 5 40 14.60 10681435 2.03
4 20:80 3 × 5 40 16.84 9326463 0.23
5 80:20 1 × 5 80 20.82 16897393 5.17
6 20:80 1 × 5 80 22.29 14019358 3.39
7 80:20 3 × 5 80 25.22 22448046 8.01
8 20:80 3 × 5 80 17.31 13538365 2.52
9 50:50 2 × 5 60 23.66 13058322 1.22
10 50:50 2 × 5 60 24.00 14430454 1.40
Note: the solvents used are m, methanol and w, water.








of marrubiin was developed.3 The optimised method allowed us to
obtain a shorter time of analysis exploiting an XBridge Phenyl (5 μm,
4.6 mm × 150 mm) column under gradient elution conditions, using a
mobile phase composed of water and methanol both with 0.1% (v/v)
formic acid. Marrubiin was identified comparing its HPLC retention
time and UV spectrum with those of the standard analysed in the
same conditions.
Quantitative determinations of this secondary metabolite
were performed using external standard by means of a six‐point
calibration curve. The equation was obtained over a wide concentra-
tion range, in accordance with the level of marrubiin expected in the
drug powder. The calibration equation thus attained was then used
to compare the chromatographic marrubiin peak areas of the
extracted samples with the external standard to achieve this
secondary metabolite quantification. The chromatographic method
response resulted a linear equation in the concentration range
considered.
3.2 | Screening of the factors relevant for marrubiin
extraction
The set up of the extraction method was conducted on the dry matrix
of unstressed M. vulgare according to the experimental procedure
described in sections 2.1–2.7. Based on our previous experience, we
applied a DoE approach for identifying the best experimental
conditions.30 The application of a DoE strategy for the development
of optimised MASE procedures on natural matrices is a recent
approach.31
Three responses were studied varying three different parameters.
As responses, we considered the total extraction yield percentage (Y1),
the total area of the peaks recorded in the HPLC‐UV/PAD chromato-
grams (Y2), and the marrubiin yield (Y3). It is well known that the
efficiency of MASE strongly relies on the selection of operating condi-
tions and parameters affecting the extraction mechanisms and yield:
the main factors affecting MASE performance are, together with sam-
ple characteristics, solvent nature and composition, extraction time
and temperature (strictly related to microwave power). Accordingly,
we studied the parameters, solvent composition (X1), extraction time
(X2) and temperature (X3), applying two full factorial experimental
designs in a sequential approach. The selected parameters were varied
within defined ranges, as reported in Tables 1 and 2. The first eight
experiments constituted the initial screening, followed by three test
experiments in which the computed models were validated. The sec-
ond set of four experiments was designed following the observations
collected in the first phase of the study. Experiment numbers 7, 12,
13, and 14 of Table 2 were used to compute a 22 full factorial design,
and experiment number 15 was used to validate this latter design. The
detailed DoE experimental plan is reported in the Supporting
Information.
Results of experiments with methanol (Table 1) showed that the
proposed model is able to predict the trend of the expected extract












1 80:20 1 × 5 40 13.84 10563133 2.92
2 20:80 1 × 5 40 18.77 6679179 1.61
3 80:20 3 × 5 40 17.85 9005601 5.25
4 20:80 3 × 5 40 23.05 7063361 2.25
5 80:20 1 × 5 80 19.27 10828100 5.39
6 20:80 1 × 5 80 20.87 7498999 2.78
7 80:20 3 × 5 80 17.35 13320100 6.24
8 20:80 3 × 5 80 22.37 6644688 4.82
9 50:50 2 × 5 60 21.45 7927552 3.49
10 50:50 2 × 5 60 19.40 12993662 4.12
11 75:25 3 × 5 80 21.27 10753422 5.89
12 100 3 × 5 120 14.53 14040263 9.20
13 100 3 × 5 80 10.10 9167573 4.98
14 80:20 3 × 5 120 21.42 11635041 8.47
15 90:10 3 × 5 100 15.47 13380524 6.45
Note: the solvents used are e, ethanol and w, water.













80 100 3 × 5 120 12.87 10200575 4.97
200 100 3 × 5 120 12.50 9509691 3.88
300 100 3 × 5 120 10.23 21595277 2.79
Note: the solvents used are e, ethanol and w, water.








yield, total area of the chromatograms and marrubiin yield. Accord-
ingly, we moved to the second set of experiments (Table 2), using
ethanol, generally recognised as an eco‐friendly and green solvent.
Results of the screening phase showed that:
• the extraction yield (Y1e) obtained using ethanol reaches higher
values when factor X1 (solvent%) is kept at its minimum level
(ethanol at the 80% level), while extraction time and temperature
are not important to enhance the extraction yield;
• the total area of the peaks (Y2e) is greater when factors X1 and X3
at their highest levels (ethanol 100% and temperature 120°C,
respectively), whereas the extraction time seems to have no effect
on the response;
• the marrubiin yield (Y3e) seems higher when all three factors X1,
X2, and X3, are at the highest levels simultaneously (i.e. ethanol
100%, time of extraction 15 min, and temperature 120°C).
To assess whether the responses could be improved, one additional
set of four experiments was then performed at the extremes of the
experimental domain. The results are reported in Table 2 (experiment
numbers 7, 12, 13, 14 for model computation and 15 for model valida-
tion). The response Y1e, extraction yield %, is modelled very accurately
by the simplified linear model without interactions of the solvent
composition and temperature, according to the equation
Y1e ¼ 15:85 ± 0:09ð Þ– 3:54 ± 0:09ð ÞX1 þ 2:12 ± 0:09ð ÞX2
which provides a good fit (r = 0.9993) and accurate prediction of the
experimental extraction yield percentage found (Table 2, experiment
number 15, relative error percentage equal to 2.5%). The marrubiin
yield (Y3) results, turned out instead to be better modelled by the
simplified linear equation
Y3e ¼ 7:2 ± 0:4ð Þ þ 1:6 ± 0:4ð ÞX3
which showed only a simple dependence of the marrubiin yield from
the extraction temperature and that the time of extraction and solvent
composition do not actually influence the results. The model correctly
predicts the marrubiin extraction yield found in the centre of the
experimental domain (Table 2, experiment number 15, measured yield
6.45 mg/g, with a relative error of 12% versus predicted value of
7.2 ± 0.4 mg/g). Conversely, the total area of the peak in the
chromatograms (Y2e) is not described by a valid model and the mean
value of the total area found, (1.20 ± 0.1)107 mAU‐s, is independent
of the variations made to the factors solvent composition and temper-
ature studied (experiment numbers 7, 12, 13, and 14, Table 2).
Based on the results discussed earlier, we can consider validated
the models for Y1e and Y3e, since the error is within the uncertainty
limits associated with the used experimental procedure.
The best results in terms of marrubiin extraction yield (Y3), whose
quantification is the main goal of the work, were obtained using 100%
ethanol, applying three cycles of microwave heating of 5 min each at
120°C (experiment number 12, Table 2). To exclude thermal marrubiin
degradation at the extraction conditions, an additional MASE experi-
ment (experiment number 12, Table 2) was carried out, adding known
amounts of marrubiin to vegetal matrix (obtained from plant grown in
Greenhouse conditions). The good recoveries obtained (99%) confirmed
the chemical stability of marrubiin under the experimental conditions.
Accordingly, these conditions have been applied for evaluating the
effect of the treatment with copper(II) to the marrubiin production.
FIGURE 3 Chromatographic profile (λ = 220 nm) and morphology of the aerial part of Marrubium vulgare grown in Greenhouse conditions (Mv)
and subsequently to an increasing stress caused by 80 (Mv_80), 200 (Mv_200) and 300 (Mv_300) mg/L of CuSO4. The star * identifies the
marrubiin peak [Colour figure can be viewed at wileyonlinelibrary.com]








3.3 | MASE extraction of M. vulgare samples grown
in Greenhouse conditions and treated with copper(II)
The optimised MASE protocol (experiment number 12, Table 2) was
applied to M. vulgare leaves obtained from plants grown in
Greenhouse conditions and treated with 80, 200 and 300 mg/L of
CuSO4 and the ethanolic extracts analysed using the HPLC‐UV/PAD
method developed here. The chromatographic profiles are shown in
Figure 3, and the results are summarised in Figure 4.
Our results showed that raw materials originating from unstressed
plant contained more marrubiin compared to leaves harvested from
plants grown in stressed conditions. In detail, the plants were treated
with CuSO4 (80, 200 and 300 mg/L) for eight weeks according to
the related literature.32-34 As highlighted in Figure 4, there are signifi-
cant differences (P < 0.05) in the amount of marrubiin, depending on
the growth conditions. Furthermore, the concentration of marrubiin
ranged from a maximum amount of 9.20 mg/g of dried plant grown
in Greenhouse conditions and progressively decreased to 4.97 mg/g,
3.88 mg/g and 2.79 mg/g subsequently to an increasing stress caused
by 80, 200 and 300 mg/L of CuSO4, respectively. A similar trend was
observed for total extraction yields (differences are significant at a sta-
tistical level, P < 0.05), suggesting a modification of the composition of
secondary metabolites in the raw materials. This hypothesis may be
corroborated by the chromatographic profiles of the extracts: the peak
area corresponding to the first compounds eluted, the most polar,
increased with stress. Therefore, we can state that there is a negative
relation between copper(II) concentration, selected as test model
substance responsible for soil pollution, and marrubiin content.
To conclude, we developed a cost effective MASE methodology
to exhaustively extract marrubiin from M. vulgare leaves. The HPLC‐
UV/PAD analysis of the raw extract allows a rapid and reliable quanti-
fication of marrubiin in M. vulgare leaves and can be applied to
evaluate the quality of a wide range of samples of white horehound.
To optimise the process, we used the statistical DoE approach. DoE
findings indicated that the highest extraction efficiency of marrubiin
with high repeatability were obtained using 100% ethanol at 120°C
for 15 min, with significant benefits in terms of extraction times and
environmental impact, given that ethanol is completely biodegradable.
The developed methodology was applied to evaluate the quality of
white horehound, grown under Greenhouse as well as under
copper(II)‐mediated stress conditions. We demonstrated that growth
conditions may affect the marrubiin content and therefore the quality
of the herbal drug.
We propose this methodology for the characterisation of M.
vulgare herbal drug samples, thus evaluating their exposure to abiotic
stress, revealing their phytochemical status, and facilitating the identi-
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